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Introduction
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Human health is impacted by a complex network of interactions between biological path-
ways, mechanisms, processes, and organs. To maintain internal homeostasis, many of these 
processes need to act in a continuously changing environment in response to stimuli such 
as exercise, diet, infections, stress, and temperature (Figure 1). The ability to appropriately 
respond to changes in environment is referred to as ‘phenotypic flexibility’. Diseases develop 
when and where these adaptive processes fail [1].
Figure 1. Many disease onsets (outer circle) are related to lifestyle; however, the mechanisms of disease progression 
and the processes that maintain optimal health are different. This figure shows three crucial processes including the 
capacity to maintain flexibility in metabolic, oxidative, and inflammatory stress. Here, flexibility is considered as the 
capacity to maintain optimal homeostasis. CVD = Cardiovascular disease; IBD = inflammatory bowel disease; IR = 
insulin resistance; SOD = superoxide dismutase. (Reproduced from van Ommen B. and Wopereis, S) [1].
The metabolic phenotype provides a readout of the metabolic state of an individual and is 
a product of interactions between several factors such as genetics, diet, lifestyle, environment 
and gut microbiota [2, 3]. To maintain health, understanding these relationships will be one of 
a major challenges for the next decades. To address this challenge, system biology powered by 
genomics, proteomics, bioinformatics, and metabolomics is providing a novel methodological 
framework to unravel the connections between health states [1, 4, 5]. This concept is illustrat-
ed in Figure 2, which shows the application of high-throughput ‘omics’ techniques and elabo-
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rate statistical analyses tools to help resolve the complex relationship between (bio) chemicals 
in human systems and their interaction with other variables including environment /lifestyle 
to produce the measured phenotype [6]. 
Figure 2. A schematic overview of the complex interactions of functional levels including metabolome, proteome, 
transcriptome and genome in biological systems. In general, the phenotype is considered as a product of the 
complex interaction of components from all of the functional levels and environmental effects. (Reproduced from 
Dunn et al.) [7].
The question now is how to measure a subtle shift towards a healthy phenotype. As life-
style and diet induced effects are rather small, sensitive methods are needed to capture these 
slight changes. 
Currently, the biomarkers used in health care research are not based on optimal health 
maintenance but on quantifying disease [1]. Since optimal health is not simply the absence 
of disease, and since the underlying biology of health and disease may be fundamentally dif-
ferent, a new generation of biomarkers is needed to quantify all aspects of systems flexibility, 
with the aim of bringing more insight into the lifestyle factor that promote health optimiza-
tion [1].
In this thesis I describe two ways to monitor phenotype shifts; either by looking directly 
into the baseline metabolome of tissues or by looking at the ability to restore metabolic ho-
meostasis in blood upon a dietary challenge. Both metabolomics and transcriptomics will be 
deployed to get a comprehensive view on the metabolic phenotype.
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Phenotyping via snapshot measurements in organs
Most studies that aim to assess a metabolic phenotype rely on circulating biofluids such 
as blood and urine [8, 9]. Such body fluids can be obtained in a straightforward manner from 
volunteers and are considered to mirror the metabolic events that occur in organs. It should 
be noted, however, that tissues and organs might be more sensitive to report on the metabolic 
phenotype as each organ has strikingly different metabolic patterns [10]. 
Figure 3. Schematic depiction of the metabolic control mechanisms that define (A) the catabolic (fasting) state and 
(B) the anabolic (postprandial) state. Metabolically active tissues have been indicated that predominantly define the 
metabolic phenotype (muscle, liver, adipose) (Reproduced from van Ommen et al. 2014)[11].
Although metabolism for a major part takes place in liver, muscle and adipose tissue (Fig-
ure 3), only few human studies have considered these tissues for defining metabolic pheno-
types [12-15]. Skeletal muscle is an interesting organ to study phenotypic shifts as the phe-
notype can be altered through exercise and nutrition. Current insights are mostly based on 
animal studies [16, 17]. The few metabolic studies that involve human muscle biopsies are 
mostly related to a few metabolites or to specific metabolite classes [14, 15]. Therefore, a com-
prehensive view of the effects on various stimuli on the muscle metabolome is still lacking.
Phenotyping via challenge responses
Phenotypic flexibility is a key factor in the relationship between human health and nutri-
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tion and points to the concept of the human body as an orchestrated machinery that adapts to 
external stimuli [11]. Considering ‘health’ as the ability to cope with daily challenges [18], cur-
rent approaches focusing on disease risk biomarkers are not sufficiently sensitive to detect the 
effects of lifestyle factors (including exercise training and nutritional interventions), which in 
general aim to improve and sustain health. Instead, one would like to design new biomarkers 
that tell something about the resilience capacity of an organism, which may be achieved by 
studying the response to specific perturbing stimuli.
In recent years, the application of meal challenges to detect subtle difference in metabolic 
resilience has gained much interest in the nutrition field [19-21]. The best known example is 
the Oral Glucose Tolerance Test (OGTT), which specifically probes the resilience of glucose 
metabolism [22]. In addition, a so called mixed meal challenge—involving a standardized 
meal comprising protein, lipids and glucose— has been employed to more broadly target phe-
notypic flexibility in multiple organs [23]. Consistent with this notion, it was shown that the 
application of a mixed meal challenge in combination with plasma metabolomics and pro-
teomics profiling revealed additional metabolic changes beyond what was observed under 
non-perturbed conditions [24]. 
Similarly, by applying a highly controlled 4 day challenge protocol—which included 36 h 
fasting, Oral Glucose and Lipid Tests (OGTTs & OLTTs), liquid test meals, physical exercise, and 
cold stress—to young healthy male subjects, inter-individual variation was increased even in 
phenotypically similar subjects. Specifically, the challenges enabled the identification of spe-
cific metabotypes that were not observable in baseline metabolite profiles [25]. These findings 
have provided detailed information on the complex metabolic changes induced by OGTTs/
OLTTs and have given novel insights into the regulation of glucose and lipid metabolism. In 
this study, we examined whether a response to a mixed-meal challenge could provide readout 
for a shift in phenotypic flexibility upon diet-induced weight loss in abdominally obese male 
subjects.
Metabolomics 
Metabolomics is the ‘systematic study of the unique chemical fingerprints which specif-
ic cellular processes leave behind’, this pertains in particular to the scientific study of their 
small-molecule metabolite profiles [26]. As the end products of cellular processes, the metab-
olome represents the collection of all metabolites in a biological cell, tissue, organ or organ-
ism [27].In recent years, several strategies to identify and quantify multiple metabolites us-
ing sophisticated analytical technologies have emerged. As a direct functional readout of the 
physiological state of an organism, ‘metabolomics’, is considered to ‘act as spoken language, 
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broadcasting signals from the genetic architecture and the environment’ [28, 29].
 A range of analytical technologies including mass spectrometry, liquid or gas chromatog-
raphy and NMR has been employed to analyse metabolites in different organisms, tissues, 
and fluids. Complementary approaches have to be established to extract, detect, quantify, and 
identify as many metabolites as possible [30].
Metabolite levels are closely linked to the phenotype of an organism. Accordingly, metab-
olomics can be considered as bridging the gap between genotype and phenotype [31], pro-
viding a more complete view of how cells function, as well as identifying novel or striking 
changes in specific metabolites. In particular, studying tissue-derived metabolite profiles is 
probably the closest way to get to the phenotype, yet it is not a well-developed technology. A 
major bottleneck to achieve extended coverage is the limited amount of tissue that can be ob-
tained from human studies. The recent development of a comprehensive targeted metabolic 
profiling platform which was optimized and validated for small muscle biopsies paved the 
way to unravel the observed phenotypical differences at a more comprehensive level [32]. 
In this thesis we covered several metabolite classes including amines, acylcarnitines, organic 
acids, oxylipins and nucleotides. Our hypothesis was to study phenotypic shifts at not only the 
single metabolite level but also at the level of related pathway (Table 1). 
Table 1. Metabolites classes measured in this thesis
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Table 1.Metabolites classes measured in this thesis 
Metabolite  classes   Platform  Relevant pathways per platform  
Amino acids  
& Biogenic 
amines 
Accq-Tag UPLC-MS/MS 
(33) 
& NMR (34) 
Stimulate protein synthesis, Muscle recovery from 
exercise 
 
Acylcarnitines Accq-Tag UPLC-MS/MS 
(33) 
Mitochondrial transport of fatty and amino acids  
Organic acids GCMS (35) TCA cycle, Carbohydrate metabolism and Fatty 
acid oxidation  
 
Oxylipins LCMS (36) Changes in inflammatory lipid metabolism 
Nucleotides Enzymatic assays (32) Energy metabolism 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Transcriptomics 
Transcriptomics uses high-throughput genomic methods, such as microarray analysis 
or RNA sequencing, to assess the expression of thousands of genes. Knowing the pattern of 
gene expression at a given time allows the identification of gene sets that are differentially ex-
pressed in response to challenge/intervention. In this way, it can be used to get more insights 
into the genome-wide effects of a specific stimulus, which in turn can help us to discover the 
effects of regulatory pathways involved in transcriptional regulation.
I n t r o d u c t I o n 
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In relation to human health, transcriptomics has already proven to be extremely valu-
able to distinguish not only a pathological state from a non-pathological state, but it can also 
show more detailed patterns that reflect different stages of a specific disease progression [37, 
38]. Hence, it can be also useful to study shifts in phenotype following specific challenges/
interventions. By integrating the knowledge derived from transcriptomics, genetics and other 
available tools, our understanding of the phenotype flexibility is expected to greatly improve. 
Gene expression studies can be performed both by directly looking into organ-specific gene 
expression or by looking at peripheral blood mononuclear cells (PBMC’s). The suitability of 
PBMCs for gene profiling is related to their active metabolism [39] and their accessibility by 
simple venipuncture [40, 41], thereby allowing for a repeated time-series analysis of changes 
in gene expression in response to dietary interventions. Still, it should be considered that while 
transcriptomic profiling of organs allows a direct view of gene expression in the tissue of in-
terest, PBMC’s are used as proxies for systemic effects. Importantly, a study by Rudkowska et 
al. supports the use of PBMCs as a surrogate model for skeletal muscle gene expression in nu-
trigenomics studies, as shown by the strong correlation (r=0.84, P<0.0001) between transcript 
expression levels of PBMCs and skeletal muscle tissue after n-3 PUFA supplementation [42].
Model populations for observing phenotype shifts
Frail and healthy elderly subjects: effect of prolonged training 
Populations around the world are aging rapidly. This trend is likely to increase further 
over the next few decades [43]. Due to the association of senescence with a wide range of 
diseases, there is an increase in demand for care at this stage of life. One of the major age-re-
lated functional declines is characterized by loss of skeletal muscle mass and function, often 
resulting in frailty. Physical activity is one of the most effective strategies to improve muscle 
mass and strength in adults [44, 45]. Different claims exist about the effectiveness of resis-
tance-type exercise to overcome muscle loss and weakness in older adults, including its ability 
to improve quality of life [46], and even reversing aging in skeletal muscle [47]. In order to 
elucidate the complex processes that occur in ageing skeletal muscle, we assessed the effect 
of prolonged resistance-type exercise training in skeletal muscle of older subjects to examine 
the possible shift from an older to younger phenotype. Looking directly into muscle gene /
metabolite profiles, we expect to gain more insight into muscle health-related factors as well 
as into the potential underlying molecular mechanisms.
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Obese subjects: effect of weight loss 
The importance of maintaining metabolic flexibility as a key factor to maintain optimal 
health calls for new research on the relationship between nutrition and health. An important 
aspect of phenotypic flexibility is the capacity to switch from carbohydrate to fat oxidation 
and vice-versa in response to certain external stimuli, which is considered crucial for optimal 
metabolic homeostasis. This capacity is in particular compromised in the obese state. As is 
shown in Figure 4, there is an association between the obese, insulin resistant, and T2D phe-
notype, as shown by an impaired fat oxidation during fasting and an impaired switch from fat 
oxidation to the glucose oxidation after a meal [48] or after insulin stimulation [49]. Based on 
these considerations, we expect an improvement in the metabolic response in obese subjects 
after weight loss (following 4 weeks of low calorie diet). Therefore, we examined whether the 
response to a mixed meal challenge could serve as a readout for a shift in phenotypic flexibil-
ity upon weight loss in obese subjects.
Figure 4. An overview of the post absorptive and postprandial adaptations in skeletal muscle substrate oxidation. 
A low respiratory quotient (RQ) indicates a relatively high fat oxidation and vice versa. The closed line represents a 
normal, healthy individual; the dotted line represents metabolic inflexibility (Reproduced from Corpeleijn et al. [50]).
Objective and outline of this thesis
In this thesis, I aim to track shifts in metabolic phenotype through two different approach-
es. First, I investigated whether prolonged resistance-type exercise training could shift the 
elderly phenotype toward a young phenotype, representing a more healthy status (Chapter 2 
and 3). To that end, I used an organ specific approach focused on skeletal muscle tissue. The 
major aim was to better understand the molecular characteristics of the frailty phenotype (as 
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an advanced stage of ageing) by evaluating the gene expression and metabolite profile in skel-
etal muscle of frail older, healthy older, and young subjects. Moreover, I aimed to specify the 
effect of resistance-type exercise training on the skeletal muscle transcriptome/metabolome 
in older people.
In Chapter 4 and 5 of this thesis I examined whether a mixed meal challenge response 
could provide an appropriate readout for a shift in phenotypical flexibility upon weight loss 
in obese male subjects. We combined metabolic profiling and whole genome gene expression 
in PBMCs to comprehensively capture the metabolic mechanisms that underlie phenotypic 
flexibility. We were particularly interested in finding out whether the study of the effect of 
weight loss on the postprandial response would provide a more sensitive readout than the 
study of the effect of weight loss under fasting homeostatic conditions.
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AbsTRAcT
The skeletal muscle system plays an important role in the independence of older adults. 
In this study we examine differences in the skeletal muscle transcriptome between healthy 
young and older subjects and (pre-) frail older adults. Additionally, we examine the effect of 
resistance-type exercise training on the muscle transcriptome in healthy older subjects and 
(pre-) frail older adults. 
Baseline transcriptome profiles were measured in muscle biopsies collected from 53 
young, 73 healthy older subjects and 61 frail older subjects. Follow-up samples from these 
frail older subjects (31 samples) and healthy older subjects (41 samples) were collected after 6 
months of progressive resistance-type exercise training. Frail older subjects trained twice per 
week and the healthy older subjects trained three times per week.
At baseline genes related to mitochondrial function and energy metabolism were differ-
entially expressed between older and young subjects, as well as between healthy and frail 
older subjects. 307 genes were differentially expressed after training in both groups. Training 
affected expression levels of genes related to extracellular matrix, glucose metabolism and 
vascularization. Expression of genes that were modulated by exercise training were indica-
tive of muscle strength at baseline. Genes that strongly correlated with strength belonged to 
the protocadherin gamma gene cluster (r=-0.73).
Our data suggest significant remaining plasticity of ageing skeletal muscle to adapt to re-
sistance-type exercise training. Some age-related changes in skeletal muscle gene expression 
appear to be partially reversed by prolonged resistance-type exercise training. The protocad-
herin gamma gene cluster may be related to muscle denervation and re-innervation in ageing 
muscle.
KEYWORDS: ageing, frailty, skeletal muscle, transcriptomics
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 InTROducTIOn
The number of people aged above 65 has increased rapidly over the past few decades, and 
is likely to increase progressively[1]. Because senescence is associated with a wide range of 
afflictions, including physical disability, cancer, heart disease and diabetes, the demand for 
care for older people will further increase. The loss of skeletal muscle mass and function with 
aging leads to frailty and results in the loss of independence of older adults. 
Frailty, and related sarcopenia, are very complex and many factors contribute to their 
aetiology. This includes physical inactivity, malnutrition, hormonal changes and changes 
within the muscle [2-4]. Mitochondrial function decreases with age [5], fast-twitch muscle fi-
bres demonstrate a smaller cross-sectional area[6], protein synthesis capacity is reduced [7], 
anabolic signals are less effective [4, 8], and there are fewer satellite cells to regulate adaptive 
responses to stimuli [9]. In older adults muscle cells can also undergo continuous cycles of 
denervation and reinnervation, which can lead to both weakness and loss of muscle mass 
[10, 11].
One of the most effective strategies to improve muscle mass and strength in adults is phys-
ical exercise [9, 12]. Resistance-type exercise is particularly suitable to curtail muscle loss and 
muscle weakness in older people. In accordance, quality of life is improved after participating 
in resistance-type exercise training [13]. Some even claim that resistance-type exercise train-
ing reverses ageing in skeletal muscle [14]. 
To elucidate some of these complex processes that occur in skeletal muscle during ageing, 
we examined the effects of prolonged resistance-type exercise training in frail and healthy 
older subjects on the skeletal muscle transcriptome. By comparing genome-level gene expres-
sion in frail and pre-frail older subjects, healthy older subjects and young subjects we aim 
to better understand the molecular causes of frailty. Secondly, we aimed to determine the 
effect of resistance-type exercise training on the skeletal muscle transcriptome in both frail 
and healthy older people. 
26
MeThOds
experimental design
We collected a total of 259 muscle biopsy samples from pre-frail and frail older subjects 
(61 subjects, 92 samples), healthy older subjects (73 subjects, 114 samples) and young males 
(53 subjects, 53 samples). Some of these samples were follow-up samples taken after 24 weeks 
of resistance-type exercise training (31 samples from the frail older subjects, 41 samples from 
the healthy older subjects). Training for both groups was similar and consisted of progressive 
full-body resistance-type exercise training. However, the frail older group had training ses-
sions twice per week, whereas the healthy older group trained three times per week. In addi-
tion, subjects took a protein or control drink for the duration of the study. The healthy older 
group received a 15 gram portion of milk protein or control supplement at breakfast. The frail 
older group received a similar drink containing 15 gram supplement drink (milk protein or 
control) at breakfast and lunch. More details can be found in the respective papers [15, 16]. 
Table 1 shows the characteristics of our study population at baseline. Table 2 shows the effect 
of the training intervention on the older subjects that were included in this study and where 
follow-up data is available.
subjects
Biopsies from frail and pre-frail older subjects were collected from participants of two 
studies performed by Tieland et al. [15, 17]. For these studies frail and pre-frail older sub-
jects were selected based on the Fried criteria for frailty [2]. These subjects will hereafter be 
referred to as frail older subjects. These characteristics are unintentional weight loss, weak-
ness, self-reported exhaustion, slow walking speed, and low physical activity. Subjects in the 
healthy older group were not considered frail by any of these criteria at the start of the in-
tervention study[16]. Several additional baseline samples from healthy older subjects were 
collected from several studies from our group [18, 19]. These samples were taken before any 
intervention was undertaken and serve as additional reference samples. Baseline samples 
from young subjects were from healthy male subjects [20]. These were also taken before any 
intervention took place and serve as reference samples. All studies were approved by the 
medical ethical committee of either Wageningen University or Maastricht University and 
comply with the Declaration of Helsinki.
Muscle biopsy
Muscle samples were obtained with a 5 mm Bergstrom muscle biopsy needle from the 
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Musculus vastus lateralis, after local anaesthesia of the skin and fascia. Samples were freed 
from any visible blood and non-muscle tissue and immediately frozen in liquid nitrogen and 
then stored at -80° C. All samples were obtained in the morning, in an overnight fasted state, 
with at least 3 days of no heavy physical activity.
sample preparation and microarray analysis
Total RNA was isolated from the skeletal muscle tissue by using Trizol reagent (Invitrogen, 
Breda, Netherlands). Thereafter RNA was purified using the Qiagen RNeasy Micro kit (Qiagen, 
Venlo, Netherlands) and RNA quality was checked using an Agilent 2100 bioanalyzer (Agilent 
Technologies, Amsterdam, Netherlands). Total RNA (100 ng) was labelled using an Ambion 
WT expression kit (Life Technologies, Bleiswijk, Netherlands) and hybridized to human whole 
genome Genechip Human Gene 1.1 ST arrays coding 19.732 genes, (Affymetrix, Santa Clara, 
CA). Sample labelling, hybridization to chips and image scanning was performed according 
manufacturer’s instructions.
data analysis
Microarray signals were normalized using robust multichip average (RMA). Data was 
filtered using Universal exPression Codes filtering (UPC) with a 50% cut-off, corresponding 
to a 50% likelihood that a gene is expressed [21]. Significant differences of individual genes 
were tested using the limma R library [22]. Baseline differences were tested between the three 
groups (frail older, healthy older or young). Our model included gender, supplementation 
and group. For the effect of exercise we included subject, gender, time and supplementa-
tion in the model. The training effect for frail older and healthy older subjects was analysed 
separately due to differences in training frequency. P-values were adjusted using false dis-
covery rate (FDR) [23]. A q-value below 0.05 was considered significant. Pathway analyses 
were performed using Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, www.qiagen.
com/ingenuity) on the filtered dataset with the UPC filtered genes used as the background. A 
sparse partial least squares (sPLS) model for leg extension 1RM was made using the caret R 
library [24]. The dataset was split into a training set (75%) and a testing set (25%) before fitting 
the model using cross-validation. This model was validated using 10 times repeated 10-fold 
cross-validation. Final number of components for the sPLS model selected by grid search was 
3. Principal Component Analysis (PCA) was performed using the FactoMineR R library [25]. 
Plots were made using the R libraries ggplot2 and gplots[26, 27].
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ResulTs
baseline differences in transcriptome
Large differences in gene expression profiles between young and older adults (healthy 
and frail) were found, with the expression of 5228 genes significantly different between young 
subjects and both groups of older subjects. However, fold changes of the majority of these 
genes were relatively subtle, which suggested small but consistent differences between these 
groups. Only 825 genes out of these 5228 genes showed fold changes higher than 1.2. Venn-di-
agrams can be found in supplementary figures 1A and 1B. The top 20 genes that were signifi-
cantly different at baseline between the three groups are presented in table 3. Top canonical 
pathways reported by IPA include oxidative phosphorylation, TCA cycle and glucose metabo-
lism (supplementary figure S2).
Table 4 shows the top 20 genes that were different between healthy and frail older subjects 
at baseline. Top genes included METTL21C, FRZB and non-coding RNA. Pathways that were 
significantly different between the frail and healthy older subjects were related to glucose me-
tabolism and RNA processing (supplementary figure S2). In general, expression of genes relat-
ed to glucose metabolism were lower in both frail older and healthy older subjects compared 
to young, with frail older subjects showing the lowest expression of the groups. Principal Com-
ponent Analysis (PCA) summarizes this observation, where the healthy older subjects seemed 
to be between the frail older subjects and the young subjects on the first two components (sup-
plementary figure S3 and S4). While pathways related to mitochondrial function were some 
of the most significantly affected pathways, the fold changes of the individual mitochondrial 
genes were relatively small but consistent. Fold changes for these mitochondrial genes were 
in the range of 1.1 and 1.2. 
effect of prolonged resistance-type exercise training
Prolonged resistance-type exercise training showed a significant effect on the gene ex-
pression profiles in both frail and healthy older people (431 and 1395 significantly changed 
genes, respectively). 307 genes were changed in both groups after resistance-type exercise 
training. Changes in expression of all these overlapping genes were in the same direction. A 
table with the top 20 genes changed by training is presented in table 5. Training resulted in 
the differential expression levels of many genes that are related to the connective tissue and 
the extracellular matrix, including collagen genes and laminin genes, suggesting significant 
tissue remodelling due to the training. Upstream analysis using IPA showed that TGF-β signal-
ling-related genes were significantly activated in both groups, primarily due to the increased 
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expression of collagen and laminin genes (supplementary figure S5). Other significant genes 
include myofibrillar proteins such as myosin heavy chain isoforms and troponin isoforms. 
Genes related to glucose metabolism shifted away from the expression levels of the old-
er subjects at baseline towards the levels of the younger phenotype. This trend is reflected 
in many other genes, where the majority of genes significantly changed by exercise training 
shifted towards ‘younger’ expression levels (325 genes out of 431 in the frail older subjects, 
1106 out of 1395 in the healthy older subjects). Figure 3 shows a heat map of 184 genes that are 
significantly changed by training in both groups and are significant when comparing young 
with either frail or healthy older subjects. Most of these genes shift towards younger levels.
To further analyse the relationship between the 307 genes that are robustly after training 
in both groups changed (q-value < 0.05) we performed sPLS regression to calculate leg exten-
sion 1RM based on gene expression in the baseline samples. The aim was to evaluate whether 
differences in expression of the genes that were changed by training represent the overall 
strength of the muscle at baseline. The samples obtained after training were excluded for this 
analysis. A plot of the predicted leg extension 1RM strength against the measured leg exten-
sion 1RM strength is presented in figure 4. Gene importance for the final model is presented 
in table 6. Cross-validation mean R2 of the model was 0.73, the mean RMSE was 17.7. The 
RMSE for the withheld testing set was 19.1. The top genes contributing to the model include 
genes from the protocadherin gamma gene cluster, CTNNBIP1, C20orf26 (CFAP61), C12orf75 
and USP54. We calculated the eigengene for all protocadherin gamma genes and correlated 
this eigengene with leg extension 1RM. The protocadherin gamma eigengene showed a strong 
direct negative correlation (Pearson r = -0.73) with 1RM leg extension strength. A plot of this 
negative correlation is presented in supplementary figure S7.
dIscussIOn
In this study we compared the transcriptomes of skeletal muscle of healthy young, healthy 
older, and frail older subjects to better understand the skeletal muscle related part of the frail 
phenotype. A schematic overview of our findings is presented in figure 5. To our knowledge 
this is the first study investigating the effect of age on the muscle transcriptome to include 
frail and pre-frail older subjects. We observed clear and pronounced differences at baseline 
between young and older subjects. In our data frailty seems to present itself in the muscle 
transcriptome primarily as a more advanced stage of ageing (see also supplementary figures 
S3 and S4). This may, at least partly, be due to the higher average age of the frail group. There 
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is, however, still significant overlap in age due to the high variation in age in both groups (79.8 
± 8.9, 74.1 ± 4.5 mean age and standard deviation for frail and healthy older subjects respec-
tively, table 1 and 2). 
baseline differences between young and older subjects
There were significant differences in genes related to mitochondrial function and oxida-
tive phosphorylation (supplementary figure S2). It is well known that mitochondrial function 
is impaired in older adults [5] which can be a responsive feature to muscle inactivity [28] and 
mitochondrial protein carbonylation [29]. In this case the average expression of mitochondri-
al genes is lowest in the frail older subjects at baseline. These expression differences may also 
represent a lower abundance of mitochondria [6]. 
There are two genes among the top differentially expressed genes between the three base-
line groups that are as yet unknown, C20orf26 (CFAP61) and C12orf75. Both these genes have 
a higher expression levels in the older subjects and training appears to attenuate expression 
of these genes. Not much is known about the function of CFAP61 except that it is highly ex-
pressed in skeletal muscle tissue and may be related to calcium signalling and/or energy con-
version [30]. C12orf75 may be related to cell proliferation and stem cell signalling [31].
In our data frail subjects showed significantly higher expression levels of METTL21C when 
compared to both the young and healthy older subjects, with a greater fold change difference 
between healthy and frail subjects than between the young and the older subjects (table 5). 
Training decreases the mean expression of METTL21C in both groups, but this does not reach 
significance using our significance cut-off. However, in the frail group it does reach a q-value 
of 0.08 after training, showing a fold change of -1.58. METTL21C encodes for a protein-lysine 
methyltransferase belonging to a group of proteins that are involved in methylation of chap-
erone proteins, where METTL21C appears to methylate HSP70 and HSP90 [32] and has recent-
ly been found to be associated with skeletal muscle development [33]. In vitro inhibition of 
METTL21C expression in myoblasts showed impaired myotube differentiation and calcium 
signalling, suggesting that METTL21C plays an important role in the function of muscle cells 
and possibly also the overall quality of the muscle. 
effect of prolonged resistance-type exercise training
The majority of genes that significantly changed following prolonged resistance-type ex-
ercise training showed a shift in the expression levels towards levels observed in the younger 
group (figure 3). A previous study has shown a similar effect[14]. Indeed, Melov et al. state that 
training reverses the effect of ageing. While there is a shift towards younger expression levels, 
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this does not necessarily mean that there is reversal of ageing. A more likely explanation is 
that the skeletal muscle in these older subjects have been ‘detrained’ due to more sedentary 
lifestyle when compared with healthy younger controls. Physical inactivity is a major contrib-
utor to age-related muscle loss and weakness and is one of the criteria of frailty [2]. In this way 
participation in prolonged resistance-type exercise training is likely to shift gene expression to 
younger levels. Furthermore, in our data the young subjects had higher muscle strength (table 
1). Training leads to subtle but consistent changes in the muscle transcriptome [34]. Thus, a 
shift towards younger expression levels would be consistent with the increased strength after 
more prolonged resistance-type exercise training. 
The genes that shift towards younger expression levels include genes related to the extra-
cellular matrix, vascularisation, glucose metabolism and muscle contraction (supplementary 
figures S2, S5 and S6). The muscle biopsies were taken at least three days after the last train-
ing session. Thus, we are not observing acute effects of a single bout of resistance-type exer-
cise, but rather longer term consistent changes in gene expression. Notably absent among the 
changes induced by prolonged resistance-type exercise training, however, are the primary 
differences observed when we compare young and older subjects: mitochondrial function. 
Possible explanations are that these changes are too subtle to pick up after 24 weeks of re-
sistance-type exercise training or that prolonged resistance-type exercise training does not 
significantly affect these genes. Timing of the muscle biopsies relative to the last training ses-
sion may also be a factor. It may be that expression of these mitochondrial genes only change 
acutely after resistance-type exercise rather than chronically.
Prolonged resistance-type exercise training showed fewer significantly affected genes in 
the frail group. Part of this can be explained by the differences in treatment. The healthy older 
subjects had training sessions three times per week whereas the frail older subjects received 
two sessions per week. The load of the training was also lower in for the frail subjects. Howev-
er, it may also be that the frail are less capable of adapting to the additional stress of prolonged 
resistance-type exercise training. Fortunately, the frail subjects still showed a significant re-
sponse to the training stimulus despite their less adaptive phenotype [2]. Others have already 
reported that older adults in general have a decreased response to resistance-type exercise 
on a transcriptome level [35], and this may also play a role in the smaller response in the frail 
older subjects compared to the healthy older subjects. 
Gene expression and muscle strength
Prolonged resistance-type exercise training led to strength increases in all individuals to the 
point that training increased strength levels in the frail older subjects close to the levels observed 
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in the healthy older subjects at baseline (Figure 1). However, it did not necessarily lead to increas-
es in lean body mass in all individuals (figure 2). This suggests that we primarily observed an in-
crease in muscle quality, cross-bridge cycling efficiency, calcium handling and/or neuromuscular 
adaptation rather than an increase in muscle cross-sectional area. Our data provide evidence 
suggesting disturbances in axon guidance and muscle innervation in the older subjects. 
We performed sPLS regression analysis to calculate leg strength based on expression lev-
els of the genes that are robustly changed after prolonged exercise training in both groups in 
the baseline samples. Our rationale was that since these genes are changed in both groups 
after training, where the leg extension 1RM is significantly higher, that expression of these 
genes could also reflect muscle strength at baseline without training. We were able to build 
a reasonably accurate regression model to calculate leg extension 1RM at baseline based on 
gene expression (mean cross-validation R2 of 0.73 and RMSE of 17.7, figure 4). Thus, expres-
sion of the genes robustly changed by exercise also seems to be indicative of muscle strength, 
not only after training but also prior to prolonged exercise training. This suggests that expres-
sion of these genes may be used as a biomarker to training status prior to study entry.
Several of the most important variables in our sPLS model for muscle strength belonged 
to the protocadherin gene cluster. Genes of the protocadherin gamma gene cluster were sig-
nificantly different between frail older subjects, healthy older subjects and young subjects 
at baseline. Expression of these genes also went down after training in both groups. Older 
subjects had higher expression of this gene than young subjects and expression was highest 
in the frail older subjects. There are good indications that this gene cluster is relevant for neu-
romuscular performance. Many of the genes from this cluster are also significantly changed 
after training in both groups. Protocadherin gamma genes ranked very highly in the variable 
importance for our correlative model for leg extension 1RM (table 6).
Protocadherin gamma genes are primarily expressed in neural tissues such as the brain and 
the spinal cord and appears to be involved in axonal guidance [36]. Protocadherin proteins show 
homeophilic binding to other protocadherin proteins and in this way these proteins provide rec-
ognition sites for axonal binding. By expressing different protocadherin gamma genes from the 
gene cluster axons can be guided to different locations [37]. In knockout mice these genes appear 
to be indirectly related to muscle function: knock-out mice show severe muscle weakness and 
tremors, although this is attributed to loss of spinal motor neurons [38, 39]. It may also be that 
it is expressed at the muscle side of the synapse to facilitate axon guidance towards muscle, and 
increased expression in this case is due to the denervation-reinnervation cycles seen in ageing 
muscle. Therefore, we hypothesise that as muscle loses innervation it increases expression of the 
protocadherin gamma cluster to facilitate axon binding from other nerves.
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Protocadherin gamma is not the only significant group of genes related to neuromuscular 
function that we found in our data. There are several other genes differentially expressed be-
tween frail and healthy older subjects that are related to the innervation of muscle, including 
acetylcholine esterase (AChE) and kyphoscoliosis peptidase (KY). Both play important roles in 
the function of the neuromuscular junction [40, 41]. The top differentially expressed gene at 
baseline, unc-13 homolog C (UNC13C), is involved in neurotransmitter release [42, 43]. Both 
MYLK4 and IGFN1 are also among the top significantly different genes between the three 
groups at baseline. Little is known about MYLK4 and IGFN1, but both have been indirectly 
associated with neuromuscular function. MYLK4 has been shown to be significantly down-
regulated in AChE knockout mice, together with KY, suggesting that it is somehow involved in 
the signal transduction [44]. Like KY, IGFN1 has been associated with both muscle structure 
and neurological function [45, 46]. This gene also binds EEF1A2, which is the gene associated 
with the wasted (Wst) mouse phenotype [46, 47]. This phenotype shows significant immuno-
logical and neuromuscular defects [48]. IGFN1 has many splicing variants, which suggests that 
it plays a pleiotropic role in the muscle. Another indication of denervation is the increased 
expression of the perinatal myosin heavy chain isoform MYH8 in older subjects. Previous 
studies have found that expression of this gene is increased in tissue where the muscle fibres 
have lost innervation [49, 50]. 
cOnclusIOns
Our data suggests a significant remaining plasticity of ageing skeletal muscle to adapt to 
regular resistance type exercise. Many age-related changes in skeletal muscle gene expression 
are partially reversed by prolonged resistance-type exercise training. Expression of the genes 
robustly changed following prolonged resistance-type exercise training in frail and healthy 
older subjects did not only reflect the effect of training itself, but also reflected muscle strength 
at baseline. Expression of the protocadherin gamma gene cluster is negatively correlated with 
muscle strength in our data and may be related to muscle denervation and re-innervation. 
clinical relevance
We have identified a gene cluster that may be related to denervation and re-innervation 
cycles in the muscle. Loss of motor neurons has been suggested to play an important role in 
age-related muscle weakness and sarcopenia, but is unfortunately not yet fully understood. 
Prolonged resistance-type exercise training was able to modulate the expression of proto-
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cadherin gamma. Hence, studying the expression of this gene may provide novel insights on 
whether or not denervation and re-innervation is modulated by interventions or lifestyle fac-
tors such as nutrition and physical activity. Furthermore, in this paper we show that steady-
state gene expression provides information on the strength of the muscle itself. This suggests 
that steady-state gene expression could potentially be used as a tool to provide insight into 
muscle strength of a subject, but theoretically also other muscle health-related factors.
limitations
While we have a large sample size for such a study, we also have a very heterogeneous 
study population. The ratio of male to female among both groups of older adults is not entirely 
equal. We have adjusted for this in our statistical analyses where possible. Another limitation 
is that the muscle biopsies from the frail older adults were obtained from a study performed 
at Wageningen University, whereas the muscle biopsies from the healthy older adults and the 
young adults were obtained from studies performed at Maastricht University. Protocols for 
muscle biopsy collection and preparation in Wageningen are based on those from Maastricht 
and thus are very similar, but there may still be some bias that we cannot account for statis-
tically. The microarray analyses were performed within the same lab at the same time by the 
same technician, which means that batch effects should be minimal. The protocols for the pro-
longed resistance-type exercise training were slightly different for the frail older adults and 
the healthy older adults. The primary difference being that the healthy older adults trained 
three times per week and the frail older adults trained twice per week. As a consequence, the 
training stimulus for the frail older adults was somewhat lower in these individuals and this 
could partially explain the decreased response among the frail older subjects. This difference 
in treatment also prevented us to compare the training responses in both groups directly.
AcknOwledGeMenTs
This project is funded by Top Institute Food and Nutrition, a public-private partnership 
on precompetitive research in food and nutrition. The public partners are responsible for the 
study design, data collection and analysis, decision to publish, and preparation of the man-
uscript. The private partners have contributed to the project through regular discussion. JA 
Timmons is supported by an MRC grant on Human Ageing (G1100015). 
E x p r E s s i o n  o f  p r o t o c a d h E r i n  g a m m a  i n  s k E l E t a l  m u s c l E 
t i s s u E  i s  a s s o c i a t E d  w i t h  a g E  a n d  m u s c l E  w E a k n E s s
35
2
ReFeRences 
1. Lutz W, Sanderson W, Scherbov S: The coming acceleration of global population age-
ing. Nature 2008, 451:716-719.
2. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy 
R, Kop WJ, Burke G, McBurnie MA: Frailty in Older Adults: Evidence for a Pheno-
type. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2001, 
56:M146-M157.
3. Clark BC, Manini TM: Sarcopenia≠ dynapenia. The Journals of Gerontology Series A: 
Biological Sciences and Medical Sciences 2008, 63:829-834.
4. Brook MS, Wilkinson DJ, Phillips BE, Perez-Schindler J, Philp A, Smith K, Atherton PJ: 
Skeletal muscle homeostasis and plasticity in youth and ageing: impact of nutri-
tion and exercise. Acta Physiologica 2015:n/a-n/a.
5. Short KR, Bigelow ML, Kahl J, Singh R, Coenen-Schimke J, Raghavakaimal S, Nair KS: De-
cline in skeletal muscle mitochondrial function with aging in humans. Proceedings 
of the National Academy of Sciences of the United States of America 2005, 102:5618-5623.
6. Evans WJ, Lexell J: Human aging, muscle mass, and fiber type composition. The Jour-
nals of Gerontology Series A: Biological Sciences and Medical Sciences 1995, 50:11-16.
7. Breen L, Phillips SM: Skeletal muscle protein metabolism in the elderly: interven-
tions to counteract the’anabolic resistance’of ageing. Nutrition & metabolism 2011, 
8:68.
8. Cuthbertson D, Smith K, Babraj J, Leese G, Waddell T, Atherton P, Wackerhage H, Taylor 
PM, Rennie MJ: Anabolic signaling deficits underlie amino acid resistance of wast-
ing, aging muscle. The FASEB Journal 2005, 19:422-424.
9. Snijders T, Verdijk LB, van Loon LJ: The impact of sarcopenia and exercise training 
on skeletal muscle satellite cells. Ageing research reviews 2009, 8:328-338.
10. Lexell J: Evidence for nervous system degeneration with advancing age. The Journal 
of nutrition 1997, 127:1011S-1013S.
11. Brooks SV, Faulkner JA: Skeletal muscle weakness in old age: underlying mecha-
nisms. Medicine and science in sports and exercise 1994, 26:432-439.
12. Morley JE: Editorial: sarcopenia revisited. The Journals of Gerontology Series A: Biolog-
ical Sciences and Medical Sciences 2003, 58:M909-M910.
13. Arent S, Landers D, Etnier J: The Effects of Exercise on Mood in Older Adults: A Me-
ta-Analytic. Journal of Ageing and Physical Activity 2000, 8:407-430.
14. Melov S, Tarnopolsky MA, Beckman K, Felkey K, Hubbard A: Resistance exercise re-
verses aging in human skeletal muscle. PLoS One 2007, 2:e465.
36
15. Tieland M, Dirks ML, van der Zwaluw N, Verdijk LB, van de Rest O, de Groot LCPGM, 
van Loon LJC: Protein Supplementation Increases Muscle Mass Gain During Pro-
longed Resistance-Type Exercise Training in Frail Elderly People: A Randomized, 
Double-Blind, Placebo-Controlled Trial. Journal of the American Medical Directors As-
sociation 2012, 13:713-719.
16. Leenders M, Verdijk LB, Van der Hoeven L, Van Kranenburg J, Nilwik R, Wodzig WKWH, 
Senden JMG, Keizer HA, Van Loon LJC: Protein supplementation during resis-
tance-type exercise training in the elderly. Medicine and science in sports and exercise 
2013, 45:542-552.
17. Tieland M, van de Rest O, Dirks ML, van der Zwaluw N, Mensink M, van Loon LJC, de 
Groot LCPGM: Protein Supplementation Improves Physical Performance in Frail 
Elderly People: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of 
the American Medical Directors Association 2012, 13:720-726.
18. Wall BT, Hamer HM, de Lange A, Kiskini A, Groen BB, Senden JM, Gijsen AP, Verdijk LB, 
van Loon LJ: Leucine co-ingestion improves post-prandial muscle protein accretion 
in elderly men. Clinical nutrition 2013, 32:412-419.
19. Leenders M, Verdijk LB, van der Hoeven L, van Kranenburg J, Nilwik R, van Loon LJ: 
Elderly men and women benefit equally from prolonged resistance-type exercise 
training. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 
2013, 68:769-779.
20. Gorissen SH, Burd NA, Hamer HM, Gijsen AP, Groen BB, van Loon LJ: Carbohydrate 
coingestion delays dietary protein digestion and absorption but does not modulate 
postprandial muscle protein accretion. The Journal of Clinical Endocrinology & Metab-
olism 2014, 99:2250-2258.
21. Piccolo SR, Sun Y, Campbell JD, Lenburg ME, Bild AH, Johnson WE: A single-sample 
microarray normalization method to facilitate personalized-medicine workflows. 
Genomics 2012, 100:337-344.
22. Smyth GK: Limma: linear models for microarray data. In Bioinformatics and compu-
tational biology solutions using R and Bioconductor. Springer; 2005: 397-420
23. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and pow-
erful approach to multiple testing. Journal of the Royal Statistical Society Series B 
(Methodological) 1995:289-300.
24. Kuhn M: Building predictive models in R using the caret package. Journal of Statisti-
cal Software 2008, 28:1-26.
25. Husson F, Josse J, Le S, Mazet J: FactoMineR: multivariate exploratory data analysis 
and data mining with R. R package version 2013, 1:102-123.
E x p r E s s i o n  o f  p r o t o c a d h E r i n  g a m m a  i n  s k E l E t a l  m u s c l E 
t i s s u E  i s  a s s o c i a t E d  w i t h  a g E  a n d  m u s c l E  w E a k n E s s
37
2
26. Wickham H: ggplot2: elegant graphics for data analysis. Springer; 2009.
27. Warnes GR, Bolker B, Bonebakker L, Gentleman R, Huber W, Liaw A, Lumley T, Mae-
chler M, Magnusson A, Moeller S: gplots: Various R programming tools for plotting 
data. R package version 2009, 2.
28. Steinbacher P, Feichtinger RG, Kedenko L, Kedenko I, Reinhardt S, Schönauer A-L, Leit-
ner I, Sänger AM, Stoiber W, Kofler B: The Single Nucleotide Polymorphism Gly482Ser 
in the PGC-1α Gene Impairs Exercise-Induced Slow-Twitch Muscle Fibre Transfor-
mation in Humans. 2015.
29. Valls MRB, Wilkinson DJ, Narici MV, Smith K, Phillips BE, Caporossi D, Atherton PJ: Pro-
tein carbonylation and heat shock proteins in human skeletal muscle: relation-
ships to age and sarcopenia. The Journals of Gerontology Series A: Biological Sciences 
and Medical Sciences 2014:glu007.
30. Dymek EE, Smith EF: A conserved CaM- and radial spoke–associated complex medi-
ates regulation of flagellar dynein activity. The Journal of Cell Biology 2007, 179:515-
526.
31. Kikuchi K, Fukuda M, Ito T, Inoue M, Yokoi T, Chiku S, Mitsuyama T, Asai K, Hirose T, Aiza-
wa Y: Transcripts of unknown function in multiple-signaling pathways involved in 
human stem cell differentiation. Nucleic Acids Research 2009, 37:4987-5000.
32. Cloutier P, Lavallée-Adam M, Faubert D, Blanchette M, Coulombe B: A Newly Uncov-
ered Group of Distantly Related Lysine Methyltransferases Preferentially Interact 
with Molecular Chaperones to Regulate Their Activity. PLoS Genet 2013, 9:e1003210.
33. Huang J, Hsu Y-H, Mo C, Abreu E, Kiel DP, Bonewald LF, Brotto M, Karasik D: METTL21C 
Is a Potential Pleiotropic Gene for Osteoporosis and Sarcopenia Acting Through 
the Modulation of the NF-κB Signaling Pathway. Journal of Bone and Mineral Research 
2014, 29:1531-1540.
34. Egan B, Zierath Juleen R: Exercise Metabolism and the Molecular Regulation of Skel-
etal Muscle Adaptation. Cell Metabolism 2013, 17:162-184.
35. Raue U, Trappe TA, Estrem ST, Qian H-R, Helvering LM, Smith RC, Trappe S: Transcrip-
tome signature of resistance exercise adaptations: mixed muscle and fiber type specific 
profiles in young and old adults.2012.
36. Chen WV, Alvarez FJ, Lefebvre JL, Friedman B, Nwakeze C, Geiman E, Smith C, Thu CA, 
Tapia JC, Tasic B: Functional significance of isoform diversification in the protocad-
herin gamma gene cluster. Neuron 2012, 75:402-409.
37. Chen WV, Maniatis T: Clustered protocadherins. Development 2013, 140:3297-3302.
38. Wang X, Weiner JA, Levi S, Craig AM, Bradley A, Sanes JR: Gamma protocadherins are 
required for survival of spinal interneurons. Neuron 2002, 36:843-854.
38
39. Weiner JA, Wang X, Tapia JC, Sanes JR: Gamma protocadherins are required for syn-
aptic development in the spinal cord. Proceedings of the National Academy of Sciences 
of the United States of America 2005, 102:8-14.
40. Fischbach GD, Frank E, Jessell TM, Rubin LL, Schuetze SM: Accumulation of acetylcho-
line receptors and acetylcholinesterase at newly formed nerve-muscle synapses. 
Pharmacological Reviews 1978, 30:411-428.
41. Blanco G, Coulton GR, Biggin A, Grainge C, Moss J, Barrett M, Berquin A, Maréchal G, 
Skynner M, van Mier P: The kyphoscoliosis (ky) mouse is deficient in hypertrophic 
responses and is caused by a mutation in a novel muscle-specific protein. Human 
molecular genetics 2001, 10:9-16.
42. Basu J, Betz A, Brose N, Rosenmund C: Munc13-1 C1 Domain Activation Lowers the Ener-
gy Barrier for Synaptic Vesicle Fusion. The Journal of Neuroscience 2007, 27:1200-1210.
43. Brose N, Rosenmund C, Rettig J: Regulation of transmitter release by Unc-13 and its 
homologues. Current Opinion in Neurobiology 2000, 10:303-311.
44. Lin H-Q, Choi R, Chan K-L, Ip D, Tsim KW-k, Wan DC-c: Differential gene expression pro-
filing on the muscle of acetylcholinesterase knockout mice: A preliminary analysis. 
Chemico-Biological Interactions 2010, 187:120-123.
45. Baker J, Riley G, Romero MR, Haynes AR, Hilton H, Simon M, Hancock J, Tateossian H, 
Ripoll VM, Blanco G: Identification of a Z-band associated protein complex involving 
KY, FLNC and IGFN1. Experimental Cell Research 2010, 316:1856-1870.
46. Mansilla F, Dominguez CAG, Yeadon JE, Corydon TJ, Burden SJ, Knudsen CR: Translation 
elongation factor eEF1A binds to a novel myosin binding protein-C-like protein. Jour-
nal of Cellular Biochemistry 2008, 105:847-858.
47. Chambers DM, Peters J, Abbott CM: The lethal mutation of the mouse wasted (wst) is 
a deletion that abolishes expression of a tissue-specific isoform of translation elon-
gation factor 1α, encoded by the Eef1a2 gene. Proceedings of the National Academy of 
Sciences 1998, 95:4463-4468.
48. Newbery HJ, Gillingwater TH, Dharmasaroja P, Peters J, Wharton SB, Thomson D, Rib-
chester RR, Abbott CM: Progressive loss of motor neuron function in wasted mice: 
effects of a spontaneous null mutation in the gene for the eEF1A2 translation factor. 
Journal of Neuropathology & Experimental Neurology 2005, 64:295-303.
49. Schiaffino S, Gorza L, Pitton G, Saggin L, Ausoni S, Sartore S, Lømo T: Embryonic and 
neonatal myosin heavy chain in denervated and paralyzed rat skeletal muscle. De-
velopmental biology 1988, 127:1-11.
50. Sun H, Li M, Gong L, Liu M, Ding F, Gu X: iTRAQ-coupled 2D LC–MS/MS analysis on 
differentially expressed proteins in denervated tibialis anterior muscle of Rattus 
norvegicus. Molecular and Cellular Biochemistry 2012, 364:193-207.
E x p r E s s i o n  o f  p r o t o c a d h E r i n  g a m m a  i n  s k E l E t a l  m u s c l E 
t i s s u E  i s  a s s o c i a t E d  w i t h  a g E  a n d  m u s c l E  w E a k n E s s
39
2
Table1. Subject characteristics of the baseline only subjects 
  FE HE YO 
N (male / female) 24 / 6 27 / 5 53 / 0 
Age (years) 79.8 ± 8.9 74.1 ± 4.5 21.3 ± 2.4 
Height (m) 1.71 ± 0.09 1.73 ± 0.08 1.84 ± 0.06 
Weight (kg) 80 ± 12.4 75.9 ± 12.9 76.5 ± 10.3 
BMI (kg / m2) 27.3 ± 4.2 25.2 ± 3.2 22.6 ± 3 
Body Fat (%) 28.8 ± 7.2 23.4 ± 5.5 15.4 ± 4.6 
Lean Mass (kg) 52.1 ± 6.3 55.5 ± 8.6 61.9 ± 6 
Leg Extension 1RM (kg) 65 ± 20 68 ± 17 124 ± 20 
Leg Press 1RM (kg) 127 ± 31 155 ± 41 203 ± 36 
Mean±SD, FE=frail older subjects, HE=healthy older subjects, YO=young male subjects. 
 
 
 
Table1. Subject characteristics of the baseline only subjects
Table 2. Subject characteristics of the subjects with before and after samples. 
 
Table 2. Subject characteristics of the subjects with before and after samples.  
  FE pre FE post HE pre HE post 
N (male / female) 11 / 20 
 
26 / 15 
 Age (years) 76.5 ± 7.0 
 
69.9 ± 5.0 
 Height (m) 1.66 ± 0.09 
 
1.71 ± 0.09 
 Weight (kg) 78.5 ± 13.6 79.6 ± 14.1* 76.7 ± 13.2 77.1 ± 13.2 
BMI (kg / m2) 28.5 ± 4.1 29 ± 4.3 * 26.1 ± 2.8 26.2 ± 2.8 
Body Fat (%) 36.7 ± 8.5 36.6 ± 8.8  25.9 ± 5.9 24.4 ± 5.9 * 
Lean Mass (kg) 46.1 ± 10.0 46.9 ± 9.9 * 54.6 ± 11.1 56.0 ± 11.3 * 
Leg Extension 1RM (kg) 59 ± 18 81 ± 24 * 81 ± 17 114 ± 23 * 
Leg Press 1RM (kg) 130 ± 35 178 ± 49 * 179 ± 40 230 ± 50 * 
FE = frail older subjects, HE = healthy older subjects, YO = young male subjects. * indicates a significant effect 
of resistance-type exercise training (p < 0.05). 
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Table 3.Top 20 genes significantly different between young and old. Table 3.Top 20 genes significantly different between young and old.  
Gene FC FE vs. HE FC FE vs. YO FC HE vs. YO q-value FE vs. HE q-value FE vs. YO q-value HE vs. YO 
IGFN1 -1.12 -6.43 -5.71 0.64 0.00 0.00 
UNC13C 1.07 6.20 5.78 0.60 0.00 0.00 
MYLK4 -1.35 -5.13 -3.81 0.07 0.00 0.00 
C12orf75 1.45 4.54 3.13 0.01 0.00 0.00 
SLC38A1 -1.11 -3.50 -3.14 0.55 0.00 0.00 
HCN1 1.16 3.36 2.90 0.30 0.00 0.00 
MYH8 1.16 3.28 2.83 0.50 0.00 0.00 
C20orf26 1.36 3.39 2.49 0.00 0.00 0.00 
NR4A3 -1.86 -3.70 -2.00 0.02 0.00 0.00 
FAM83B 1.11 2.91 2.63 0.39 0.00 0.00 
DAAM2 -1.06 -2.51 -2.36 0.42 0.00 0.00 
NNMT 1.33 2.71 2.04 0.03 0.00 0.00 
ZNF382 1.21 -2.09 -2.54 0.05 0.00 0.00 
TPPP3 1.33 2.62 1.97 0.01 0.00 0.00 
COL28A1 1.07 2.36 2.20 0.42 0.00 0.00 
METTL21EP 1.05 -2.19 -2.29 0.78 0.00 0.00 
HIST1H3E 1.11 -2.08 -2.30 0.30 0.00 0.00 
SNORD115-32 1.02 2.17 2.14 0.91 0.00 0.00 
SERPINA5 1.04 -2.11 -2.19 0.89 0.00 0.00 
METTL21C 1.98 2.84 1.44 0.00 0.00 0.03 
FE = frail older subjects, HE = healthy older subjects, YO = young men. 
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Table 4. Top 20 genes significantly different between the frail 
elderly and the healthy elderly at baseline. 
Table 4. Top 20 genes significantly different between the frail  
elderly and the healthy elderly at baseline.  
Gene FC FE vs. HE q-value FE vs. HE 
METTL21C 1.98 0.00 
NR4A3 -1.86 0.02 
VTRNA1-1 -1.71 0.00 
MIR206 1.58 0.00 
SNORA38B -1.58 0.00 
S100A8 1.51 0.04 
FRZB -1.48 0.03 
HES1 -1.47 0.00 
P2RY13 1.46 0.00 
MIR133B 1.45 0.01 
C12orf75 1.45 0.01 
SNORA60 -1.44 0.00 
SNORD60 -1.43 0.00 
LYZ 1.43 0.03 
SNORD80 -1.42 0.00 
SNORD82 -1.42 0.00 
SNORD29 -1.41 0.00 
EVI2B 1.40 0.01 
UPK3A -1.40 0.00 
ID1 -1.40 0.00 
FE = frail older subjects, HE = healthy older subjects. 
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Table 5. Top 20 genes significantly different in both frail elderly and healthy elderly subjects after training.  
Gene FC FE training FC HE training q-value FE training q-value HE training 
FRZB 1.97 1.55 0.00 0.00 
IGFN1 1.58 1.80 0.04 0.00 
MYLK4 1.45 1.69 0.01 0.00 
COL3A1 1.45 1.68 0.01 0.00 
ANKRD2 -1.44 -1.61 0.01 0.00 
THBS4 1.34 1.66 0.05 0.00 
PFKFB3 1.61 1.38 0.01 0.01 
COL4A1 1.35 1.46 0.00 0.00 
CAPN6 1.37 1.45 0.03 0.00 
COL1A2 1.35 1.45 0.03 0.00 
EDNRB 1.24 1.56 0.01 0.00 
GCNT2 -1.51 -1.28 0.00 0.00 
C20orf26 -1.24 -1.54 0.03 0.00 
C12orf75 -1.42 -1.33 0.01 0.00 
CCDC80 1.34 1.40 0.03 0.00 
OLFML2B 1.38 1.34 0.00 0.00 
SPARC 1.28 1.44 0.00 0.00 
COL4A2 1.32 1.37 0.00 0.00 
LGI1 -1.31 -1.33 0.02 0.00 
ACOT11 -1.30 -1.34 0.04 0.00 
FE = frail older subjects, HE = healthy older subjects. 
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Table 6. Variable importance and coefficients of the top 20 variables for the sPLS model. 
Gene Variable Importance Coefficient 
C20orf26 100 -1.93835 
PCDHGA10 99.3099 -0.828 
PCDHGB5 97.59634 -1.17955 
PCDHGB1 95.06749 -1.02454 
CTNNBIP1 91.85769 1.12848 
USP54 90.58105 -0.85727 
PCDHGA8 83.51363 -0.91253 
PCDHGB7 82.41083 -0.80005 
MYOZ2 81.3163 -0.61206 
PCDHGA11 78.54377 -0.6435 
C12orf75 78.18419 -0.82036 
PCDHGA7 77.82971 -0.85683 
PCDHGA2 76.42625 -0.91682 
HEXIM2 75.94954 0.241251 
GRSF1 75.24609 0.38796 
GCNT2 75.11434 -1.0698 
FBP2 72.2918 0.262855 
PLEKHO1 68.54881 0.238599 
CRY2 68.13805 -1.59754 
PABPC4 67.4792 0.848579 
 
Table 6. Variable importance and coefficients of the top 20 variables for the sPLS model.
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Figure 1. A and B – Change of leg extension 1RM after prolonged exercise training for each individual. Left are frail elderly 
subjects, right are healthy elderly subjects.  
 
 
Figure 1. A and B – Change of leg extension 1RM after prolonged exercise training for each 
individual. Left are frail elderly subjects, right are healthy elderly subjects. 
 
 
 
Figure 2A and B. Change of lean body mass after prolonged exercise training for each individual. Left are frail 
older subjects, right are healthy older subjects. 
 
 
Figure 2. A and B. Change of lean body mass after prolonged exercise training for each 
individual. Left are frail older subjects, right are healthy older subjects.
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Figure 3. Heatmap of 184 genes that are significantly different between young and older subjects, and are 
significantly changed by prolonged resistance-type exercise training in both groups.  
 
Figure 3. Heatmap of 184 genes that are significantly different between young and older subjects, and are 
significantly changed by prolonged resistance-type exercise training in both groups. 
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Figure 4. Scatter plot of predicted leg extension 1RM of the baseline samples using sPLS and the actual 
measured 1RM. Red dots indicate samples that were part of the testing data set (25% of the total data set).  
 
Figure 4. Scatter plot of predicted leg extension 1RM of the baseline samples using sPLS and the actual 
easured 1RM. Re  dots indicate samples that were part of the testing data set (25% of th  total data set). 
Figure 5. Schematic summary of our findings. 
 
 
Figure 5. Schematic summary of our findings.  
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suPPleMenTARy MATeRIAl
Figure s1A.Venn diagram of significant genes (q-value < 0.05) changed after prolonged exercise training in frail (FE 
– training, green) and healthy older subjects (HE – training, red). FE vs HE are genes significantly different at baseline 
between frail and healthy older subjects (blue). 
Figure s1b. Venn diagram of significant genes (q-value < 0.05) at baseline between the young (YO) group and 
both frail (FE) and healthy older subjects (HE). Due to the high number of significant genes with relatively small 
differences an additional fold-change cut-off was used for these data (fold change > 1.2).
 
 
Figure S1A.Venn diagram of significant genes (q-value < 0.05) changed after prolonged exercise training in 
frail (FE – training, green) and healthy older subjects (HE – training, red). FE vs HE are genes significantly 
different at baseline between frail and healthy older subjects (blue).  
 
 
Figure S1B. Venn diagram of significant genes (q-value < 0.05) at baseline between the young (YO) group and 
both frail (FE) and healthy older subjects (HE). Due to the high number of significant genes with relatively small 
differences an additional fold-change cut-off was used for these data (fold change > 1.2). 
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Figure S2. Top 40 (by p-value) significantly changed canonical pathways from Ingenuity Pathway Analysis. 
First two columns represent the prolonged exercise training effect in frail (FE) and healthy (HE) older subjects. 
Last three columns represent baseline differences between frail older subjects (FE), healthy older subjects (HE), 
and young subjects (YO). Colours indicate significance. 
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Figure s2. Top 40 (by p-value) significantly changed canonical pathways from Ingenuity Pathway Analysis. First two 
columns represent the prolonged exercise training effect in frail (FE) and healthy (HE) older subjects. Last three 
columns represent baseline differences between frail older subjects (FE), healthy older subjects (HE), and young 
subjects (YO). Colours indicate significance.
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Figure s3. PCA of all UPC filtered genes for all groups, before and after prolonged 
exercise training. Ellipses indicate 95% confidence interval.
 
Figure S3. PCA of all UPC filtered genes for all groups, before and after prolonged exercise training. Ellipses 
indicate 95% confidence interval. 
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Figure S4.PCA of 307 exercise responsive genes for all groups, before and after prolonged exercise training. 
Ellipses indicate 95% confidence interval. 
 
Figure s4.PCA of 307 exercise responsive genes for all groups, before and after prolonged 
exercise training. Ellipses indicate 95% confidence interval.
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Figure s5. Top 40 (by score) significant upstream regulators from Ingenuity Pathway Analysis. 
First two columns represent the prolonged exercise training effect in frail (FE) and healthy (HE) 
older subjects. Last three columns represent baseline differences between frail older subjects (FE), 
healthy older subjects (HE), and young subjects (YO). Colours indicate predicted activation.
 
 
Figure S5. Top 40 (by score) significant upstream regulators from Ingenuity Pathway Analysis. First two 
columns represent the prolonged exercise training effect in frail (FE) and healthy (HE) older subjects. Last three 
columns represent baseline differences between frail older subjects (FE), healthy older subjects (HE), and young 
subjects (YO). Colours indicate predicted activation. 
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Figure s6. Top 40 (by score) significantly changed diseases and functions from Ingenuity Pathway Analysis. First 
two columns represent the prolonged exercise training effect in frail (FE) and healthy (HE) older subjects. Last three 
columns represent baseline differences between frail older subjects (FE), healthy older subjects (HE), and young 
subjects (YO). Colours indicate predicted activation.
 
 
Figure S6. Top 40 (by score) significantly changed diseases and functions from Ingenuity Pathway Analysis. 
First two columns represent the prolonged exercise training effect in frail (FE) and healthy (HE) older subjects. 
Last three columns represent baseline differences between frail older subjects (FE), healthy older subjects (HE), 
and young subjects (YO). Colours indicate predicted activation. 
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Figure s7. Negative Correlation between the PCDHG gene cluster (eigengene as calculated 
using the NIPALS algorithm) and leg extension 1RM. 
 
Figure S7.Negative Correlation bet een the PC  gene cluster (eigengene as calculated using the NIPALS 
algorithm) and leg extension 1RM.  
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AbsTRAcT
Populations around the world are aging rapidly and concomitant loss of physiological 
functions negatively affects quality of life at older age. A major contributor to the frailty syn-
drome of ageing is loss of skeletal muscle. In this study we assessed the skeletal muscle biopsy 
metabolome of healthy young, healthy older and frail older subjects to determine the effect 
of age and frailty on the metabolic signature of skeletal muscle tissue. Moreover, effects of 
prolonged whole-body resistance type exercise training on the muscle biopsy metabolome 
of older subjects were examined. The baseline metabolome was measured in muscle biop-
sies collected from 30 young, 66 healthy older subjects and 43 frail older subjects. Follow-up 
samples from frail older (24 samples) and healthy older subjects (38 samples) were collected 
after 6 months of prolonged resistance-type exercise training. Young subjects were included 
in order to have a reference for expected shifts of the older towards a younger metabolic phe-
notype. Primary differences in skeletal muscle metabolite levels between young and healthy 
older subjects were related to mitochondrial function, fiber type, and tissue turnover. Simi-
lar differences were observed when comparing frail with healthy older subjects. Prolonged 
resistance-type exercise training revealed a correlative adaptive response of amino acids, 
especially branched chain amino acids, and genes related to tissue remodeling. The impact 
of exercise on branched chain amino acids derived acylcarnitines in older subjects points 
to a downward shift in branched chain amino acid catabolism upon training. We observed 
modest correlations between muscle metabolite and plasma levels. This prohibits the use of 
the latter as read-outs of muscle metabolism and stresses the need for direct assessment in 
muscle tissue biopsies. 
KEYWORDS: muscle biopsy, frailty, aging, tissue remodeling
T h e  m u s c l e  m e T a b o l o m e  d i f f e r s  b e T w e e n  h e a l T h y 
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inTroducTion
Populations around the world are aging rapidly and concomitant loss of physiological 
functions compromises independence at older age. It has been estimated that people older 
than 60 y will make up 22% of the world population and people older than 80 y will account 
for 4.4% of the world population in 2050 [1]. A major contributor to the frailty syndrome of 
ageing is skeletal muscle loss, which can lead to increased disability in the older population. 
In most people muscle mass and strength start to decline around the age of 35 y with more 
progressive muscle loss observed after the age of 65 y [2-6].
From a recent study [7] we learned that prolonged resistance-type exercise training par-
tially shifts the skeletal muscle transcriptome of older subjects toward an expression pattern 
observed in muscle tissue of young subjects, with changes in gene expression related to vas-
cularisation, tissue remodelling and glucose metabolism. We hypothesize a similar shift to-
wards the young phenotype in the muscle metabolome after resistance-type exercise training 
in older subjects. The transcriptome analysis also revealed substantial differences between 
healthy young men, healthy older subjects and frail older subjects before any intervention 
was undertaken. Particularly genes related to mitochondrial function were downregulated in 
older subjects compared to young. 
Although the effects at gene expression level are expected to be reflected in metabolic reg-
ulation, our insights are limited to only few studies, mostly in animals. Recent work showed 
that ageing affects glucose and fatty acid metabolism in muscle of mice [8]. A study on aged 
rats suggests a muscle group-specific perturbation of lipid and glucose metabolism consistent 
with mitochondrial dysfunction [9]. A recent study in humans showed that lipid content and 
oxidative activity in skeletal muscle are related to muscle fiber type in ageing and metabol-
ic syndrome [10]. Another human study showed that upon training mitochondrial function 
and intermediary metabolism were reprogrammed in insulininsensitive obese subjects [11]. 
Within these human studies the deployed metabolic profiling platforms had limited coverage 
and focused on specific sub-metabolomes. 
A major bottleneck in achieving extended coverage was the limited amount of muscle tissue 
material that can be obtained from human studies. The recent development of a comprehen-
sive targeted metabolic profiling platform [12] optimized and validated for small muscle biopsies 
paved the way to understand the observed phenotypical differences at a more comprehensive 
level. Here we establish the effect of aging and frailty on the skeletal muscle metabolome. We 
further examine the impact of prolonged resistance-type exercise training on the metabolome of 
frail and healthy older subjects. We included a population of young subjects in our study in order 
to have a reference for expected shifts of the older towards a younger metabolic phenotype. 
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MATeRIAls And MeThOds
experimental design
Muscle biopsies (Vastus lateralis) and circulating metabolites samples were collected from 
pre-frail, frail older [13, 14], healthy older [15, 16] and young subjects [17]. Medical history of 
all subjects was evaluated by medical questionnaires which were analyzed by a physician. 
Subjects who were unable to participate in the training due to pain, were excluded prior to 
starting the intervention. Included subjects who showed severe discomfort during the train-
ing sessions were excluded from further participation in the study. Baseline metabolite levels 
were measured in skeletal muscle tissue of 30 young, 66 healthy and 43 frail older subjects 
(Table 1). We also measured metabolites in plasma and serum for 50 young, 76 healthy and 62 
frail older subjects (Supplementary Table S1). The transcriptome of our muscle biopsy set was 
measured in an earlier study[7]. 
 Samples from healthy young male subjects were derived from several studies performed 
within our group, in which exactly the same technique and processing was used for sample 
collection. We used young male subjects as a reference group and samples were only taken 
at baseline. Samples from the frail and healthy older subjects were obtained from two study 
centers. More details of the studies can be found in the respective papers [13, 16]. 
In addition, muscle biopsies were obtained after 6 months of resistance-type exercise 
training for 38 healthy and 24 frail older subjects. All muscle biopsies and circulating metab-
olites samples were obtained in the morning, in an overnight fasted state, after standardized 
meal the evening before, and no strenuous physical activity for 3 days prior to muscle biopsy 
collection. 
Fried criteria [18] were used to assess the frailty in older subjects, in which frailty is 
viewed in terms of the unintentional weight loss, weakness, self-reported exhaustion, slow 
walking speed, and low physical activity. Based on the above mentioned criteria, the healthy 
older subjects were not considered frail or pre-frail at the start of the intervention study [19].
In our study population, all older subjects regardless of their health status (frail or healthy) 
improved in muscle performance following 6 months resistance-type exercise training (Sup-
plementary Figure S1 Table S2 ) as illustrated by significantly increased leg extension and 
leg press strength after training (P-value < 0.01) [7, 13, 19]. Both healthy older and frail older 
subjects followed similar progressive full-body resistance type exercise training. In brief, the 
training consisted of a 5 minute warm-up on a cycle ergometer, followed by 4 sets on the leg-
press and leg-extension machines. In addition, 3 sets on chest press, lat pulldown, ped-dec and 
vertical row machines were performed (Technogym, Rotterdam, The Netherlands).However, 
the healthy older subjects trained 3 times per week and frail subjects trained 2 times per week. 
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Moreover, subjects received a protein or control supplement during the study. Healthy older 
subjects took 15 gram milk protein or control drink at breakfast and frail older subjects took a 
similar 15 gram drink (milk protein or control) at breakfast and lunch every day throughout 
the entire 6 months intervention. Full details can be found in the earlier papers on the phe-
notypical impact of training on our study population [13, 19].All studies were approved by 
The Medical Ethics Committee of either Wageningen University or Maastricht University and 
comply with the Declaration of Helsinki.
Metabolomics analysis of circulating metabolites
Amino acids and biogenic amines were derivatized (Acc-Tag) in 5 µL aliquots of plas-
ma. Samples were analyzed using an ACQUITY UPLC system with autosampler (Waters, Et-
ten-Leur, The Netherlands) coupled with a Xevo Tandem quadrupole mass spectrometer (Wa-
ters) operated using QuanLynx data acquisition software (version 4.1; Waters). An Accq-Tag 
Ultra column (Waters) was used. The Xevo TQ was used in the positive-ion electrospray mode 
and all analytes were monitored in Multiple Reaction Monitoring (MRM) using nominal mass 
resolution. Acquired data were evaluated using TargetLynx software (Waters), by integration 
of assigned MRM peaks and normalization using proper internal standards[20].
Acylcarnitines, trimethylamine-N-oxide, choline, betaine, deoxycarnitine and carnitine 
were analyzed in 5 µL plasma, spiked with an internal standard, using a UPLC-MS/MS. Also 
here an Accq-Tag Ultra column was used. The Xevo TQ was used in the positive-ion electro-
spray mode and all analytes were monitored in Multiple Reaction Monitoring (MRM) using 
nominal mass resolution. In-house developed algorithms [21] were applied using the pooled 
QC samples to compensate for shifts in the sensitivity of the mass spectrometer over the batch.
Organic acids were measured by GC-MS using 50 µL of plasma sample prepared using a 
two-step derivatization procedure with subsequent oximation using methoxyamine hydro-
chloride (MeOX) and silylation using N-Methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA. 
Samples were measured on an Agilent GC (7890A) coupled to Agilent Quadrupole-MS with EI 
source (Agilent MSD 5975C). Separation was performed using a HP-5MS column (30 m x 0.25 
m x 0.25 μm; Agilent). The raw data were pre-processed using Agilent MassHunter Quanti-
tative Analysis software for GC-MS (Agilent, Version B.04.00), and quantitation of metabolite 
response was calculated as the peak area ratios of the target analyte to the respective internal 
standard. In-house developed algorithms were applied using the pooled QC samples to com-
pensate for shifts in the sensitivity of the mass spectrometer over the batch. Serum metabolite 
concentrations determined by NMR were measured as described by Mihaleva et al. [22]. In 
short, serum samples were ultrafiltrated and automated quantum mechanical line shape fit-
ting of 1H NMR spectra was performed using PERCH.
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In tissue metabolome analysis
Metabolites were extracted from 10 mg of wet muscle tissue. This tissue was further lyo-
philized and weighted to determine the dry tissue mass. After pulverizing the tissue, metabo-
lites were extracted using methanol/chloroform/water (MCW). The extraction method used in 
this study has extensively been described and characterized elsewhere [12]. 
Amines, acylcarnitines and oxylipins were measured using the platforms also used for 
measurement of these metabolites in plasma. The validation of these methods for human tis-
sue biopsies is described in detail elsewhere [21]. To compensate for shifts in the sensitivity 
of the mass spectrometer over multiple batches of measurements, in-house developed algo-
rithms were applied [21]. The metabolite response was determined by the peak area ratio of 
the target analyte to the appropriate internal standard. These response ratios were used in the 
subsequent data analysis. ATP, ADP, creatine and phosphocreatine were determined spectro-
photometrically using established enzymatic assays. For the first 3 metabolites, commercially 
available fluorimetric assay kits were used (BioVision cat.# K354-100, K355-100 and K635-100) 
following the manufacturer’s instructions. Phosphocreatine was measured according to a 
colorimetric assay kit protocol described by Szas et al.[23]. In total 96 metabolites including 
amine, acylcarnitines, organic acids, oxylipins and a number of nucleotides were measured. 
statistical analysis
Statistical analysis was performed on log-transformed data. We used analysis of variance 
(ANOVA) for between group comparisons at baseline. P-value<0.05 was considered signifi-
cant. We used linear mixed models for assessment of the training effect. Our model included 
exercise training, subject, sex, protein supplementation and within subject correlation. Anal-
yses of the training effect was performed separately for frail and healthy older subjects due 
to differences in training frequency. To summarize acylcarnitines into one single metabolite 
(eigen metabolite), the Non-linear Iterative partial least squares (NIPALS) algorithm [24] of the 
mixOmics R library was used to calculate the Singular Value Decomposition (SVD) of acylcar-
nitines. The mixOmics R library was used to perform multilevel sparse partial least squares 
(sPLS) [25, 26]for integration of metabolomics and transcriptomics. A canonical correlation 
cut-off of 0.80 was used for building the network. FactoMineR was used to perform principal 
component analysis (PCA) [27]. All analyses were done using R (version 3.02). 
ASCA (ANOVA Simultaneous Component Analysis) was performed to determine global dif-
ferences on metabolites. ASCA is a multivariate method that partitions variation in the data and 
enables to interpret these partitions by simultaneous component analysis [28]. Analysis was per-
formed separately for the frail and healthy older subjects, using delta values of each metabolite 
for each individual (value after training - value before training) with supplement, sex and their 
interaction in the model as factors. Analysis was done under Matlab  (version R2012a).
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resuLTs
Baseline comparisons between healthy older, frail older and young subjects
Comparison of the circulating metabolites profiles of young and healthy older subjects 
revealed a range of metabolites that differed significantly between both groups. Analysis of 
variance (ANOVA) showed that amino acids and acylcarnitines were responsible for the main 
differences in circulating metabolites between older and young subjects. These differences 
were in line with previous observations of age-related effects on the circulating metabolome 
[8, 29, 30].
Figure 1 shows a principal component analysis (PCA) of the biogenic amine profiles of the 
muscle biopsies obtained from young, healthy older and frail older subjects, before and after 
exercise. We observed clear age-related differences in the biogenic amine profiles of skeletal 
muscle, as well as a difference between healthy and frail older subjects. The PCA plot also 
revealed an effect of prolonged resistance-type exercise training on amine concentrations in 
muscle tissue. PCA revealed a similar effect for organic acids in muscle (Supplementary Fig-
ure S2). 
ANOVA yielded a series of skeletal muscle metabolites that significantly differ between 
healthy older subjects and young subjects. Many of these metabolites are amino acids and 
organic acids (Table 2). The outcome of ANOVA modeling of muscle metabolites in healthy vs. 
frail older subjects is presented in Table 3.
effect of prolonged resistance-type exercise training in frail and healthy 
older subjects
In the PCA plot in Figure 1 we can observe that prolonged resistance-type exercise training 
has an effect on the biogenic amine profile of skeletal muscle tissue of frail and healthy older 
subjects. The trends in the PCA plot suggest that upon training both healthy and frail older sub-
jects shift towards a younger phenotype (see also the plot for the average value of isoleucine 
in Supplementary Figure S3,a). The variation in this PCA plot may not only be due to pheno-
type (young, healthy and frail old) and exercise, but also to sex and protein supplementation. 
Hence we performed ANOVA Simultaneous Component Analysis (ASCA) to account for these 
different sources of biological variation. We observed that prolonged resistance-type exercise 
training had a weak effect on muscle tissue metabolite levels. No significant interaction of 
protein supplementation with training in both frail and healthy older subjects could be ob-
served. Interaction of sex with training was not significant in healthy older subjects, but was 
significant in frail older subjects (P-value=0.03). 
Next we used linear mixed models on univariate metabolite levels to account for phe-
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notype, exercise, protein supplementation and sex as sources of biological variation. We ob-
served that prolonged resistance-type exercise training affected muscle levels of acylcarni-
tines in both the healthy older and frail older subjects (Table 4 and 5, respectively). These 
effects pertain to propionyl (C3), methylmalonyl (C4-DC), and isovaleryl (C5) acylcarnitines 
as products of the oxidation of amino acids, branched chain amino acids (BCAA), and C6-C20 
acylcarnitines as products of fatty acid oxidation [31]. For several acylcarnitines the exercise 
effects were nearly significant (P-value >0.05), hence we used the singular value decompo-
sition to summarize the levels of fatty acid derived and amino acid derived acylcarnitines 
(denoted as FAAC and AAAC, respectively in Figure 4 and 5). Subsequently, we also performed 
linear mixed models to determine the effect of training on the fatty acid derived and amino 
acid derived acylcarnitines. The amino acid derived acylcarnitines levels were significantly 
decreased after training for both healthy and frail older subjects (see example of the effects 
for propionylcarnitine in Supplementary Figure S3, b). 
We used multilevel sPLS to integrate muscle changes in the transcriptome and metabolome 
after training. Here the goal was to investigate the interaction of two matched data sets and the 
selection of subsets of either positively or negatively correlated variables across all subjects. 
This multivariate approach highlighted the training effects within subjects separately from the 
biological variation between subjects. We applied canonical mode, which highlights the stron-
gest correlations between the two data sets. Subsequently, we selected significantly changed 
genes based on training (FDR<0.05) in both frail and healthy older subjects. We observed that 
amino acids, particularly branched chain amino acids, correlate with genes related to connec-
tive tissue/extracellular matrix such as collagen, laminin and SPARC (Figure 2). 
correlation between muscle and plasma metabolites levels
Within this study we simultaneously collected fasting plasma and muscle biopsies. We 
investigated to what extent baseline plasma metabolite levels reflect muscle metabolite levels. 
We first constructed separate correlation heatmaps for muscle and plasma metabolites within 
each compartment. In Figure 3a-b one can observe that metabolites that are in the same group 
of metabolites (e.g. amino acids, acylcarnitines) are correlated to each other within both plas-
ma and muscle. However, the correlation heatmap of muscle and plasma metabolites (Figure 
3c) showed only minor to moderate correlations between muscle and plasma metabolites 
(Pearson correlation between 0.3 and 0.5). The correlation networks (Figure 3d) show that 
strongest correlations pertain to 3-hydroxybutyric acid, 4-hydroxyproline, proline, branched 
chain amino acids and several acylcarnitines. Correlation of serum and muscle metabolites 
are presented in Supplementary Figure S4. Results are generally in line with plasma-muscle 
metabolite correlations.
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dIscussIOn
Comprehensive metabolic profiling of muscle biopsies: age and resistance-
type exercise training effects in a heterogeneous study population
Comprehensive metabolic profiling of muscle biopsies revealed baseline differences between 
the muscle biopsy metabolomes of healthy young, healthy older and frail older subjects. Fur-
thermore, distinct effects of prolonged resistance-type exercise training in the latter two groups 
could be observed. Critical was the deployment of five robust profiling platforms using a single 
and thoroughly validated muscle-biopsy extraction procedure [12]. The analytical variation in 
these profiles, was around 20-30%, which was smaller than the biological variation in the mus-
cle biopsies. In order to separate the sources of biological variation in our heterogeneous study 
population we relied on univariate linear mixed models. The metabolic effects of sex and sup-
plementation however turned out to be relatively minor compared to phenotype and response 
to prolonged resistance-type exercise training. A multivariate approach (ASCA) did not show any 
significant effects of training, probably because not all sources of biological variation could ad-
equately be accounted for [32]. In the following discussion we limit ourselves to univariate ap-
proach since it more strictly accounts for heterogeneity of our study population. 
baseline comparisons
TCA cycle metabolites (succinic acid, fumaric acid, 2-ketoglutaric acid) were lower in the 
healthy older subjects compared to young subjects. These differences were accompanied by low-
er levels of ATP, ADP, branched chain amino acids and acylcarnitines in the healthy older sub-
jects. This indicates impaired mitochondrial function or a lower number of mitochondria in the 
muscle of the older subjects. It may also be a reflection of the lower habitual physical activity of 
the older subjects. These observations are in line with data on the transcriptomics profile of these 
subjects, which show that genes related to mitochondrial function and oxidative phosphoryla-
tion have decreased expression in the older subjects compared to young subjects, with the lowest 
expression occurring in the frail older subjects [7]. This is also in agreement with other studies [8, 
33-37], where the mitochondrial electron-transport chain is also among the significantly different 
pathways in muscle metabolism when comparing older and young subjects. 
Worth mentioning are the lower levels of 4-hydroxyproline and proline in the healthy old-
er subjects compared to the young subjects. Both of these amino acids have been associated 
with collagen turnover [38, 39]. Two precursors of proline, ornithine and arginine, have high-
er muscle levels in the older subjects. Higher levels of ornithine and arginine, together with 
lower levels of 4-hydroxyproline and proline, may be due to dysfunction of the mitochondrial 
ornithine aminotransferase [40], leading to accumulation of arginine and ornithine. This is in 
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line with slightly lower expression of genes related to tissue remodeling, such as collagen in the 
older subjects compared to the young subjects [7]. 
In healthy older subjects we observed higher muscle levels of β-isoamino butyric acid (BAIBA) 
than in young subjects. Hypothetically, this metabolite is produced upon exercise by expression 
of PGC-1α and has been proposed as a myokine stimulating browning of white adipose tissue and 
hepatic β-oxidation [41]. In our study population we observe gene transcription downregulation 
of PGC-1α target genes in healthy older subjects with respect to young and in frail older subjects 
with respect to healthy older subjects [7]. At posttranslational level activity of PGC-1α is modulat-
ed by NAD+ dependent deacetylation by SIRT1 (Figure 4-b) [42]. Since NAD+ levels are decreasing 
with age [43], we expect also here a downregulation of PGC-1α [44]. The expected decrease of 
β-isoamino butyric acid (BAIBA) levels is however only observed when comparing frail to healthy 
older subjects, whereas we observe a significant increase in BAIBA in healthy older subjects com-
pared to young subjects. Thus, the observed changes in baseline levels of BAIBA levels in muscle 
in our study population do not appear to be consistent with age-related down regulation of PGC-
1α. Hence we cannot confirm the recently stated hypothesis that BAIBA acts as a PGC-1α induced 
myokine. An explanation could be that in our study differences in PGC-1α expression are caused 
by age and frailty dependent processes, whereas previously described PGC-1α -mediated effects on 
BAIBA were caused by acute exercise. 
Two polyamines, spermine and spermidine, were found to be significantly different in the 
frail compared to the healthy older subjects. Polyamines are involved in tissue regeneration and 
cell proliferation and differences are associated with both exercise and muscle pathology [45-47]. 
The genes directly involved in the polyamine pathway are however not differentially expressed 
between frail and healthy older subjects. Hence the observed differences in polyamine levels be-
tween the frail and healthy older subjects are more likely to be attributed to effects at the level of 
enzyme activity or metabolite transport. Previous studies have shown that perturbations in poly-
amine metabolism are associated with neuromuscular disorders [48, 49]. On the transcriptome 
level we indeed found indications of neuromuscular perturbations in the frail older subjects [7]. In 
addition, increased spermine levels were recently linked to skeletal muscle atrophy [50]. However, 
our data suggests that at baseline this process is in the opposite direction when comparing frail 
and healthy older subjects, even though frail older subjects generally have less skeletal muscle 
and are likely to exhibit more extensive muscle atrophy. Ost et al. recently reported that spermi-
dine is increased in the skeletal muscle of mice overexpressing uncoupling protein 1. The authors 
proposed that this might be an adaptive response to cope with the additional oxidative stress [51]. 
The level of carnosine is decreased in healthy older subjects relative to young subjects, and 
in frail relative to healthy older subjects. Carnosine is an abundant metabolite in muscle where 
it plays an important role in intracellular pH buffering [52]. Carnosine has also been associated 
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with chelation of metal ions and antioxidant activity [53]. Carnosine levels are higher in type II 
muscle fibers compared to type I. A likely explanation for the significantly lower levels of car-
nosine in healthy and frail older subjects is therefore the decrease of muscle fiber II/I ratio with 
respectively age and lack of exercise[54].
Several oxylipins derived from linoleic acid (LA) and α-linoleic acid (ALA) occur at higher 
levels in the muscle of the healthy older subjects compared to young subjects. On the other hand, 
metabolites derived from the D-6 desaturase product dihomo-γ-linoleic acid (DGLA) are reduced 
in healthy older subjects. We postulate that due to reduced D-6 desaturase activity linoleic acid 
and α-linoleic acid accumulate in the muscle of the healthy older subjects, whereas downstream 
D-6 desaturase product dihomo-γ-linoleic acid products are depleted [55]. 
effect of prolonged resistance-type exercise training
We compared the effect of prolonged resistance-type exercise training in both healthy and 
frail older subjects with all metabolites using multilevel sPLS. There was a profound correla-
tion between the adaptive response to training between the transcriptome and amino acids in 
the muscle metabolome (canonical correlations between 0.7 and 0.8). There were particularly 
high correlations between expression changes of extracellular matrix genes and amino acids. 
Although it is unlikely that there is a direct link between expression of these genes and levels of 
these metabolites, it does imply that these changes in amino acid levels are part of the adaptive 
response to resistance-type exercise training. 
At the metabolite level, the most striking effects of resistance-type exercise training in frail and 
healthy older subjects were observed for the C3 (propionyl) and C5 (isovaleryl) muscle acylcarni-
tines derived from branched chain amino acids. After training, the amino acid derived acylcarni-
tines showed a significant decrease both in the healthy and frail older subjects, accompanied by an 
increase of branched chain amino acids. A likely explanation is that the flux-determining mitochon-
drial branched chain α-keto acid hydrogenase (BCKDH) complex [56] has a compromised response 
to prolonged resistance-type exercise training. As is schematically depicted in Figure 4-a, the BCKDH 
complex can respond to exercise via different mechanisms. PGC-1 is a known activator of BCKDH, 
but training did not have an effect on its gene expression in our study. Exercise is known to increase 
NAD+ levels [44] and could thus activate PGC-1α in a post-translational manner via SIRT1. Apparently 
also this mechanism is not activated by training in the older subjects. These effects are specific for 
branched chain amino acids oxidation and no significant effects on fatty acid derived acylcarnitines 
were found. A decrease in branched chain amino acids oxidation may stimulate mTOR related path-
ways activation and protein synthesis [57, 58], which is beneficial for older subjects. As this mecha-
nism occurs at enzymatic level, the available metabolomics and transcriptomics data can however 
not confirm this hypothesis and in future studies proteomics would be called for.
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correlation of plasma and muscle metabolome
The weak correlations between plasma and muscle metabolite levels indicate that plas-
ma levels only partially reflect muscle metabolism, even though muscle is one of the largest 
metabolically active tissues in the human body. This seems to suggest that these metabolites 
are also produced by other metabolic compartments. In a recent study, lack of correlation 
between acylcarnitine levels in plasma and tissues in mice was attributed to differences in 
turnover in plasma and muscle compartments, and contribution of other compartments 
than muscle to plasma acylcarnitine levels [59]. The same rationale very likely also applies to 
amino acids involved in collagen metabolism (proline, 4-hydroxyproline), which can also be 
formed in bone. Adipose tissue is also a metabolically active compartment for branched chain 
amino acids besides muscle [60], and this will likely weaken plasma-muscle level correlations. 
As a consequence, correlations between plasma metabolites and muscle metabolites are too 
modest to support their use as direct read-outs of muscle metabolism [61, 62]
cOnclusIOn
The major differences in muscle metabolome of healthy older and young subjects relate to 
mitochondrial function, fiber-type composition, and tissue turnover. Similar differences were ob-
served when comparing frail older subjects with healthy older subjects. Prolonged resistance-type 
exercise training showed a correlative adaptive response of amino acids and genes responsible for 
tissue remodeling. The effect of exercise on amino acid derived acylcarnitines in healthy and frail 
older subjects points towards decreased branched chain amino acids catabolism likely due to atten-
uated activation of the flux-determining mitochondrial branched chain α-keto acid hydrogenase 
complex in older subjects. Only modest correlations between muscle metabolite and plasma levels 
were found, which prohibits the use of the latter as read-outs of muscle metabolism.
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Table 1.Characteristics of subjects of which skeletal muscle tissue biopsies were studied
Table 1.Characteristics of subjects of which skeletal muscle tissue biopsies were studied 
   Young Healthy older Frail older 
N (male / female) 30/0 47/19 25/18 
Age (years) 21.7 ± 2.5 71.7 ± 5.2 77.5 ± 8.0 
Height (m) 1.83 ± 0.06 1.72 ± 0.08 1.67 ± 0.09 
Weight (kg) 76.7 ± 11.8 75.9 ± 13.3 77.5 ± 11.1 
BMIa (kg / m2) 22.6 ± 2.7 25.5 ± 3.0 27.5 ± 3.7 
Body Fat (%) 14.9 ± 4.9 24.5 ± 5.6 32.1 ± 8.8 
 Data was presented as mean ±SD. a: body mass index. 
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Table 2. Muscle metabolites that are significantly different between healthy 
older and young males a
 
 
 
 
 
 
 
Table 2. Muscle metabolites that are significantly different between healthy older and young males a 
Metabolite P-value 
FCb 
(Older/Young)    
TCA Cycle 
Succinic acid 0.02 0.76 
2-ketoglutaric acid 0.03 0.76 
Fumaric acid 0.04 0.82 
Lactic acid 0.05 0.69 
Energy 
ATP <0.01 0.75 
ADP 0.01 0.88 
Branched chain amino acids 
Valine <0.01 0.81 
Leucine <0.01 0.81 
Isoleucine 0.03 0.84 
Acylcarnitines 
Acetylcarnitine (C2) <0.01 0.49 
Malonylcarnitine (C3-DC) <0.01 0.46 
Intracellular buffering 
Carnosine <0.01 0.7 
Arginine, Proline Pathway 
Ornithine <0.01 1.55 
Arginine <0.01 1.34 
4-hydroxy-proline 0.01 0.69 
Proline 0.02 0.84 
Glycylglycine 0.05 0.87 
Methionine <0.01 0.8 
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Table 2 continued 
Other amino acids 
Lysine <0.01 1.44 
Aspartic acid <0.01 1.45 
Oxylipins 
LA (LOX) 
9-HODE <0.01 1.4 
13-HODE 0.01 1.37 
13-KODE 0.03 1.3 
LA(CYP450) 
  
9,10-EpOME 0.04 1.39 
ALA (LOX) 
9-HOTrE 0.01 1.71 
DGLA (LOX) 
15S-HETrE 0.02 0.83 
8-HETrE 0.03 0.85 
Aminobutyric acids 
 β amino isobutyric acid <0.01 1.61 
α-aminobutyric acid 0.01 0.82 
   
a: Out of a comprehensive muscle biopsy metabolic profile those metabolites are  
presented that are significantly (P-value =<0.05) different between young  
and old subjects according to univariate ANOVA models. b: Fold Change    
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Table 3.Muscle metabolites that are significantly different between frail and healthy older subjects.a 
Metabolite Group  Sex  Interaction  FCb(Frail/Healthy)   
TCA Cycle 
Citric acid <0.01 NS c NS 0.54 
Acylcarnitines 
Isovalerylcarnitine (C5) <0.01 NS NS 0.42 
Octenoylcarnitine (C8) 0.03 0.03 NS 0.77 
Malonylcarnitine(C3-DC) 0.02 NS NS 0.77 
Carnitine (C0) 0.01 NS NS 0.75 
Intracellular buffering 
Carnosine 0.01 NS NS 0.8 
Oxylipins 
LA (CYP450) 
12,13DiHOME 0.04 NS 0.03 1.18 
DGLA (LOX) 
8HETrE 0.03 NS NS 0.81 
15SHETrE <0.01 NS NS 0.77 
Polyamine metabolism         
Spermidine 0.01 0.02 NS 1.24 
Spermine 0.04 NS NS 0.9 
Other amino acids  
Histidine <0.01 NS NS 0.79 
Asparagine 0.01 NS NS 0.81 
Taurine 0.01 NS NS 0.79 
Serine 0.01 NS NS 0.86 
Glycine 0.02 NS NS 0.81 
oacetylserine 0.02 NS NS 0.9 
Homoserine 0.02 NS NS 0.85 
Tyrosine 0.02 NS NS 0.83 
Tryptophan 0.02 0.04 NS 0.83 
Methionine 0.02 NS NS 0.83 
Glutamine 0.03 NS NS 0.82 
Pyroglutamic acid 0.03 NS NS 0.83 
Glutamic acid 0.04 NS NS 0.82 
Glycylglycine <0.01 NS NS 0.77 
Aminobutyric acids 
β amino isobutyric acid 0.05 NS NS 0.79 
a: Out of a comprehensive muscle biopsy metabolic profile those metabolites are presented that are significantly (P-value 
=<0.05) different between frail and healthy older subjects according to a univariate ANOVA models that accounted for 
Group effects (Frail vs. Healthy), Sex effect, and Group and Sex interaction; Significance of Group (Frail vs. Healthy older 
subjects) and Group & Sex interactions has been indicated; b:fold change;  c: not significant 
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Table 4. Training effect on muscle metabolites in healthy older subjects a 
Metabolite Training FC(post/pre training)b 
Pipecolic acid 0.002 1.64 
Isovalerylcarnitine (C5) 0.005 0.56 
Linoleylcarnitine (C18:2) 0.01 0.61 
Oleylcarnitine (C18:1) 0.01 0.7 
Propionylcarnitine (C3) 0.01 0.73 
Palmitoylcarnitine (C16) 0.02 0.75 
11.12.EpETrE 0.03 1.26 
Tetradecenoylcarnitine (C14:1 0.03 0.47 
AAACc 0.02 0.77 
FAACd NS 0.96 
a: Metabolites are presented that significantly (P-value =<0.05) differ pre- and 
Post-training in healthy older subjects according to univariate linear mixed models. 
We note that we constructed also linear mixed models that account for other factors  
and their interactions, but these were not found to be significant. b: fold change,  
c,d: Single Value Decomposition (SVD) were calculated for amino and fatty acid  
acylcarnitines, denoted as AAAC and FAAC, respectively. 
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Table 5. Training effect on muscle metabolites in frail older subjects a 
Metabolite Training Supplement Sex Interaction FC (post/pre training)b 
Propionylcarnitine (C3) <0.01 NSc NS NS 0.75 
Glucose <0.01 NS <0.01 NS 1.35 
Lactic acid 0.01 NS <0.01 NS 1.55 
Tetradecenoylcarnitine (C14:1) 0.03 NS NS NS 2.00 
Methionine 0.04 <0.01 NS NS 1.22 
Tryptophan 0.04 NS NS NS 1.21 
β Alanine 0.05 NS NS 0.01 0.92 
Isoleucine 0.05 <0.01 0.02 NS 1.21 
Myristoylcarnitine (C14) 0.05 NS NS NS 1.73 
AAACd 0.01 NS NS NS 0.76 
FAACe NS NS NS NS 1.95 
           
a: Metabolites are presented that significantly (P-value =<0.05) differ pre- and post-training in frail older 
subjects according to univariate linear mixed models that account for Supplement, Sex and (Training and 
Supplement) Interaction. We note that we constructed also linear mixed models that account for other 
interactions, but these were not found to be significant. b: fold change, c: Not Significant, d & e: Single Value 
Decomposition (SVD) were calculated for amino acid and fatty acid acylcarnitines (AAAC and FAAC, 
respectively).  
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Figure 1. Principal component analysis (PCA) plot of biogenic amines detected in muscle biopsies. To visualize 
whether groups are significantly different from each other, confidence ellipses (95% Confidence Interval) were 
drawn around them.
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visualize whether groups are significantly different from each other, confidence ellipses (95% 
Confidence Interval) were drawn around them. 
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Figure 2. Correlation network of muscle metabolites and genes. Only significantly changed genes were selected 
(FDR<0.05). Metabolite canonical correlation cutoff <= 0.80. Circle: gene, rectangle: metabolite. Green: positive 
correlation.
 
 
 
 
Figure 2. Correlation network of muscle metabolites and genes. Only significantly changed genes 
were selected (FDR<0.05). Metabolite canonical correlation cutoff <= 0.80. Circle: gene, rectangle: 
metabolite. Green: positive correlation. 
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Figure 3. Correlation heatmap of muscle to muscle metabolites (a), plasma to plasma metabolites (b), 
muscle to plasma metabolites (c). Pearson correlation were used. (d) Correlation network of the most 
strongly correlated muscle and plasma metabolites (Pearson correlation). Red and blue indicate 
positive and negative correlations, respectively. Thick lines: correlation ~0.5, thin lines: 0.3 
<correlation <0.5. Pink nodes: muscle tissue (T) metabolites and yellow nodes: plasma (P) 
metabolites. 
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Figure 3. Correlation heatmap of muscle to muscle metabolites (a), plasma to plasma metabolites (b), muscle to 
plasma metabolites (c). Pearson correlation were used. (d) Correlation network of the most strongly correlated 
muscle and plasma metabolites (Pearson correlation). Red and blue indicate positive and negative correlations, 
respectively. Thick lines: correlation ~0.5, thin lines: 0.3 <correlation <0.5. Pink nodes: muscle tissue (T) metabolites 
and yellow nodes: plasma (P) metabolites.
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Figure 4. (a) Schematic representation of mitochondrial oxidation of free fatty acids (FFA) and branched chain amino 
acids (BCAA). Arrows indicate effect of prolonged resistance-type exercise training on older subjects (healthy and 
frail) on BCAA (increase) and acylcarnitines (decrease) as well as the proposed (dashed-arrows) downregulation of 
the branched chain α-keto acid hydrogenase (BCKDH) complex. (b) Schematic representation of age-related NAD+ 
dependent acetylation of PGC1α. Dashed arrows indicate NAD+ and SIRT1 dependent downregulation of PGC-1α 
and β-isoamino butyric acid (BAIBA).
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training on older subjects (healthy and frail) on BCAA (increase) and acylcarnitines (decrease) as well 
as the proposed (dashed-arrows) downregulation of the branched chain α-keto acid hydrogenase 
(BCKDH) complex. (b) Schematic representation of age-related NAD+ dependent acetylation of 
PGC1α. Dashed arrows indicate NAD+ and SIRT1 dependent downregulation of PGC-1α and β-
isoamino butyric acid (BAIBA). 
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suPPleMenTARy MATeRIAl
Figure s1. Change of leg extension 1RM after resistance type exercise training. Left are Frail older subjects, right are 
Healthy older subjects.
 
 
Figure S1. Change of leg extension 1RM after resistance type exercise training. Left are Frail older 
subjects, right are Healthy older subjects. 
 
Figure s2. PCA plot of metabolites detected by the organic acid platform in muscle tissue. To visualize whether 
groups are significantly different from each other, confidence ellipses (95% confidence interval) were drawn around 
them. Post: after training, pre: before training. 
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Figure S3.Group means with 95 percent confidence intervals for (a) isoleucine and (b) 
propionylcarnitine. Standard deviations were relatively constant across groups. Frail_pre: frail older 
subjects before training, Frail_post: frail older subjects after training, Healthy_pre: healthy older 
subjects before training, Healthy_post: healthy older subjects after training.  
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3Figure s4. Correlation heatmap muscle and serum metabolite. Pearson correlation were used. Red indicates positive correlation and blue indicates negative correlation.
 
 
Figure S4. Correlation heatmap muscle and serum metabolite. Pearson correlation were used. Red 
indicates positive correlation and blue indicates negative correlation. 
 
 
 
 
Table S1. Characteristics of subjects of which plasma samples were studied 
  Young Healthy older Frail older 
N (male / female) 50/0 51/25    35/27 
Age (years) 21.7 ± 2.3  71.5 ± 5.1 78.1 ± 8.1 
Height (m) 1.83 ± 0.05 1.71 ± 0.08 1.69 ± 0.09 
Weight (kg) 76.4 ± 10.3 76.3 ± 12.9 79.2 ± 12.9 
BMIa (kg / m2) 23.0 ± 2.9 25.5 ± 3.0 27.8 ± 4.1 
Body Fat (%) 15.4 ± 4.5 24.7 ± 5.7 32.66 ± 8.7 
a:body mass index. 
 
 
Table S2.Characteristics of the older subjects with before and after training samples. 
  
Frail  
older prea 
Frail 
 older post b 
Healthy  
older pre 
Healthy  
older post 
N (male / female) 10/14  22/16  
Age (years) 76.0 ± 7.0  69.3 ± 4.0  
Height (m) 1.66 ± 0.09  1.70 ± 0.09  
Weight (kg) 77.7 ± 13.6 78.5 ± 14.0 75.9 ± 13.4 76.2 ± 13.6 
BMIc (kg / m2) 27.9 ± 3.8 28.2 ± 3.9 26.0 ± 2.8 26.0 ± 2.8 
Body Fat (%) 35.4 ± 8.3 35.2 ± 8.8 26.4 ± 5.4 24.7 ± 5.0* 
Lean Mass (kg) 46.9 ± 9.9 47.4 ± 10.1* 53.6 ± 11.2 55.1 ± 11.5 
Leg Extension 1RM (kg) 60.1 ± 18.9 82.7 ± 23.3* 79.8 ± 18.2 112.6 ± 22.5* 
Leg Press 1RM (kg) 130.1± 33 176 ± 43.0* 175.9 ± 40.4 227.0 ± 49.9* 
a:pre indicates before training. b: post indicates after training. c: Body Mass Index. * indicates a significant 
effect of resistance-type exercise training (P-value < 0.05).  
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AbsTRAcT
The response to dietary challenges has been proposed as a more accurate measure of met-
abolic health than static measurements performed in the fasted state. We examined whether 
the response to a mixed-meal challenge could provide a readout for a weight lossinduced 
phenotype shift in abdominally obese male subjects. Fifteen lean subjects (BMI= 23.0±2.0kg/
m2) were compared to 29 abdominally obese subjects (BMI= 30.3±2.4 kg/m2) in order to have 
a benchmark for weight loss-induced phenotypic shifts. Levels of several plasma metabolites 
were significantly different between lean and abdominally obese at baseline as well as during 
postprandial metabolic responses. Genes related to oxidative phosphorylation in peripheral 
blood mononuclear cells (PBMCs) were expressed at higher levels in abdominally obese sub-
jects as compared to lean subjects at fasting, which was partially reverted after weight loss. 
The impact of weight loss on the postprandial response was modest, both at the metabolic and 
gene expression level in PBMCs. We conclude that mixed-meal challenges are not necessarily 
superior to measurements in the fasted state to assess metabolic health. Furthermore, the 
mechanisms accounting for the observed differences between lean and abdominally obese 
in the fasted state are different from those underlying the differences observed during the 
postprandial response.
KEYWORDS. Mixed-meal challenge, Metabolic health, Phenotype shift
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InTROducTIOn
Healthy individuals are able to respond to external stimuli by keeping biological parame-
ters within narrow homeostatic bandwidths. As a consequence, current approaches focusing 
on disease risk biomarkers mostly lack the sensitivity to detect the effects of lifestyle and di-
etary interventions aimed at improving or sustaining health. Hence, there is a growing aware-
ness that ‘health’ should not just be defined as ‘the absence of disease’, but is more accurately 
described as ‘resilience of homeostatic control’, i.e. the ability to cope with daily challenges [1] 
without drifting out of the regulated homeostatic/allostatic zone [2]. The concept of the human 
body as an orchestrated machinery that continuously adapts to a changing environment has 
been embraced by the nutritional field and coined as ‘phenotypic flexibility’[3]. The earlier 
introduced concept of ‘metabolic flexibility’ departs from a more narrow definition of phe-
notypic flexibility and specifically refers to the ability of organs to change fuel use depending 
on availability [4]. The capacity to switch from carbohydrate to fat oxidation and vice versa 
depending on their supply and demand is crucial for optimal metabolic homeostasis, and thus 
an important aspect of phenotypic flexibility. In both concepts, the resilience capacity can be 
tested by the assessment of the stress response to short-term perturbations. 
Specific dietary challenge tests have been described, each probing the resilience of differ-
ent metabolic regulatory processes. The best known challenge test is the oral glucose toler-
ance test (OGTT), which specifically probes the resilience of glucose metabolism [5]. The oral 
lipid and protein tolerance tests (OLTT and OPTT, respectively) probe the resilience of other, 
and partially overlapping metabolic regulatory processes. The use of a mixed-meal challenge, 
comprising protein, glucose and lipids, has been proposed to target multiple organs and more 
broadly encompass phenotypic flexibility [6]. By challenging metabolic regulatory processes 
by means of a dietary challenge, dynamic changes in nutrient metabolism might be uncovered, 
allowing better exploration of the individual capacity to cope with metabolic stressors [7]. 
Next to metabolite profiling, which has already been shown to be useful in revealing the 
complex changes upon dietary challenges, gene expression of peripheral blood mononuclear 
cells (PBMCs) has been brought forward as readout of biological processes such as inflam-
mation, metabolism [8], oxidative stress and inflammatory status [9-11]. PBMCs can be easily 
collected in adequate quantities for transcriptomics studies, and it has been shown that nu-
tritional components can modulate pro- and anti-inflammatory mechanisms [8, 12]. A previ-
ous study has indicated that long-term consumption of a Mediterranean diet (high content of 
unsaturated fats and polyphenols) reduces metabolic stress and oxidative phosphorylation 
activity in PBMCs obtained from overweight men and women [13]. Furthermore, it has also 
been shown that diet induced weight loss modulates immune-inflammatory and antioxidant 
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responses and mRNA expression in PBMCs [14]. 
We examined whether a mixed-meal challenge response could provide a sensitive read-
out for a shift in phenotypical flexibility upon weight loss in abdominally obese male subjects. 
By combining metabolite profiling in plasma and whole genome gene expression in PBMCs, 
we aimed at comprehensively describing the changes in the metabolome and gene expres-
sion underlying phenotypic flexibility. We were in particular interested whether the effect 
of weight loss on the postprandial response would provide a more sensitive readout than the 
observation in the fasting state. In order to have a benchmark for this comparison, we first 
compared fasting baseline and postprandial response between lean and abdominally obese 
subjects. Subsequently, we assessed the effect of dietary weight loss on the fasting baseline 
and postprandial response in abdominally obese men. 
MATeRIAls And MeThOds
subject characteristics
Fifteen lean men with a waist circumference below 94 cm (BMI= 23.0 ± 2.0kg/m2) and 
29 abdominally obese men with a waist circumference between 102-110 cm participated in 
the study (BMI= 30.3 ± 2.4 kg/m2). Baseline characteristics of subjects of which microarrays 
and metabolomics were performed are displayed in Table1. All volunteers were apparently 
healthy and did not receive proton pump inhibitors, anti-hypertensive medication or drugs 
known to affect lipid or glucose metabolism.
study design 
Full details of the study have been published before [15]. In brief, abdominally obese men 
received a mixed-meal challenge prior to and after an 8-week weight loss or no-weight loss 
control intervention. Lean subjects were included as a reference group and only received the 
mixed meal challenge at baseline (Figure 1). Prior to the intervention (D1), all subjects under-
went a mixed-meal challenge. The standardized mixed meal consisted of two muffins and 
300 ml 0% fat milk, which provided 4.6 MJ (4598 KJ or 1100 kcal): 56.6 g fat, 26.5 g protein and 
121 g carbohydrate. Blood samples were collected at fasting and immediately after ingestion 
of the challenge over 4 hours at regular intervals (0, 30, 60, 120, 180, 240 minutes). Subjects 
assigned to diet-induced weight-loss (WL, Figure 1) program consumed a commercially avail-
able very low energy diet (Modifast; Nutrition et Santé, Benelux, Breda, The Netherlands) for 
4-5 weeks providing 2.1 MJ/day. Once the waist circumference was below 102 cm (the NCEP 
ATP II cut-off value) within this period, subjects consumed a mixed-solid energy-restricted diet 
up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, subjects 
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consumed a diet matching their energy requirements to maintain their newly achieved body 
weights (weight-stable conditions) for at least 2 weeks. Subjects underwent the same mixed-
meal challenge again after the weight loss intervention (D2). Blood samples were collected at 
the same time intervals as on D1. Subjects assigned to the control (CTRL, Figure 1) intervention 
underwent the same tests, but maintained their habitual diet, physical activity levels and al-
cohol consumption during 8 weeks. The period between the first and second measurements 
was the same for the weight loss intervention (WL) and control (CTRL) groups. More details 
on the composition of low energy diet and mixed meal challenge can be found elsewhere [15].
sample collection
On the day before blood sampling, subjects were asked not to perform any strenuous 
physical exercise or to consume alcohol. On the morning of blood sampling - after a 12 hour 
overnight fast (from 8 PM) subjects were only allowed to drink a glass of water in the morning. 
Subjects were also asked not to consume high-fat foods on the day prior to the test days and 
to come to the test centre by public transport or car to standardize measurements as much as 
possible.
An intravenous cannula was inserted and blood samples were taken at fasting and after 
mixed meal consumption both before and after the weight loss intervention at 6 time points 
(fasting (T0) and 30, 60,120,180 and 240 minutes in the postprandial state). Metabolic profiling 
was performed on all time points and transcriptomics analysis of PBMCs only at fasting (T0) 
and after 4 hours in the postprandial state (T4). 
PbMc and RnA isolation
PBMCs were isolated before and 4 h after mixed meal challenge by using BD Vacutainer 
Cell Preparation Tubes. RNA was isolated (RNeasy Micro kit, Qiagen, Venlo, the Netherlands), 
quantified (Nanodrop ND 1000, Nanodrop technologies, Wilmington, DE, USA) and integrity 
was checked by an Agilent 2100 Bioanalyser with RNA 6000 microchips (Agilent Technologies, 
South Queensferry, UK). Samples were included for microarray analysis if RNA integrity num-
ber (RIN) was > 7.
Microarray processing
PBMC samples from 15 lean and 29 abdominally obese subjects yielded enough RNA of 
sufficient quality at all collection points to perform microarray analysis. Microarray analysis 
was performed for each individual at fasting (T0) and 4 h (T4) in the postprandial state. To-
tal RNA was labelled using a one-cycle cDNA labelling kit (MessageAmp™ II-Biotin Enhanced 
Kit; Ambion, Inc., Nieuwerkerk a/d IJssel, Netherlands) and hybridized to GeneChip® Human 
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Gene 1.1 ST Array targeting 19 738 unique gene identifiers (Affymetrix, Inc. Santa Clara, CA, 
USA). Sample labelling, hybridization to chips, and image scanning were performed according 
to the manufacturers’ instructions.
Microarray analysis
Microarray signals were normalized using robust multichip average (RMA). Data was fil-
tered using Universal expression Codes filtering (UPC) with a 50% cut-off, corresponding to a 
50% likelihood that a gene is expressed [16]. Significant differences of individual genes were 
tested using the limma R library [17]. At fasting, the expression of genes between groups was 
defined as different when P was < 0.05 in a t-test with empirical Bayes correction. Gene ex-
pression was defined as postprandial changed between T0 and T4 h when the P was< 0.05 in 
a paired t-test with empirical Bayesian correction. Data were further analysed with gene set 
enrichment analysis (GSEA) using pre-ranked lists based on the t-statistic [18]. Gene sets with 
a false discovery rate (FDR Q<0.2) were defined as significantly regulated. Plots were made 
using the R libraries ggplot2 and gplots [19, 20].
Plasma metabolic profiling
Amino acids and biogenic amines were derivatized (Acc-Tag) in 5 µL aliquots of plasma 
and analyzed using an ACQUITY UPLC system equipped with autosampler (Waters, Etten-Leur, 
The Netherlands) and coupled to a Xevo Tandem quadrupole mass spectrometer (Waters) 
operated using QuanLynx data acquisition software (version 4.1; Waters). An Accq-Tag Ultra 
column (Waters) was used. The Xevo TQ was used in the positive-ion electrospray mode and 
all analytes were monitored in Multiple Reaction Monitoring (MRM) using nominal mass res-
olution. Acquired data were evaluated using TargetLynx software (Waters), by integration of 
assigned MRM peaks and normalization using proper internal standards [21]. Acylcarnitines, 
trimethylamine-N-oxide, choline, betaine, deoxycarnitine and carnitine were analyzed in 5 µL 
plasma, spiked with an internal standard, using a UPLC-MS/MS. Also here an Accq-Tag Ultra 
column was used. The Xevo TQ was used in the positive-ion electrospray mode and all ana-
lytes were monitored in Multiple Reaction Monitoring (MRM) using nominal mass resolution. 
In-house developed algorithms[22] were applied using the pooled QC samples to compensate 
for shifts in the sensitivity of the mass spectrometer over the batch. Organic acids were mea-
sured by GC-MS using 50 µL of plasma sample prepared using a two-step derivatization pro-
cedure with subsequent oximation using methoxyamine hydrochloride (MeOX) and silylation 
using N-Methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA. Samples were measured on an 
Agilent GC (7890A) coupled to Agilent Quadrupole-MS with EI source (Agilent MSD 5975C). 
Separation was performed using a HP-5MS column (30 m x 0.25 m x 0.25 μm; Agilent). The raw 
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data were pre-processed using Agilent MassHunter Quantitative Analysis software for GC-MS 
(Agilent, Version B.04.00), and quantitation of metabolite response was calculated as the peak 
area ratios of the target analyte to the respective internal standard. Oxylipins were analyzed 
as previously described [23]. In short, compound extraction was performed with SPE using a 
hydrophilic-lipophilic balance and samples were analyzed by LC using a C18 column coupled 
to ESI on a triple quadrupole mass spectrometer, where oxylipins were detected in negative 
ion mode using dynamic SRM. while chromatographic separation was achieved with a C18 
column. Peak areas of target metabolites were corrected by appropriate internal standards 
and calculated response ratios were used throughout the analysis. In-house developed algo-
rithms were applied using the pooled QC samples to compensate for shifts in the sensitivity of 
the mass spectrometer over the batch. Serum metabolite concentrations determined by NMR 
were measured as described by Mihaleva et al. [24]. Briefly, high resolution 1H NMR spectra 
were acquired on ultrafiltrated serum samples at 300K using a Bruker Avance III 600 MHz 
spectrometer. Automated quantum mechanical line shape fitting of the1H NMR spectra was 
performed using PERCH NMR software to obtain absolute concentrations of 44 metabolites.
Metabolomics statistical analysis 
We used Spearman rank correlations to correlate plasma metabolite concentrations and 
phenotypical parameters (LBM, HOMA). These correlations were also determined for nadir 
and Δ-nadir acylcarnitine values [25]. Nadir acylcarnitine values were defined as the lowest 
value achieved during the 4 hours after the meal. Δ-nadir was calculated as difference be-
tween nadir and T0 values. The postprandial response was considered as the incremental 
area under the curve (iAUC) [26]. For the iAUC calculation, the values at fasting (T0) were 
subtracted from the total AUC. Comparison between abdominally obese and lean group was 
performed using analysis of variance (ANOVA). To evaluate the intervention effect on fasting 
metabolites (T0) and the intervention effect on postprandial response (iAUC) in abdominally 
obese subjects, statistical analysis was performed using linear mixed models. A P<0.05 was 
considered to be statistically significant. 
Local false discovery rate (lFDR) was used to correct for multiple testing [27-29]. All calcu-
lations were performed under R (version 3.2.1).
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ResulTs 
Metabolic differences between lean and abdominally obese subjects 
In order to have a benchmark for the comparison of abdominally obese subjects before 
and after weight loss, we first considered the difference between lean and abdominally 
obese subjects (Figure 1). In the fasted state, 19 plasma metabolites were significantly differ-
ent between abdominally obese subjects and lean subjects (Table 2), including various ami-
no  acids, a fatty acid derived acylcarnitine (FAAC), and metabolites related to the TCA cycle. 
For a number of oxylipins we observed significantly lower plasma levels in the abdominal-
ly obese subjects compared to the lean subjects. Upon the mixed meal challenge, four types 
of postprandial metabolic responses could be recognized, i.e. metabolite changes related to 
glucose metabolism, amino acid metabolism, lipid metabolism, and ketogenesis [30]. Figure 
2 presents typical postprandial curves for these response types. Both lean and abdominally 
obese subjects followed similar responses over time. Metabolites for which the longitudinal 
response, expressed as iAUC, significantly (P<0.05) differed between abdominally obese and 
lean subjects are presented in Table 2. The 8 metabolites that were different between lean and 
abdominally obese included a number of amino acids, but not branched chain amino acids. 
Interestingly, 2-hydroxyisovalerate, a catabolite of branched chain amino acids was also sig-
nificantly different.
In the fasted state, 1862 genes were differently expressed (P< 0.05) in PBMCs between lean 
and abdominally obese subjects. The mixed meal challenge changed the expression of 1305 
genes in abdominally obese and 1707 genes in lean subjects. The response to the meal chal-
lenge of 1537 genes differed between lean and abdominally obese (Δ abdominally obese T4-T0 
vs. Δ lean T4-T0). A total of 359 genes were both differentially expressed between abdominally 
obese and lean after fasting and differed between abdominally obese and lean subjects in 
response to the mixed meal challenge (Figure S1). In the fasting samples, GSEA identified gene 
sets that were enriched in abdominally obese compared to lean subjects (FDR <0.2), which 
mainly belonged to oxidative phosphorylation and the electron transport chain. Gene sets in-
volved in immune regulation were enriched in lean compared to abdominally obese subjects 
(Supplementary Table S1). In the postprandial state, genes related to immune pathways and 
glucose metabolism were enriched in abdominally obese as compared to lean (Δ abdominal-
ly obese T4-T0 vs. Δ lean T4-T0, Supplementary Table S2). In total, in the fasting state 9 gene 
sets were positively enriched and 9 gene sets were negatively enriched in abdominally obese 
compared to lean subjects (FDR<0.2). In the postprandial state, 114 gene sets were upregulated 
in abdominally obese subjects compared to lean subjects, while 15 gene sets were downreg-
ulated.
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Impact of weight loss on fasting metabolism in abdominally obese subjects
All subjects who received the low-calorie diet significantly lost weight (P<0.05) (Table 1). 
To establish whether 
weight loss has any effect on the fasting levels of metabolites in abdominally obese sub-
jects, Δ values were calculated per metabolite per subject (T0 after –T0 before). Table 3 shows 
the three metabolites that were different before and after the weight loss intervention in ab-
dominally obese subjects in the fasted state. We also assessed the connection between weight 
loss and ratios between acetylcarnitine (C2) and longer chain (Cn) acylcarnitines. These (C2/Cn) 
acylcarnitine ratios have previously been suggested as read-outs for lipid β-oxidation and in-
deed significantly correlated with HOMA (Supplementary Material, Table S3). Although these 
correlations suggest that acylcarnitine ratios partly reflect insulin resistance, we could not 
find any significant effect of weight loss on these acylcarnitine ratios, whereas we did observe 
an improvement in the HOMA index [15].
We next determined the effect of weight loss on gene expression in PBMCs in the fasted 
state. Weight loss changed the expression of 835 genes in the abdominally obese subjects (T0 
after weight loss vs. T0 before weight loss, Figure S2). GSEA identified a number of differently 
enriched (FDR <0.04) pathways, including respiratory electron transport, and oxidative phos-
phorylation, which were negatively enriched after weight loss in abdominally obese subjects. 
Gene sets related to immune regulation and insulin signalling were positively enriched after 
weight loss (Supplementary Table S4). After weight loss, genes in oxidative phosphorylation 
and to a lesser extent in carbohydrate metabolism showed expression levels that were closer 
to expression levels in lean subjects (Figure 3).
Impact of weight loss on postprandial metabolic response in abdominally 
obese subjects
The weight loss intervention had a subtle effect on the postprandial metabolic response 
in plasma, of which several examples are presented in Figure 2. For 11 metabolites the post-
prandial response as expressed as incremental area under the curve (iAUC) was significantly 
different. For a major part these metabolites consisted of oxylipins derived from enzymatic 
oxidation of arachidonic acid (Table 3). We also observed shifts in the response to the mixed-
meal challenge after the control intervention (Supplementary Table S5).
To identify differences in PBMC gene expression in response to the mixed-meal challenge 
before and after weight loss, differences were calculated as ∆ values in both groups (T4-T0, 
D2 vs. T4-T0, D1). We identified 384 genes that showed a different postprandial response after 
the weight-loss intervention as compared to the response before weight loss. Furthermore, 
we identified 226 genes that showed a different postprandial response after the control inter-
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vention (Figure S2). GSEA showed that oxidative phosphorylation and the electron transport 
chain were the main affected pathways. Before the intervention oxidative phosphorylation 
and the electron transport chain were downregulated upon the mixed-meal challenge, where-
as after the weight loss intervention oxidative phosphorylation and the electron transport 
chain were upregulated (Figure 3). In contrast, gene sets related to the immune system and 
carbohydrate metabolism showed the opposite pattern with down-regulation upon a mixed-
meal challenge before the intervention and a dampened response or even up-regulation upon 
a mixed-meal challenge after the intervention (Figure 3, Supplementary Table S6).
In short, GSEA showed that at fasting, 161 gene sets were upregulated and 120 gene sets 
were down regulated (FDR< 0.2) in the WL abdominally obese group (Supplementary Table 
S4), while in the abdominally obese control group 219 gene sets were upregulated and 3 gene 
sets were downregulated (data not shown). GSEA showed that upon mixed meal challenge, 6 
gene sets were upregulated and95 gene sets were down regulated (FDR< 0.2) in WL abdomi-
nally obese group (Supplementary Table S6), while in CTRL abdominally obese group only 45 
gene sets were downregulated (data not shown).
dIscussIOn
In this study, we examined whether a standardized mixed-meal challenge could reveal a 
weight loss-induced shift from the abdominally obese phenotype towards a lean one. We were 
particularly interested in finding out whether measurement of the response to a dietary chal-
lenge would reveal additional changes in metabolic phenotype compared to measurements 
in the fasting state.
Metabolic differences between lean and abdominally obese
The observed differences in the fasting levels of BCAAs reflect differences in metabolic 
homeostasis between lean and abdominally obese and are in line with previous observations 
[31]. The shift in fasting levels of these metabolites can be explained by their positive correla-
tion with insulin resistance, which was significantly different for the lean and abdominally 
obese subjects [31, 32]. We could however not confirm previously observed differences in me-
tabolites related to the TCA cycle between the abdominally obese and lean subjects [31]. For a 
range of oxylipins significantly lower plasma levels were observed in abdominally obese sub-
jects relative to the lean group, which we attribute to a decrease in enzymatic lipid oxidation.
Recently, ratios between C2/Cn acylcarnitines were brought forward as putative read-outs 
for β-oxidation rate [7]. Although these ratios correlated with HOMA (Supplementary Table 
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S3), we could not find a difference of C2/Cn acylcarnitine ratios between the lean and abdom-
inally obese groups, even though insulin sensitivity differed between the two groups. This 
suggests that while these ratios are correlated with insulin sensitivity, they do not provide an 
increased sensitivity compared to classical markers. 
The lean and abdominally obese subjects also differed in their postprandial mixed meal 
response. The individual variation, however, was rather large, as shown in Figure 2. An elabo-
rate interpretation of the differences in response between lean and abdominally obese is given 
in the Supplementary Material. Briefly, we could reproduce previously observed differences 
in the postprandial responses of amino acids between lean and abdominally obese [33]. We 
could, however, not reproduce earlier observations showing differences in the postprandial 
responses of free fatty acids between lean and abdominally obese. We attributed this to di-
etary intake of fatty acids during the postprandial phase. We also did not observe differences in 
postprandial response of fatty acid derived acylcarnitines and hence could not confirm earlier 
observations that lean and abdominally obese differ in β-oxidation of fatty acids [33]. Also no 
differences in postprandial responses of BCAAs between lean and abdominally obese could be 
discerned, very likely also due to direct dietary intake of amino acids. We did however observe 
a striking difference for a BCAA transamination product, i.e. 2-hydroxyisovalerate (P< 0.05). 
This metabolite require the branched chain amino transferase (BCAT) and keto acid dehydro-
genase (BCKDH) complex for further catabolism to propionic acid. The function of the BCKDH 
complex is known to be compromised in insulin resistant subjects, leading to increased fasting 
levels of BCAA [33]. Compromised BCKDH function should also increase postprandial accumu-
lation of other upstream metabolites such as 2-hydroxyisovalerate. This is indeed what was 
observed in the abdominally obese relative to lean subjects [34]. We also observed difference 
for a range of oxylipins after a mixed meal challenge in lean and abdominally obese subjects. 
A recent study did however not show differences in postprandial response of oxylipins be-
tween lean and abdominally obese subjects upon high fat challenges [35]. This indicates that 
the postprandial response of oxylipins is not only determined by the lean-abdominally obese 
phenotype but also depends on the composition of the meal challenge. 
Although the lean and abdominally obese showed several distinct differences in the post-
prandial metabolic response, these differences were less pronounced when compared to a 
previous study using an OGTT challenge [36]. That study showed blunted responses of BCAAs 
and FFAs, in contrast to our study. We attribute this to dietary intake of these metabolites since 
our mixed meal challenge was quite rich in protein and fatty acids. This likely shrouds obser-
vation of differences in postprandial response due to phenotypical differences.
Gene sets related to oxidative phosphorylation were higher expressed in abdominally 
obese in comparison to lean subjects at baseline in the fasting state. This is consistent with 
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a previous study that found that dietary background can affect PBMC gene expression. Con-
sumption of monounsaturated fatty acids and Mediterranean diet compared with the satu-
rated fatty acid diet decreased the expression of genes involved in oxidative phosphorylation 
in abdominally overweight males and females [13]. Differences were also found in gene sets 
related to the immune system. These gene sets were lower expressed in abdominally obese 
when compared to lean subjects. However, these effects were relatively small, yet consistent 
with a previous study that also showed rather small differences in a number of immune re-
lated gene sets that showed lower expression in abdominally obese subjects when compared 
to lean subjects [12].
In contrast to the fasting state, we observed that in the postprandial state expression of genes 
related to immune pathways was increased in abdominally obese relative to lean subjects. In 
addition, we observed larger changes in expression of gene sets involved in carbohydrate me-
tabolism in the abdominally obese, which could be due to differences in insulin sensitivity and 
the activity of energy metabolism pathways. The observed differences in PBMC gene expression 
between abdominally obese and lean subjects at baseline and after the mixed meal challenge 
point towards a difference in haemostasis and immune function between the two groups. 
Based on the number of genes differently expressed between lean and abdominally obese 
we can conclude that our mixed meal challenge was not able to magnify differences in tran-
scriptional response in PBMC between lean and abdominally obese when compared to the 
fasting state (fasting: 1862 genes and postprandial: 1537 genes). This is in contrast to a study 
by Esser et al. demonstrating that an OLTT challenge with 95g of fat high in SFA or MUFA 
increased the number of genes significantly differentially expressed between lean and ab-
dominally obese subjects. This study also showed a higher number of changed genes in ab-
dominally obese relative to lean subjects when comparing the MUFA and the SFA challenges. 
The authors hypothesised that a MUFA challenge is more potent in inducing transcriptional 
differences between lean and abdominally obese in PBMCs than a SFA challenge. Our mixed 
meal challenge was higher in carbohydrate and protein and lower in fat content. These fats 
were also predominantly saturated, which may explain the weaker gene expression response 
to our mixed meal challenge. This weaker response can also be explained by large variety in 
response induced by the absorption a complex mixture of nutrients. 
effect of weight loss on fasting metabolism in abdominally obese subjects
The effect of weight loss on fasting metabolism of abdominally obese subjects only in-
volved two amino acids and creatinine. This stands in contrast to the previously observed 
changes in baseline levels of BCAAs, AAACs, carnitine and metabolites of the TCA cycle [37, 
38]. It is also in contrast to the observed improvement of insulin sensitivity upon weight loss 
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in our study population, indicating that the abdominally obese phenotype partially reversed 
towards a lean one [31, 32]. Furthermore, we did not observe an effect of weight loss on C2/Cn 
acylcarnitine ratios.
In our study, weight loss affected the expression of 835 genes in the fasting state. Weight 
loss resulted in lower expression of genes involved in oxidative phosphorylation PBMCs at 
baseline. These genes also show lower expression levels in lean compared to abdominally 
obese individuals (Figure 3). Furthermore, baseline expression of genes involved in carbo-
hydrate metabolism is different between lean and abdominally obese subject. However, the 
expression levels of these genes do not seem to change towards the expression levels observed 
in the lean upon weight loss. Moreover, gene sets involved in immune regulation were higher 
expressed after weight loss, while these gene sets were enriched in lean subjects compared to 
abdominally obese subjects before the intervention. A possible explanation for the observed 
differences in expressions of immune-related genes is a shift in cell population occurring 
during the study. Unfortunately, differentiated blood cell counts were not performed in the 
current study so we cannot confirm this. Therefore, we cannot conclude that the observed 
differences are due to a difference in immune status between lean and abdominally obese.
 We also observed significant differences in the control group, which was not expected 
since our control group matched in BMI and waist circumference at the start of the inter-
vention and the control group did not lose any weight. These differences suggest a seasonal 
effect; however, due to the design of the study this explanation is unlikely. Our remaining 
explanation is that the participants in the control group changed their behaviour during the 
course of the study.
effect of weight loss on postprandial metabolic response in abdominally 
obese subjects
The predominant effect of the weight loss intervention on the postprandial response in 
abdominally obese subjects involved 3 amino acids, 5 oxylipins, choline, creatine and glucose. 
Several differences in the postprandial response that were observed between lean and ab-
dominally obese subjects, however, were not observed after weight loss in the abdominally 
obese. Lower glucose levels after weight loss suggests that the mixed meal challenge stimu-
lates a more prolonged insulin response, which is in line with previous observations [6]. In 
our study the weight loss intervention induced a small number of shifts in fasting metabolite 
level; the impact of the mixed meal on the postprandial metabolic response involved more 
metabolites but was still subtle. This is in line with Geidenstam et al. who also found only 
a modest number of differences in the postprandial metabolic response upon OGTT, mostly 
branched and aromatic acids, after weight loss and a maintenance period in abdominally 
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obese subjects. The authors attribute this to the heterogeneity in the postprandial response 
of abdominally obese to an OGTT challenge. The heterogeneity in postprandial response to a 
mixed meal most likely also explains why also in our study only modest postprandial effects of 
weight loss were observed. In contrast, a recent study by Kardinaal et al. [39], suggested that a 
change in challenge response is a more sensitive biomarker of metabolic resilience than chang-
es in fasting metabolism. This discrepancy might be due to either their particular study popu-
lation, which consisted of a homogeneous group of males with metabolic syndrome, whereas 
within our study the subjects were a more heterogeneous group of healthy abdominally obese. 
The study from Kardinaal et al. also used a high fat challenge, which may provoke a more tar-
geted postprandial response as the mixed meal used in our study. In our study the strong and 
rapid direct uptake of amino acids and fatty acids from the mixed meal may have shrouded 
observation of postprandial metabolic differences. Therefore the recent recommendation of 
a mixed meal as the optimal challenge for demonstrating subtle improvements in metabolic 
flexibility has been expounded with regard to the composition of such a challenge [6]. 
Genes related to carbohydrate metabolism were downregulated in abdominally obese sub-
jects upon a mixed meal challenge after weight loss compared to before the weight loss inter-
vention. Figure 3 shows that the reduced response of genes in the carbohydrate metabolism 
to the challenge results in expression levels that are more comparable to expression levels 
observed in lean subjects. As insulin sensitivity is also improved after weight loss the atten-
uation of the expression of genes in carbohydrate metabolism seems consistent with this im-
provement in insulin sensitivity. Similarly, genes related to inflammatory pathways were also 
showed a dampened response in the abdominally obese after weight loss, which is also more 
in line with the response observed in lean subjects. Overall, we conclude that the post-prandial 
responses to weight loss seem to shift towards the lean response after weight loss with regard 
to carbohydrate metabolism and the inflammatory response. Although the observed shift sug-
gest that subjects after weight loss have a more lean phenotype, they do not reach the level of 
lean subjects, which is in line with the actual weight loss. Furthermore, at the end of the study 
the subjects were maintaining weight. This may result in a less pronounced response when 
comparing to studies in which subjects were still losing weight at the time of measurement.
cOnclusIOn
Our results are in line with recent observations that the metabolic phenotype of abdom-
inally obese and lean subjects is different with respect to both the plasma metabolome and 
PBMC gene expression in the fasting state. The difference in phenotypic flexibility between 
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lean and abdominally obese was also reflected in the mixed meal postprandial response of the 
plasma metabolome and PBMC gene expression. The difference in response of a downstream 
metabolite of a branched chain amino acid suggests compromised function of the BCKDH 
complex in the abdominally obese. The metabolites and genes that differ at baseline show 
minor overlap with those that are differ in their postprandial response. This indicates that the 
mechanisms accounting for the observed differences between lean and abdominally obese 
in the fasted state are different from the mechanisms underlying the differences during the 
postprandial mixed meal response.
Compared to the difference in lean-abdominally obese metabolic phenotype, weight loss 
had a small effect on the fasting plasma metabolome. Also the effect of weight loss on baseline 
gene expression in PBMCs was smaller; the main effect was a shift of genes related to oxida-
tive phosphorylation towards the lean phenotype. The impact of weight loss on the mixed 
meal postprandial response of plasma metabolites and PBMC gene expression was modest 
and mainly point to altered enzymatic lipid oxidation and carbohydrate metabolism upon 
weight loss. The weight loss induced shifts of baseline and postprandial response of plasma 
metabolome and PBMC gene expression showed little overlap with the differences between 
lean-abdominally obese metabolic phenotype. 
The modest number of significant differences in postprandial metabolic responses be-
tween lean-abdominally obese and abdominally obese before and after weight loss may be 
explained by the complex composition of the mixed meal. Hence, the composition of meal 
challenges should be considered carefully in order to provoke a distinct postprandial meta-
bolic response.
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Figure 1. Schematic overview of the study design. D1, D2: before and after intervention, 
respectively. WL: weight loss intervention group, CTRL: control group. The arrows indicate 
the phenotype comparisons made in this study (lean vs abdominally obese, before and after 
interventions. 
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Figure 1. Schematic overview of the study design. D1, D2: before and after intervention, respectively. WL: weight 
loss intervention group, CTRL: contr l group. The arrows indicate the ph n type compariso s made in this study 
(lean vs abdominally obese, before and after interventions.
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Figure 2. Postprandial mixed meal response curves of, valine, glucose, palmitoylcarnitine and 
acetoacetate, as representative metabolites from glycolysis, amino acid metabolism, lipolysis 
and ketogenesis, respectively. Mean curves are presented for lean (black) and abdominally 
obese subjects are presented , the latter before (green) and after (blue) weight loss intervention 
(see Figure 1). The bars represent variation within these groups. 
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Figure 3.Overview of lean-abdominally obese differences in expression of genes related to 
(Left) oxidative phosphorylation and (Right) carbohydrate metabolism in PBMCs at fasting 
(T0) and during postprandial response (∆Lean vs. ∆ Abdominally obese postprandial) to a 
mixed meal challenge. Also shown are effects of weight loss on gene expression in PBMCs of 
abdominally obese subjects at baseline (abdominally obese after weight loss vs. abdominally 
obese before weight loss) and during postprandial phase (∆ abdominally obese after weight 
loss vs. ∆ abdominally obese before weight loss). The heatmap is based on moderates t-
statistics for each comparison which has the same interpretation as an ordinary t-statistic 
except that the standard errors have been moderated across genes using a simple Bayesian 
model. 
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Table 1.Characteristics of lean subjects and abdominally obese subjects before and after 
weight loss or control interventions. 
 Lean  WL(D1) WL(D2) CTRL(D1) CTRL(D2) 
Number 15 14 14 15 15 
Age (y)  47.4 ±17 44 ± 15  44.8 ± 14.0  
Weight (kg) 73  ±  7.5 96.6 ± 8.6 87.3 ± 8.6* 98.9 ± 9.9 98.1  ± 9.5 
Height (m) 1.8 ± 0.1 1.8 ± 0.1  1.8 ± 0.1  
BMI (kg/m2) 23.0 ± 2.0 30.0 ± 1.8 26.9 ± 1.6* 30.7 ± 2.9 30.4 ± 2.8 
Waist circumference (cm) 85.4 ± 6.7 106.8 ± 3.6 95.7 ± 4.5* 106.8 ± 3.9 106.2 ± 3.8 
Hip circumference (cm) 95.9 ± 4.1 108.4 ± 4.9 102.7 ± 4.5* 109.5 ± 7.0 109.3 ± 7.8 
LBM (kg) 54.2 ± 6.7 67.1 ± 6.9 61.5 ± 8.9 69.2 ±  10.4 69.8 ± 10.7 
Fat mass (%) 19.0 ± 6.5 29.5 ± 4.4 25.8 ± 5.0 29.8 ± 4.3 28.3 ± 4.1 
Glucose (mmol/L) 5.1 ± 2.9 5.3 ± 0.47 5.0 ± 0.33 5.3 ± 0.48 5.3 ± 0.37 
Insulin (uU/mL) 7.0 ± 1.7 12.5 ± 5.5 7.8 ± 3.4* 12.0 ± 6.5 12.1 ± 5.2 
Data are presented as mean ± SD. *: A significant effect of weight loss (P<0.05). WL: weight loss 
intervention, 
 
CTRL: control group, D1, D2: before and after intervention (see also Figure 1), 
 
 
  
BMI: Body mass index, LBM: lean body mass. 
Table 1. Characteristics of lean subjects and abdominally obese subjects before and after weight loss or control 
interventions.
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Table 2. Significant (P<0.05, lFDR< 0.2) differences between fasting metabolite concentrations (FC) and 
postprandial mixed meal response (iAUC) in plasma between lean and abdominally obese subjects.
 
Table 2. Significant (P<0.05, lFDR< 0.2) differences between fasting metabolite 
concentrations (FC) and postprandial mixed meal response (iAUC) in plasma between lean 
and abdominally obese subjects. 
 
 
P(Fasting) 
FC (Abdominally obese 
T0/Lean T0) 
P( iAUC) 
Acylcarnitines 
 
 
Palmitoylcarnitine <0.01 1.25  
Amino acids and 
 related metabolites 
 
 
Serine <0.01 0.86  
Beta alanine 0.02 1.07  
Asparagine 0.02 0.9  
Creatinine <0.01 1.21  
 Isoleucine <0.01 1.24  
 Alanine <0.01 1.18 <0.01 
 Tyrosine <0.01 1.2  
 Valine 0.01 1.13  
Keto-Leucine 0.01 1.13  
 Carnitine 0.02 1.07  
 Leucine 0.03 1.11  
Proline   <0.01 
Methylmalonic acid   <0.01 
Threonine   0.01 
Histidine   0.01 
Methionine   0.01 
Phosphocholine   0.01 
2.hydroxyisovalerate   0.01 
Oxylipins 
  
 
 5-HETE <0.01 0.61  
 12-13-EpOME 0.01 0.65  
 9-HODE 0.02 0.71  
 9-HOTrE 0.02 0.68  
TCA cycle and related metabolites 
 
 
Glyceric acid <0.01 0.95  
 Beta glucose 0.02 1.09  
 Alpha glucose 0.02 1.08  
FC: Fold change. Differences in response were calculated on the basis of iAUC. iAUC: incremental area under the 
curve. 
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Table 3. Effect of weight loss (P<0.05, lFDR<0.2) on fasted state (T0, FC) metabolite 
concentrations and postprandial mixed meal challenge response (iAUC) in plasma of 
abdominally obese subjects.  
Metabolites P FC(WL) P(iAUC) 
Amino acids and related 
metabolites 
   
Glycine <0.01 1.18  
Creatinine <0.01 0.88  
Glutamine   <0.01 
Histidine   <0.01 
Creatine   <0.01 
Pyroglutamic acid   <0.01 
Glutamic acid <0.01 0.66  
Oxylipins    
 TXB2   <0.01 
 PGE2   <0.01 
12S.HHTrE   <0.01 
5.HETE   <0.01 
11.HETE   0.02 
TCA cycle and related 
metabolites 
   
Glucose   0.01 
Acylcarnitines    
Choline   0.01 
FC: Fold change (T0, after weight loss/T0, before weight loss). Differences in postprandial response 
 were determined on the basis of iAUC. iAUC: incremental area under the curve significant at P<0.05. 
 
 
Table 3. Effect of weight loss (P<0.05, lFDR<0.2) on fasted state (T0, FC) metabolite concentrations and postprandial 
mixed eal challenge response (iAUC) in plasma of abdominally obese subjects. 
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suPPleMenTARy MATeRIAl
Postprandial metabolic response in lean and abdominally obese subjects
Despite the significant inter-individual variation between the time-responses, yet differen-
tiating features can be recognized according to four dominant postprandial metabolic events 
[30, 41] : glycolysis, lipolysis, ketogenesis, proteolysis and amino acid oxidation
Glycolysis In lean volunteers the mixed meal provoked a prolonged insulin response, in 
line with previous observations [6]. As a consequence postprandial effects on glycolysis, lip-
olysis and ketogenesis can be expected [30]. Indeed, the initial postprandial increase of glucose 
was rapidly followed by a strong insulin-induced decrease. This pattern was also observed for 
lactate [30] and downstream TCA metabolites [41]. The postprandial response of glucose did 
not differ significantly between the lean and abdominally obese group (lFDR> 0.2), which was 
also the case for most downstream TCA metabolites, except for citrate.
Lipolysis The essential fatty acids linoleic acid (LA) and alpha linolenic acid (ALA) follow 
the characteristic insulin-induced non esterified fatty acid response (NEFA), which is a strong 
decrease followed by an increase after 1 hour (Supplementary Figure S3-a ). Hence in our 
study mixed meal challenge did not induce the lag phase response for longer chain (C>16) fatty 
acids [41] that was previously observed for another mixed meal challenge. Apparently, for 
mixed meal challenge in our study, insulin-induced depletion of FFAs is dominant over intake 
of FFAs. Also the FFA response did not differ significantly between the lean and abdominally 
obese group. 
Within this study we assessed oxylipins since they have been associated with a range of 
inflammatory mechanisms. The enzymatic oxidation pathways of the oxylipins are known, 
but our attempt to model their postprandial response with a recently introduced first order 
kinetic model [42] was not successful. Only modest correlations between oxylipins and their 
precursors were found (Supplementary Table S7) which we attribute this to complexity of 
having both an insulin effect combined with dietary intake of fatty acids in the mixed meal 
challenge. The postprandial response of several oxylipins was however different between the 
lean an abdominally obese group, which suggests differences in lipid oxidation between the 
abdominally obese and lean groups.
Once the free fatty acids (FFAs) are destined as fuel they enter the mitochondria as acyl-
carnitines in order to undergo stepwise β-oxidation to acetylcarnitine which enters the TCA 
cycle for energy production. Plasma levels of fatty acid derived acylcarnitines (FAAC, Sup-
plementary Table S8) reflect increased FFA availability and/or a shift in β-oxidation flux. In 
the lean subjects, the mixed meal challenge induced a monotonous postprandial decrease of 
both fatty acid derived acylcarnitines and acetylcarnitine, in line with reduced availability of 
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FFAs and/or reduced β-oxidation upon switching from b-oxidation to glycolysis [43]. The ratio 
between C2 (acetyl) carnitine and fatty acid derived acylcarnitines has been proposed as di-
rect readouts for intracellular β-oxidation [7]. During the postprandial phase we observe that 
for the C2/FAAC ratios interindividual difference is more pronounced at fasting rather than 
response (Supplementary Figure S3-b). We could however not observe a difference between 
the abdominally obese and lean groups for these C2/FAAC rations. 
Nadir acylcarnitine levels have been proposed as a single parameter summary of their 
postprandial response [25]. We found correlations with phenotypical parameters such as 
HOMA and lean body mass (Supplementary Table S9). Although this suggests that postprandi-
al acylcarnitine responses are related to fatty acid oxidation flux, we could not observe statis-
tically significant differences between the lean and abdominally obese group.
Ketogenesis In lean volunteers we observe a monotonous postprandial decrease of the ke-
tone bodies β-hydroxybutyric acid, and acetone (Supplementary Figure S3-c ) which is in line 
with previous observations upon administration of mixed meal challenge[41]. The decrease 
can be explained by direct inhibition of ketogenesis by insulin and indirectly by decrease of 
FFA due to inhibition of lipolysis. Acetoacetate however, goes up due to enhanced postpran-
dial amino acid flux (Figure 1). In the abdominally obese none of the ketone bodies showed a 
postprandial response.
Proteolysis and amino acid oxidation Upon administration of the mixed meal challenge 
insulin-induced inhibition of proteolysis is expected. An indication for an impact on muscle 
metabolism is the weak postprandial decrease in creatinine for lean subjects (Supplementary 
S5-d), which is in contrast to a previous observation [41]. The postprandial response in the 
abdominally obese did however not differ significantly from[33] the lean group. 
Unfortunately, observation at the level of amino acids is obscured by direct dietary uptake 
upon the mixed meal challenge [33]. Nevertheless, still several amino acids differ in their post-
prandial response in lean vs abdominally obese, in line with a recent study [33]. In this study 
these effects were attributed to impairment of the TCA cycle in abdominally obese, this was 
confirmed by differences in postprandial response of citrate and succinate. 
The mixed meal challenge induces a strong postprandial increase of BCAA which can be 
explained by direct uptake and transamination of other dietary amino acids in the splanchnic 
bed [44]. After the steep increase of BCAAs, their levels drop rapidly due to insulin-induced 
uptake in muscle or other tissues[45]. Within the muscle, BCAAs (leucine in particular) are 
rapidly transaminated to branched chain α-keto acids (BCKAs) and excess nitrogen is subse-
quently released as glutamine. Indeed we observed a second peak in the glutamine response 
curve which we attribute to BCAA’s transferring their amine group (Supplementary Figure 
S3-e ) [46]. The BCKAs are oxidized to C4-5-CoA derivatives of CoA to finally produce acetoace-
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tate, C2(acetyl)-CoA and C3 (proprionyl)-CoA, all of which can enter the TCA cycle [45]. Excess 
levels of the C3-5 fatty acids appear in plasma as amino acid derived acylcarnitines (AAAC, 
Supplementary Table S3) which can be considered as proxies of BCAA oxidation. The kinetic 
profile of the AAACs generally follows the BCAA profile (only propionyl and isovaleryl with 
a bit delay compare to BCAAs. During the postprandial phase we observe that for the BCAA/
AAAC ratios inter-individual differences are more pronounced at fasting rather than for their 
postprandial response (Supplementary Figure S3-f). The postprandial response of the BCAAs 
and AAACs does not differ between lean and abdominally obese, but interestingly we observe 
significant differences in the response of two branched chain keto acids (α-ketoisovaleric acid, 
2-hydroxyisovalerate) and methylmalonic acid (Supplementary Figure S3-g). This indicates 
that in the abdominally obese group oxidation of mitochondrial BCAA by the BCKDH com-
plex might be impaired, causing temporary postprandial accumulation of these downstream 
BCAAs catabolites[34].
W e i g h t  l o s s  m o d e r a t e l y  a f f e c t s  t h e  m i x e d  m e a l  c h a l l e n g e 
r e s p o n s e  o f  t h e  p l a s m a  m e t a b o l o m e  a n d  t r a n s c r i p t o m e  o f 
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Figure s1. Flow diagram showing the number of genes of which the expression was significantly different between 
lean (n=15) and abdominally obese (n=29) subjects at fasting, the number of genes that changed in expression 
after a mixed meal challenge and the number of genes that changed differently in expression in abdominally obese 
relative to the lean subjects after a mixed meal challenge. A change was significant if P< 0.05. 
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Figure S1. Flow diagram showing the number of genes of which the expression was 
significantly different between lean(n=15) and abdominally obese (n=29) subjects at fasting, 
the number of genes that changed in expression after a mixed meal challenge and the number 
of genes that changed differently in expression in abdominally obese relative to the lean 
subjects after a mixed meal challenge. A change was significant if P< 0.05.  
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Figure s2. Flow diagram showing the number of genes of which the expression was significantly different in 
abdominally obese (n=29) before weight loss (D1) in response to mixed meal challenge, the number of genes that 
changed significantly in expression before (D1) and after (D2) intervention (WL, CRTL) in response to mixed meal 
challenge, the number of genes that changed significantly at T0 comparing subjects in WL or CTRL before and after 
intervention. A change was significant if P< 0.05.
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Figure S2. Flow diagram showing the number of genes of which the expression was 
significantly different in abdominally obese (n=29) before weight loss (D1) in response to 
mixed meal challenge, the number of genes that changed significantly in expression before 
(D1) and after (D2) intervention (WL, CRTL) in response to mixed meal challenge, the 
numb r of genes that changed significantly at T0 comparing subjects in WL or CTRL before 
and after intervention. A change was significant if P< 0.05. 
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Figure S3. Mean postprandial response curves for linoleic acid and α-linolenic acid (a). Mean 
postprandial curve (lean subjects only) of ratio between acetylcarnitine (c2) and fatty acid 
derived acylcarnitines; each color indicates one individual (b). Mean postprandial curve of 
ketone bodies (c), carnitine (d), glutamine and isoleucine (e). Individual plot (lean subjects 
only) of ratio between Isoleucine and 2-ethylbutyroylcarnitine; each color indicate one 
individual (f); Mean postprandial curve for alpha ketoisovaleric acid and 2-
hydroxyisovalerate (g). 
 
 
Figure s3. Mean postprandial response curves for linoleic acid and α-linolenic acid (a). Mean postprandial curve 
(lean subjects on y) of ratio between acetylcar itine (c2) and fatty ac  derived acylcar itines; each color indicates 
one individual (b). Mean postprandial curve of ketone bodies (c), carnitine (d), glutamine and isoleucine (e). 
Individual plot (lean subjects only) of ratio between Isoleucine and 2-ethylbutyroylcarnitine; each color indicate one 
individual (f); Mean postprandial curve for alpha ketoisovaleric acid and 2-hydroxyisovalerate (g).
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Table s1. Overview of significantly (FDR<0.2) positively /negatively enriched gene sets between abdominally obese 
vs. lean subjects at fasting (T0). 
Table S1. Overview of significantly (FDR<0.2) positively /negatively enriched gene sets 
between abdominally obese vs. lean subjects at fastin  (T0).  
 
Positively enriched gene sets 
NAME SIZE NES FDR q-val 
REACT_RESPIRATORY ELECTRON TRANSPORT 56 2.08 0.01 
WIP_HS_OXIDATIVE_PHOSPHORYLATION 46 2.03 0.02 
KEGG_OXIDATIVE PHOSPHORYLATION 92 2.02 0.01 
REACT_RESPIRATORY ELECTRON TRANSPORT 69 2.00 0.01 
WIP_HS_ELECTRON_TRANSPORT_CHAIN 76 1.92 0.04 
KEGG_PARKINSON'S DISEASE 86 1.91 0.04 
REACT_DESTABILIZATION OF MRNA BY KSRP 15 1.84 0.08 
REACT_DEADENYLATION-DEPENDENT MRNA DECAY 39 1.84 0.07 
KEGG_RNA DEGRADATION 60 1.80 0.11 
 
Negatively enriched gene sets 
NAME SIZE NES FDR q-val 
NCI_IL23PATHWAY 18 -2.08 0.08 
WIP_HS_NOTCH_SIGNALING_PATHWAY 24 -2.00 0.09 
BIOC_IL1RPATHWAY 22 -1.89 0.20 
NCI_ATF2_PATHWAY 27 -1.86 0.18 
BIOC_KERATINOCYTEPATHWAY 35 -1.84 0.18 
BIOC_NTHIPATHWAY 20 -1.81 0.20 
WIP_HS_OXIDATIVE_STRESS 18 -1.79 0.19 
KEGG_OSTEOCLAST DIFFERENTIATION 94 -1.77 0.20 
NCI_AP1_PATHWAY 36 -1.77 0.18 
 
Size indicates the number of total genes which are involve in the corresponding pathway. (NES):  
    normalised enrichment scores and (FDR): false discovery rate. 
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Table S2. Overview of significantly (FDR<0.2) up- and down-regulated gene sets during 
postprandial mixed meal challenge response between abdominally obese and lean subjects. 
 
Upregulated gene sets 
NAME SIZE NES FDR 
 q-val 
Direction 
    obese    Lean 
NCI_IL6_7PATHWAY 35 2.13 0.01 up         down 
NCI_IFNGPATHWAY 35 2.01 0.04 up         down 
KEGG_LYSOSOME 97 2.01 0.03 up         down 
KEGG_TUBERCULOSIS 114 2.00 0.02 up         down 
WIP_HS_TYPE_II_INTERFERON_SIGNALING_(IFNG) 27 1.99 0.02 up         down 
KEGG_STAPHYLOCOCCUS AUREUS INFECTION 28 1.99 0.02 up         down 
KEGG_PORPHYRIN AND CHLOROPHYLL 
METABOLISM 
18 1.98 0.02 up         down 
KEGG_INFLUENZA A 121 1.97 0.02 up         down 
KEGG_LEISHMANIASIS 51 1.96 0.02 up         down 
KEGG_PERTUSSIS 43 1.94 0.02 up         down 
KEGG_STARCH AND SUCROSE METABOLISM 20 1.89 0.04 up         down 
WIP_HS_EPITHELIUM_TARBASE 200 1.89 0.04 up         down 
NCI_ENDOTHELINPATHWAY 36 1.89 0.03 up         down 
REACT_TOLL LIKE RECEPTOR 7_8 (TLR7_8) CASCADE 60 1.89 0.03 up         down 
REACT_MYD88 DEPENDENT CASCADE INITIATED 
ON ENDOSOME 
60 1.89 0.03 up         down 
NCI_UPA_UPAR_PATHWAY 19 1.89 0.03 up         down 
REACT_TOLL LIKE RECEPTOR 9 (TLR9) CASCADE 62 1.87 0.03 up         down 
KEGG_SALMONELLA INFECTION 52 1.86 0.04 up         down 
WIP_HS_PROSTAGLANDIN_SYNTHESIS_AND_REGU
LATION 
16 1.86 0.04 up         down 
REACT_METABOLISM OF CARBOHYDRATES 88 1.84 0.04 up         down 
KEGG_PHAGOSOME 94 1.83 0.05 up         down 
REACT_TRAF6 MEDIATED INDUCTION OF  
NFKB AND MAP KINASES UPON TLR7_8 OR 9 
ACTIVATION 
59 1.82 0.05 up         down 
NCI_ANTHRAXPATHWAY 16 1.82 0.05 up         down 
NCI_ATF2_PATHWAY 27 1.81 0.05 up         down 
REACT_GOLGI ASSOCIATED VESICLE BIOGENESIS 42 1.81 0.05 up         down 
REACT_CLATHRIN DERIVED VESICLE BUDDING 49 1.81 0.05 up         down 
REACT_TRANS-GOLGI NETWORK VESICLE BUDDING 49 1.80 0.05 up         down 
KEGG_OSTEOCLAST DIFFERENTIATION 94 1.78 0.06 up         down 
BIOC_KERATINOCYTEPATHWAY 35 1.78 0.06 down   down 
WIP_HS_IL-6_SIGNALING_PATHWAY 35 1.78 0.06 up         down 
KEGG_NEUROACTIVE LIGAND-RECEPTOR 
INTERACTION 
38 1.77 0.06 up         down 
WIP_HS_LEUKOCYTE_TARBASE 107 1.76 0.07 up         down 
 
 
 
 
Table s2. Overview of significantly (FDR<0.2) up- and down-regulated gene sets during postprandial 
mixed meal challenge response between abdominally obese and lean subjects.
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Table S2. Upregulated gene sets continued 
 
    
REACT_MEMBRANE TRAFFICKING 97 1.75 0.07 up         down 
BIOC_TIDPATHWAY 15 1.75 0.07 up         down 
NCI_TOLL_ENDOGENOUS_PATHWAY 19 1.75 0.07 up         down 
WIP_HS_OXIDATIVE_STRESS 18 1.74 0.08 up         down 
KEGG_COMPLEMENT AND COAGULATION 
CASCADES 
15 1.74 0.08 up         down 
NCI_HES_HEYPATHWAY 28 1.74 0.07 up         down 
BIOC_IL1RPATHWAY 22 1.73 0.08 up         down 
REACT_P75 NTR RECEPTOR-MEDIATED SIGNALLING 62 1.73 0.07 up         down 
REACT_MAP KINASE ACTIVATION IN TLR CASCADE 42 1.73 0.08 up         down 
WIP_HS_REGULATION_OF_TOLL-
LIKE_RECEPTOR_SIGNALING_PATHWAY 
96 1.72 0.08 up         down 
KEGG_MALARIA 23 1.72 0.07 up         down 
NCI_LYSOPHOSPHOLIPID_PATHWAY 38 1.72 0.07 up         down 
KEGG_FRUCTOSE AND MANNOSE METABOLISM 22 1.71 0.08 up         down 
WIP_HS_SENESCENCE_AND_AUTOPHAGY 61 1.69 0.10 up         down 
WIP_HS_SQUAMOUS_CELL_TARBASE 94 1.69 0.10 up         down 
REACT_CYTOKINE SIGNALING IN IMMUNE SYSTEM 154 1.69 0.10 up         down 
REACT_GLUCOSE METABOLISM 44 1.68 0.10 up         down 
NCI_HNF3APATHWAY 18 1.68 0.10 up         down 
REACT_ASSOCIATION OF TRIC_CCT WITH TARGET 
 PROTEINS DURING BIOSYNTHESIS 
23 1.67 0.11 up         down 
KEGG_FATTY ACID METABOLISM 26 1.67 0.10 down   down 
WIP_HS_NOD_PATHWAY 28 1.67 0.10 up         down 
REACT_INTERLEUKIN-1 SIGNALING 34 1.67 0.11 up         down 
REACT_ERK_MAPK TARGETS 17 1.66 0.11 up         down 
REACT_MAPK TARGETS_ NUCLEAR EVENTS 
MEDIATED 
 BY MAP KINASES 
25 1.66 0.11 up         down 
WIP_HS_PHYSIOLOGICAL_AND_PATHOLOGICAL_ 
HYPERTROPHY_OF_THE_HEART 
17 1.65 0.11 down   down 
KEGG_PENTOSE PHOSPHATE PATHWAY 19 1.65 0.12 up         down 
REACT_TRAF6 MEDIATED INDUCTION OF 
PROINFLAMMATORY CYTOKINES 
51 1.65 0.12 up         down 
KEGG_GALACTOSE METABOLISM 17 1.64 0.12 up         down 
WIP_HS_IL-3_SIGNALING_PATHWAY 37 1.63 0.12 up         down 
REACT_SIGNALING BY INTERLEUKINS 85 1.63 0.13 up         down 
WIP_HS_GPCR_LIGAND_BINDING 24 1.63 0.13 up         down 
REACT_INTERFERON SIGNALING 75 1.63 0.12 up         down 
REACT_NRAGE SIGNALS DEATH THROUGH JNK 30 1.62 0.13 up         down 
REACT_HEXOSE TRANSPORT 33 1.62 0.13 up         down 
NCI_P38ALPHABETADOWNSTREAMPATHWAY 29 1.62 0.13 up         down 
KEGG_SPHINGOLIPID METABOLISM 23 1.62 0.13 up         down 
NCI_GMCSF_PATHWAY 31 1.62 0.13 up         down 
WIP_HS_KIT_RECEPTOR_SIGNALING_PATHWAY 39 1.62 0.13 up         down 
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Downregulated gene sets 
  
  Size indicates the number of total genes which are involve in the corresponding pathway. (NES):  
    normalised enrichment scores and (FDR): false discovery rate. 
 
 
 
 
 
 
NCI_KITPATHWAY 37 1.51 0.19 up         down 
 
 
 
 
 
Table S2. Upregulated gene sets continued 
 
    
NCI_RAC1_REG_PATHWAY 28 1.51 0.19 up         down 
NCI_S1P_S1P3_PATHWAY 20 1.51 0.19 up         down 
NAME SIZE NES FDR q-val Direction 
    obese Lean 
 
NCI_CD8TCRPATHWAY 47 -2.12 0.02 down    up 
REACT_GENERATION OF SECOND MESSENGER  
MOLECULES 
29 -1.91 0.13 down    up 
REACT_BRANCHED-CHAIN AMINO ACID CATABOLISM 15 -1.87 0.12 down    up 
REACT_BIOSYNTHESIS OF THE N-GLYCAN PRECURSOR 24 -1.83 0.14 down    up 
WIP_HS_GENERIC_TRANSCRIPTION_PATHWAY 15 -1.81 0.12 down    up 
NCI_TCR_PATHWAY 58 -1.70 0.26 down    up 
KEGG_T CELL RECEPTOR SIGNALING PATHWAY 81 -1.69 0.24 down    up 
NCI_CD8TCRDOWNSTREAMPATHWAY 46 -1.69 0.22 down    up 
WIP_HS_INFLAMMATORY_RESPONSE_PATHWAY 15 -1.68 0.20 down    up 
BIOC_AMIPATHWAY 17 -1.67 0.20 up          up 
KEGG_ABC TRANSPORTERS 19 -1.67 0.18 up          up 
REACT_TCR SIGNALING 57 -1.66 0.18 up          up 
REACT_GENERIC TRANSCRIPTION PATHWAY 134 -1.65 0.18 down    up 
BIOC_CSKPATHWAY 17 -1.62 0.19 down    up 
NCI_IL2_STAT5PATHWAY  25 -1.61 0.20 up          up 
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KEGG_TOLL-LIKE RECEPTOR SIGNALING PATHWAY 69 1.62 0.13 up         down 
NCI_MAPKTRKPATHWAY 27 1.61 0.13 up         down 
REACT_GLUCOSE TRANSPORT 33 1.61 0.13 up         down 
KEGG_FC GAMMA R-MEDIATED PHAGOCYTOSIS 73 1.61 0.13 up         down 
NCI_RB_1PATHWAY 42 1.61 0.13 up         down 
KEGG_RHEUMATOID ARTHRITIS 48 1.60 0.14 up         down 
BIOC_NTHIPATHWAY 20 1.59 0.14 up         down 
WIP_HS_IL-5_SIGNALING_PATHWAY 29 1.59 0.14 up         down 
WIP_HS_TOLL-
LIKE_RECEPTOR_SIGNALING_PATHWAY 
69 1.59 0.15 up         down 
REACT_TOLL LIKE RECEPTOR 3 (TLR3) CASCADE 56 1.59 0.15 up         down 
REACT_INFLAMMASOMES 16 1.58 0.15 up         down 
KEGG_PPAR SIGNALING PATHWAY 22 1.58 0.15 up         down 
NCI_ARF_3PATHWAY 19 1.58 0.15 up         down 
REACT_INTERFERON GAMMA SIGNALING 54 1.57 0.15 up         down 
NCI_RAC1_PATHWAY 44 1.57 0.16 up         down 
REACT_INTERFERON ALPHA_BETA SIGNALING 43 1.57 0.16 up         down 
KEGG_ADIPOCYTOKINE SIGNALING PATHWAY 40 1.57 0.16 up         down 
KEGG_NEUROTROPHIN SIGNALING PATHWAY 88 1.56 0.17 up         down 
WIP_HS_MRNA_PROCESSING 114 1.55 0.17 up         down 
WIP_HS_FOLATE_METABOLISM 29 1.55 0.17 up         down 
WIP_HS_LYMPHOCYTE_TARBASE 305 1.55 0.17 up         down 
REACT_RECYCLING PATHWAY OF L1 26 1.55 0.17 up         down 
BIOC_HIVNEFPATHWAY 45 1.55 0.17 up         down 
KEGG_NOD-LIKE RECEPTOR SIGNALING PATHWAY 43 1.55 0.17 up         down 
REACT_NUCLEAR EVENTS (KINASE AND 
TRANSCRIPTION  
FACTOR ACTIVATION) 
20 1.54 0.17 up         down 
WIP_HS_APOPTOTIC_EXECUTION_PHASE 22 1.54 0.18 up         down 
KEGG_GLYCOLYSIS _ GLUCONEOGENESIS 33 1.54 0.18 up         down 
WIP_HS_INTRINSIC_PATHWAY_FOR_APOPTOSIS 16 1.54 0.17 up         down 
NCI_IL8CXCR1_PATHWAY 22 1.54 0.18 up         down 
REACT_G ALPHA (12_13) SIGNALLING EVENTS 47 1.54 0.18 up         down 
NCI_CDC42_PATHWAY 52 1.54 0.18 up         down 
REACT_CHAPERONIN-MEDIATED PROTEIN FOLDING 33 1.53 0.19 up         down 
WIP_HS_TNF-ALPHA-NF-KB_SIGNALING_PATHWAY 161 1.52 0.19 up         down 
NCI_TXA2PATHWAY 40 1.52 0.19 up         down 
NCI_CERAMIDE_PATHWAY 37 1.52 0.19 up         down 
REACT_L1CAM INTERACTIONS 50 1.52 0.19 up         down 
KEGG_AMOEBIASIS 40 1.52 0.19 up         down 
NCI_HIF1_TFPATHWAY 44 1.52 0.19 up         down 
KEGG_BLADDER CANCER 21 1.51 0.19 up         down 
NCI_RHOA_REG_PATHWAY 25 1.51 0.19 up         down 
W e i g h t  l o s s  m o d e r a t e l y  a f f e c t s  t h e  m i x e d  m e a l  c h a l l e n g e 
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Downregulated gene sets 
  
  Size indicates the number of total genes which are involve in the corresponding pathway. (NES):  
    normalised enrichment scores and (FDR): false discovery rate. 
 
 
 
 
 
 
NCI_KITPATHWAY 37 1.51 0.19 up         down 
 
 
 
 
 
Table S2. Upregulated gene sets continued 
 
    
NCI_RAC1_REG_PATHWAY 28 1.51 0.19 up         down 
NCI_S1P_S1P3_PATHWAY 20 1.51 0.19 up         down 
NAME SIZE NES FDR q-val Direction 
    obese Lean 
 
NCI_CD8TCRPATHWAY 47 -2.12 0.02 down    up 
REACT_GENERATION OF SECOND MESSENGER  
MOLECULES 
29 -1.91 0.13 down    up 
REACT_BRANCHED-CHAIN AMINO ACID CATABOLISM 15 -1.87 0.12 down    up 
REACT_BIOSYNTHESIS OF THE N-GLYCAN PRECURSOR 24 -1.83 0.14 down    up 
WIP_HS_GENERIC_TRANSCRIPTION_PATHWAY 15 -1.81 0.12 down    up 
NCI_TCR_PATHWAY 58 -1.70 0.26 down    up 
KEGG_T CELL RECEPTOR SIGNALING PATHWAY 81 -1.69 0.24 down    up 
NCI_CD8TCRDOWNSTREAMPATHWAY 46 -1.69 0.22 down    up 
WIP_HS_INFLAMMATORY_RESPONSE_PATHWAY 15 -1.68 0.20 down    up 
BIOC_AMIPATHWAY 17 -1.67 0.20 up          up 
KEGG_ABC TRANSPORTERS 19 -1.67 0.18 up          up 
REACT_TCR SIGNALING 57 -1.66 0.18 up          up 
REACT_GENERIC TRANSCRIPTION PATHWAY 134 -1.65 0.18 down    up 
BIOC_CSKPATHWAY 17 -1.62 0.19 down    up 
NCI_IL2_STAT5PATHWAY  25 -1.61 0.20 up          up 
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Table S3. Correlation of the fasting plasma metabolome at baseline with HOMA 
A  Acylcarnitine C2/Cn vs. HOMA C2vs. HOMA Cn vs. HOMA 
 Cn P ρ P ρ P ρ 
 AAAC       
 C4 (butyryl) <0.001 -0.44 0.70 -0.04 <0.001 0.41 
 C3 (propionyl) 0.01 -0.30   0.003 0.38 
 C5(2-
methylbutyroyl) 0.09 -0.21 
  0.02 0.28 
 C0 (carnitine) 0.1 -0.20   0.07 0.22 
 FAAC       
 C6 (hexanoyl) <0.001 -0.55   0.01 0.31 
 C18 (stearoyl) 0.4 -0.10 
  
0.9 0.01 
 C16 (palmitoyl) 0.07 -0.22   0.1 0.20 
 C14 (myristol) 0.1 -0.20   0.3 0.10 
B      AA vs. HOMA 
 BCAA     P ρ 
 Isoleucine     0.06 0.34 
 Leucine     0.02 0.30 
 Valine     0.02 0.30 
 Amino acids     P ρ 
 Tyrosine     <0.001 0.57 
 Phenyl alanine     0.02 0.30 
 2aminoadipic acid     0.06 0.24 
 
 
AAAC: amino acid derived acylcarnitine, FAAC: fatty acid derived acylcarnitines. AA: amino acid.  
ρ: Spearman's rank correlation coefficient. Fasting levels (T0) of all subjects (lean and abdominally ob
ese) before  
and after interventions were included. 
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Table S4. Overview of significantly (FDR<0.05) upregulated and downregulated gene sets in 
WL abdominally obese subjects at fasting (T0) before and after weight loss intervention (D2 
vs. D1) 
Upregulated gene sets 
NAME SIZE NES FDR q-val 
NCI_IL12_2PATHWAY 45 2.27 0 
KEGG_T CELL RECEPTOR SIGNALING PATHWAY 81 2.14 0.01 
KEGG_T CELL RECEPTOR SIGNALING PATHWAY 81 2.14 0.01 
BIOC_NTHIPATHWAY 20 2.05 0.02 
BIOC_PPARAPATHWAY 35 2.03 0.02 
NCI_FGF_PATHWAY 26 1.99 0.03 
NCI_FCER1PATHWAY 51 1.97 0.03 
REACT_NRAGE SIGNALS DEATH THROUGH JNK 30 1.95 0.03 
REACT_SIGNALING BY RHO GTPASES 77 1.94 0.03 
KEGG_SALMONELLA INFECTION 52 1.94 0.03 
REACT_RHO GTPASE CYCLE 77 1.94 0.03 
BIOC_IL1RPATHWAY 22 1.92 0.03 
NCI_TCRCALCIUMPATHWAY 18 1.91 0.03 
WIP_HS_NOD_PATHWAY 28 1.9 0.03 
KEGG_NEUROTROPHIN SIGNALING PATHWAY 88 1.9 0.03 
NCI_AP1_PATHWAY 36 1.89 0.03 
NCI_IL23PATHWAY 18 1.88 0.03 
REACT_SIGNALING BY GPCR 152 1.88 0.03 
REACT_INTERACTIONS OF THE IMMUNOGLOBULIN 
SUPERFAMILY (IGSF)  31 1.88 0.03 
KEGG_LEISHMANIASIS 51 1.88 0.03 
KEGG_CARBOHYDRATE DIGESTION AND ABSORPTION 19 1.87 0.03 
NCI_ERBB4_PATHWAY 20 1.86 0.03 
NCI_HIF1_TFPATHWAY 44 1.86 0.03 
KEGG_TOLL-LIKE RECEPTOR SIGNALING PATHWAY 69 1.86 0.03 
KEGG_NOD-LIKE RECEPTOR SIGNALING PATHWAY 43 1.84 0.04 
WIP_HS_RANKL-RANK_SIGNALING_PATHWAY 41 1.84 0.04 
REACT_G ALPHA (12_13) SIGNALLING EVENTS 47 1.84 0.04 
WIP_HS_TOLL-LIKE_RECEPTOR_SIGNALING_PATHWAY 69 1.83 0.04 
NCI_EPHBFWDPATHWAY 21 1.83 0.03 
NCI_ATF2_PATHWAY 27 1.83 0.03 
WIP_HS_INSULIN_SIGNALING 113 1.82 0.04 
NCI_IL1PATHWAY 26 1.82 0.04 
KEGG_OSTEOCLAST DIFFERENTIATION 94 1.81 0.04 
REACT_GPCR DOWNSTREAM SIGNALING 143 1.81 0.04 
NCI_CD8TCRDOWNSTREAMPATHWAY 46 1.8 0.04 
BIOC_KERATINOCYTEPATHWAY 35 1.8 0.04 
NCI_CXCR4_PATHWAY 78 1.8 0.04 
REACT_ION CHANNEL TRANSPORT 18 1.79 0.04 
Table s4. Overview of significantly (FDR<0.05) upregulated and downregulated gene sets in WL abdominally obese 
subjects at fasting (T0) before and after weight loss intervention (D2 vs. D1)
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Table S4. Upregulated gene sets continued    
KEGG_MTOR SIGNALING PATHWAY 36 1.79 0.04 
BIOC_TOLLPATHWAY 28 1.79 0.04 
 
Downregulated gene sets  
 
NAME SIZE NES FDR q-val 
KEGG_PARKINSON'S DISEASE 86 -2.5 0 
REACT_RESPIRATORY ELECTRON TRANSPORT 56 -2.45 0 
KEGG_OXIDATIVE PHOSPHORYLATION 92 -2.42 0 
WIP_HS_OXIDATIVE_PHOSPHORYLATION 46 -2.36 0 
WIP_HS_ELECTRON_TRANSPORT_CHAIN 76 -2.24 0 
REACT_FORMATION OF THE TERNARY COMPLEX, AND SUBSEQUENTLY, 
THE 43S COMPLEX 
39 -2.21 0 
REACT_PLATELET DEGRANULATION 46 -2.19 0 
REACT_CDK-MEDIATED PHOSPHORYLATION AND REMOVAL OF CDC6 45 -2.17 0 
REACT_UBIQUITIN-DEPENDENT DEGRADATION OF CYCLIN D1 45 -2.15 0 
REACT_UBIQUITIN-DEPENDENT DEGRADATION OF CYCLIN D 45 -2.13 0 
KEGG_PROTEASOME 40 -2.13 0 
REACT_DESTABILIZATION OF MRNA BY AUF1 (HNRNP D0) 50 -2.12 0 
REACT_SCF(SKP2)-MEDIATED DEGRADATION OF P27_P21 49 -2.11 0 
REACT_REGULATION OF APOPTOSIS 51 -2.09 0 
REACT_REGULATION OF ACTIVATED PAK-2P34 BY PROTEASOME 
MEDIATED DEGRADATION 
45 -2.09 0 
REACT_RESPONSE TO ELEVATED PLATELET CYTOSOLIC CA2+ 50 -2.07 0 
WIP_HS_PROTEASOME_DEGRADATION 56 -2.07 0 
REACT_P53-INDEPENDENT DNA DAMAGE RESPONSE 45 -2.04 0 
REACT_REGULATION OF ORNITHINE DECARBOXYLASE (ODC) 44 -2.03 0.01 
REACT_AUTODEGRADATION OF CDH1 BY CDH1_APC_C 55 -2.02 0 
REACT_VIF-MEDIATED DEGRADATION OF APOBEC3G 49 -2.02 0 
REACT_UBIQUITIN MEDIATED DEGRADATION OF PHOSPHORYLATED 
CDC25A 
45 -2.02 0 
REACT_APC_C_CDC20 MEDIATED DEGRADATION OF SECURIN 55 -2.01 0.01 
REACT_P53-INDEPENDENT G1_S DNA DAMAGE CHECKPOINT 45 -1.99 0.01 
REACT_CDT1 ASSOCIATION WITH THE CDC6_ORC_ORIGIN COMPLEX 49 -1.98 0.01 
REACT_DNA REPLICATION PRE-INITIATION 60 -1.97 0.01 
REACT_M_G1 TRANSITION 60 -1.97 0.01 
REACT_ACTIVATION OF APC_C AND APC_C_CDC20 MEDIATED 
DEGRADATION OF MITOTIC PROTEINS 
56 -1.97 0.01 
REACT_APC_C_CDC20 MEDIATED DEGRADATION OF MITOTIC PROTEINS 56 -1.97 0.01 
REACT_CYCLIN E ASSOCIATED EVENTS DURING G1_S TRANSITION 54 -1.97 0.01 
REACT_SCF-BETA-TRCP MEDIATED DEGRADATION OF EMI1 48 -1.96 0.01 
REACT_CDC20_PHOSPHO-APC_C MEDIATED DEGRADATION OF CYCLIN A 56 -1.95 0.01 
REACT_MITOTIC G1-G1_S PHASES 76 -1.93 0.01 
REACT_SYNTHESIS OF DNA 73 -1.92 0.01 
REACT_CYCLIN A_CDK2-ASSOCIATED EVENTS AT S PHASE ENTRY 56 -1.91 0.01 
REACT_REGULATION OF APC_C ACTIVATORS BETWEEN G1_S AND EARLY 
ANAPHASE 
61 -1.91 0.01 
W e i g h t  l o s s  m o d e r a t e l y  a f f e c t s  t h e  m i x e d  m e a l  c h a l l e n g e 
r e s p o n s e  o f  t h e  p l a s m a  m e t a b o l o m e  a n d  t r a n s c r i p t o m e  o f 
p e r i p h e r a l  b l o o d  m o n o n u c l e a r  c e l l s  i n  o b e s e  s u b j e c t s
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Table S4. Downregulated gene sets continued    
KEGG_RIBOSOME 66 -1.91 0.01 
KEGG_HUNTINGTON'S DISEASE 126 -1.89 0.01 
REACT_FORMATION OF A POOL OF FREE 40S SUBUNITS 74 -1.88 0.01 
REACT_ASSEMBLY OF THE PRE-REPLICATIVE COMPLEX 53 -1.88 0.01 
REACT_REGULATION OF DNA REPLICATION 58 -1.87 0.01 
REACT_G1_S TRANSITION 72 -1.87 0.01 
REACT_AUTODEGRADATION OF THE E3 UBIQUITIN LIGASE COP1 47 -1.86 0.01 
REACT_VIRAL MRNA TRANSLATION 63 -1.86 0.01 
REACT_PREFOLDIN MEDIATED TRANSFER OF SUBSTRATE  TO CCT_TRIC 18 -1.86 0.01 
REACT_COOPERATION OF PREFOLDIN AND TRIC_CCT  IN ACTIN AND 
TUBULIN FOLDING 
18 -1.85 0.01 
REACT_INFLUENZA VIRAL RNA TRANSCRIPTION AND REPLICATION 63 -1.85 0.01 
REACT_SWITCHING OF ORIGINS TO A POST-REPLICATIVE STATE 58 -1.85 0.01 
BIOC_PROTEASOMEPATHWAY 20 -1.84 0.01 
REACT_ORC1 REMOVAL FROM CHROMATIN 58 -1.84 0.01 
REACT_VPU MEDIATED DEGRADATION OF CD4 47 -1.84 0.01 
KEGG_ALZHEIMER'S DISEASE 112 -1.83 0.01 
REACT_RIBOSOMAL SCANNING AND START CODON RECOGNITION 44 -1.83 0.01 
REACT_EUKARYOTIC TRANSLATION TERMINATION 65 -1.82 0.02 
REACT_REMOVAL OF LICENSING FACTORS FROM ORIGINS 58 -1.81 0.02 
REACT_P53-DEPENDENT G1 DNA DAMAGE RESPONSE 51 -1.81 0.02 
REACT_S PHASE 82 -1.8 0.02 
REACT_P53-DEPENDENT G1_S DNA DAMAGE CHECKPOINT 51 -1.8 0.02 
REACT_APC_C-MEDIATED DEGRADATION OF CELL CYCLE PROTEINS 63 -1.79 0.02 
REACT_TRANSLATION INITIATION COMPLEX FORMATION 44 -1.78 0.02 
REACT_REGULATION OF MITOTIC CELL CYCLE 63 -1.77 0.02 
REACT_STABILIZATION OF P53 48 -1.77 0.02 
REACT_NONSENSE MEDIATED DECAY INDEPENDENT OF THE EXON 
JUNCTION COMPLEX 
70 -1.77 0.02 
REACT_G1_S DNA DAMAGE CHECKPOINTS 51 -1.76 0.02 
REACT_SIGNALING BY WNT 60 -1.75 0.02 
REACT_EUKARYOTIC TRANSLATION ELONGATION 67 -1.75 0.02 
REACT_DEGRADATION OF BETA-CATENIN BY THE DESTRUCTION 
COMPLEX 
60 -1.74 0.02 
REACT_REGULATION OF BETA-CELL DEVELOPMENT 67 -1.73 0.03 
REACT_INSULIN SYNTHESIS AND PROCESSING 101 -1.72 0.03 
KEGG_SPLICEOSOME 111 -1.71 0.03 
REACT_REGULATION OF GENE EXPRESSION IN BETA CELLS 67 -1.71 0.03 
REACT_POST-ELONGATION PROCESSING OF INTRONLESS PRE-MRNA 17 -1.7 0.03 
REACT_CHROMOSOME MAINTENANCE 47 -1.69 0.03 
REACT_NUCLEOSOME ASSEMBLY 25 -1.69 0.03 
PPARA_TARGETS 81 -1.68 0.04 
REACT_PROCESSING OF CAPPED INTRONLESS PRE-MRNA 17 -1.68 0.04 
    
 
Size indicates the number of total genes which are involve in the corresponding pathway. (NES): normalised 
enrichment scores and (FDR): false discovery rate 
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Table S5.Fasting (T0) and postprandial effects of abdominally obese 
 that underwent the control intervention.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Metabolites FC(T0) iAUC 
  P 
Acylcarnitines 
 
 
2.Methylbutyroylcarnitine 1.13 
Propionylcarnitine 1.17 
Isobutyrylcarnitine 1.22 0.04 
Stearoylcarnitine  0.01 
Octanoylcarnitine  0.04 
Decanoylcarnitine  0.04 
Amino acids and related 
metabolites 
 
 
Choline 1.02  
Methionine 1.17  
Phosphocholine 1.15  
Dimethylglycine 1.21*  
Leucine 1.06  
Isoleucine 1.07  
Arginine 1.15*  
Tyrosine 1.07 0.02 
Valine 1.1* <0.01 * 
N6.N6.N6.trimethyl.L.lysine 1.08*  
Ornithine 1.06  
Phenylalanine 1.1  
2.aminoadipic.acid 1.12 0.01 
Sarcosine  0.01 
Dimethylglycine  0.03 
Dimethylamine  0.04 
TCA cycle and related 
metabolites 
 
 
Aspartic acid 1.18  
Fumaric acid  <0.01* 
Oxylipins   
12.13.DiHOME  <0.01 
FC: Fold change (T0, T2, before and after control 
intervention, respectively), iAUC: Incremental area under 
the curve, *: Significant at P<0.05,lFDR<0.2. 
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Table S6. Overview of significantly (FDR<0.2) upregulated and downregulated gene sets in 
abdominally obese subjects in response to mixed meal challenge before and after weight loss 
intervention (Δ T4-T0, D2, vs. Δ T4-T0, D1). 
Upregulated gene sets 
NAME SIZE NES FDR q-val Direction 
    D2    D1 
 
WIP_HS_OXIDATIVE_PHOSPHORYLATION 46 2.09 0.03 up     down 
KEGG_OXIDATIVE PHOSPHORYLATION 92 1.94 0.09 up     down 
WIP_HS_ELECTRON_TRANSPORT_CHAIN 76 1.87 0.14 up     down 
REACT_RESPIRATORY ELECTRON TRANSPORT 56 1.84 0.14 up     down 
REACT_RESPIRATORY ELECTRON TRANSPORT 69 1.83 0.12 up     down 
KEGG_PARKINSON'S DISEASE 86 1.77 0.18 up     down 
 
 
Downregulated gene sets 
NAME SIZE NES FDR  
q-val 
Direction 
    D2     D1 
KEGG_GALACTOSE METABOLISM 17 -2.26 0.00 down   up 
NCI_HIF1_TFPATHWAY 44 -2.07 0.03 down   up 
WIP_HS_ESTROGEN_SIGNALING_PATHWAY 17 -2.01 0.05 down   up 
KEGG_CARBOHYDRATE DIGESTION AND ABSORPTION 19 -1.92 0.06 down   up 
BIOC_KERATINOCYTEPATHWAY 35 -1.93 0.07 down   up 
REACT_NRAGE SIGNALS DEATH THROUGH JNK 30 -1.93 0.08 down   up 
WIP_HS_PHYSIOLOGICAL_AND_PATHOLOGICAL_HYPERTROPHY_O
F_THE_HEART 
17 -1.95 0.08 down   up 
NCI_IL6_7PATHWAY 35 -1.82 0.09 down   up 
REACT_ION TRANSPORT BY P-TYPE ATPASES 17 -1.82 0.09 down   up 
NCI_EPOPATHWAY 27 -1.80 0.09 down   up 
WIP_HS_IL-3_SIGNALING_PATHWAY 37 -1.88 0.09 down   up 
BIOC_NTHIPATHWAY 20 -1.83 0.09 down   up 
WIP_HS_SREBP_SIGNALLING 22 -1.85 0.09 down   up 
NCI_ERBB2ERBB3PATHWAY 31 -1.80 0.09 down   up 
KEGG_PHOSPHATIDYLINOSITOL SIGNALING SYSTEM 55 -1.84 0.09 down   up 
WIP_HS_WNT_SIGNALING_PATHWAY 28 -1.83 0.10 down   up 
REACT_ION CHANNEL TRANSPORT 18 -1.86 0.10 down   up 
NCI_IL2_1PATHWAY 46 -1.81 0.10 down   up 
WIP_HS_RANKL-RANK_SIGNALING_PATHWAY 41 -1.86 0.10 down   up 
WIP_HS_KIT_RECEPTOR_SIGNALING_PATHWAY 39 -1.77 0.12 down   up 
REACT_GLUCOSE TRANSPORT 33 -1.75 0.12 down   up 
REACT_HEXOSE TRANSPORT 33 -1.73 0.12 down   up 
NCI_MAPKTRKPATHWAY 27 -1.74 0.13 down   up 
 
Table s6. Overview of significantly (FDR<0.2) upregulated and downregulated gene sets in 
abdominally obese subjects in response to mixed meal challenge before and after weight loss 
intervention (Δ T4-T0, D2, vs. Δ T4-T0, D1).
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Table S6. Downregulated gene sets continued     
KEGG_ADIPOCYTOKINE SIGNALING PATHWAY 40 -1.75 0.13 down   up 
WIP_HS_MICRORNAS_IN_CARDIOMYOCYTE_HYPERTROPHY 53 -1.76 0.13 down   up 
NCI_ATF2_PATHWAY 27 -1.75 0.13 down   up 
KEGG_STARCH AND SUCROSE METABOLISM 20 -1.72 0.13 down   up 
NCI_AVB3_OPN_PATHWAY 26 -1.73 0.13 down   up 
NCI_IL1PATHWAY 26 -1.74 0.13 down   up 
NCI_NECTIN_PATHWAY 19 -1.71 0.13 down   up 
NCI_AMB2_NEUTROPHILS_PATHWAY 25 -1.71 0.13 down   up 
NCI_AR_TF_PATHWAY 39 -1.71 0.13 down   up 
KEGG_NEUROTROPHIN SIGNALING PATHWAY 88 -1.68 0.14 down   up 
WIP_HS_IL-1_PATHWAY 42 -1.68 0.14 down   up 
BIOC_IL1RPATHWAY 22 -1.69 0.14 down   up 
KEGG_FOCAL ADHESION 93 -1.68 0.15 down   up 
REACT_SIGNALLING TO ERKS 25 -1.69 0.15 down   up 
NCI_IL23PATHWAY 18 -1.65 0.15 down   up 
REACT_RHO GTPASE CYCLE 77 -1.65 0.15 down   up 
REACT_P75 NTR RECEPTOR-MEDIATED SIGNALLING 62 -1.65 0.15 down   up 
REACT_SIGNALING BY RHO GTPASES 77 -1.65 0.15 down   up 
NCI_ANGIOPOIETINRECEPTOR_PATHWAY 34 -1.67 0.15 down   up 
KEGG_ECM-RECEPTOR INTERACTION 15 -1.65 0.16 down   up 
NCI_PI3KCIPATHWAY 41 -1.66 0.16 down   up 
BIOC_IL7PATHWAY 15 -1.64 0.16 down   up 
REACT_INTEGRIN CELL SURFACE INTERACTIONS 37 -1.64 0.16 down   up 
BIOC_GLEEVECPATHWAY 21 -1.63 0.16 down   up 
WIP_HS_IL-7_SIGNALING_PATHWAY 22 -1.65 0.16 down   up 
NCI_VEGFR1_2_PATHWAY 56 -1.63 0.16 down   up 
REACT_MITOCHONDRIAL TRNA AMINOACYLATION 15 -1.66 0.16 down   up 
WIP_HS_FOCAL_ADHESION 91 -1.63 0.16 down   up 
REACT_SIGNALLING BY NGF 160 -1.66 0.16 down   up 
BIOC_PPARAPATHWAY 35 -1.62 0.17 down   up 
REACT_INTERACTIONS OF THE IMMUNOGLOBULIN SUPERFAMILY 
(IGSF) MEMBER PROTEINS 
31 -1.58 0.17 down   up 
KEGG_MISMATCH REPAIR 18 -1.59 0.17 down   up 
REACT_NCAM SIGNALING FOR NEURITE OUT-GROWTH 21 -1.59 0.17 down   up 
WIP_HS_INTEGRIN-MEDIATED_CELL_ADHESION 59 -1.62 0.17 down   up 
REACT_NETRIN-1 SIGNALING 19 -1.57 0.17 down   up 
WIP_HS_EGF_RECEPTOR_SIGNALING_PATHWAY 116 -1.58 0.17 down   up 
KEGG_FC EPSILON RI SIGNALING PATHWAY 51 -1.59 0.17 down   up 
WIP_HS_IL-4_SIGNALING_PATHWAY 36 -1.59 0.17 down   up 
NCI_GMCSF_PATHWAY 31 -1.59 0.17 down   up 
KEGG_ALDOSTERONE-REGULATED SODIUM REABSORPTION 17 -1.58 0.17 down   up 
REACT_REGULATION OF GLUCOKINASE BY GLUCOKINASE 
REGULATORY PROTEIN 
27 -1.58 0.17 down   up 
NCI_NETRIN_PATHWAY 19 -1.58 0.17 down   up 
NCI_NETRIN_PATHWAY 19 -1.58 0.17 down   up 
NCI_ATM_PATHWAY 27 -1.59 0.17 down   up 
BIOC_EDG1PATHWAY 15 -1.58 0.17 down   up 
 
W e i g h t  l o s s  m o d e r a t e l y  a f f e c t s  t h e  m i x e d  m e a l  c h a l l e n g e 
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Size indicates the number of total genes which are involve in the corresponding pathway.(NES): normalised 
enrichment scores and (FDR): false discovery rate 
 
 
 
 
 
 
 
Table S6. Downregulated gene sets continued     
REACT_GTP HYDROLYSIS AND JOINING OF THE 60S RIBOSOMAL 
SUBUNIT 
83 -1.57 0.17 down   up 
REACT_SIGNALING BY INTERLEUKINS 85 -1.57 0.17 down   up 
BIOC_TNFR2PATHWAY 16 -1.61 0.17 down   up 
KEGG_RIBOSOME BIOGENESIS IN EUKARYOTES 57 -1.60 0.17 down   up 
REACT_EFFECTS OF PIP2 HYDROLYSIS 15 -1.61 0.17 down   up 
NCI_FAK_PATHWAY 47 -1.60 0.17 down   up 
NCI_IFNGPATHWAY 35 -1.60 0.18 down   up 
BIOC_INTEGRINPATHWAY 26 -1.56 0.18 down   up 
WIP_HS_EBV_LMP1_SIGNALING 16 -1.56 0.18 down   up 
NCI_MTOR_4PATHWAY 58 -1.60 0.18 down   up 
REACT_SIGNALLING TO RAS 18 -1.60 0.18 down   up 
NCI_CXCR4_PATHWAY 78 -1.55 0.18 down   up 
KEGG_TIGHT JUNCTION 61 -1.54 0.18 down   up 
NCI_CD40_PATHWAY 23 -1.55 0.18 down   up 
REACT_GLOBAL GENOMIC NER (GG-NER) 27 -1.55 0.18 down   up 
KEGG_INOSITOL PHOSPHATE METABOLISM 42 -1.55 0.19 down   up 
KEGG_HOMOLOGOUS RECOMBINATION 17 -1.54 0.19 down   up 
BIOC_IL2RBPATHWAY 28 -1.54 0.19 down   up 
NCI_REG_GR_PATHWAY 54 -1.53 0.19 down   up 
KEGG_VEGF SIGNALING PATHWAY 45 -1.53 0.19 down   up 
REACT_NUCLEAR IMPORT OF REV PROTEIN 30 -1.53 0.19 down   up 
WIP_HS_INSULIN_SIGNALING 113 -1.53 0.19 down   up 
REACT_APOPTOTIC EXECUTION  PHASE 36 -1.50 0.19 down   up 
NCI_ERBB4_PATHWAY 20 -1.50 0.20 down   up 
     
134
Table S7. Overview of downstream oxylipins produced from AA, LA, ALA, DGLA, EPA, 
and DHA by the COX, LOX and CYP oxidizing enzymes. Spearman correlations between 
oxylipins and their precursors (AA and LA) have been presented (P<0.05)  
Precursor Downstream oxylipin Enzyme P Ρ 
 
 
AA 
5.HETE 5-LOX  <0.001 0.34 
11.HETE COX2 <0.001 0.37 
PGE2 COX <0.001 0.24 
TXB2 COX <0.001 0.22 
12S.HHTrE COX0 <0.001 0.17 
 
 
LA 
12.13.EpOME CYP450 NS  
9.HODE 5-LOX NS  
13.HODE 15-LOX <0.001 0.30 
12.13.DiHOME CYP4500 0.003 -0.14 
9.12.13.TriHOME CYP450 <0.001 -0.42 
ALA 9.HOTrE LOX <0.001 -0.20 
DGLA PGF1a COX   
EPA 17.18.DiHETE CYP450   
DHA 19.20.DiHDPA CYP450   
10.HDoHE Auto-oxidation   
ρ: Spearman rank correlation coefficient, NS: Not significant. 
 
 
Table s7. Overview of downstream oxylipin  produced from AA, LA, ALA, DGLA, EPA, and DHA by the COX, LOX 
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Table S7. Overview of downstream oxylipins produced from AA, LA, ALA, DGLA, EPA, 
and DHA by the COX, LOX and CYP oxidizing enzymes. Spearman correlations between 
oxylipins and their precursors (AA and LA) have been presented (P<0.05)  
Precursor Downstream oxylipin Enzyme P Ρ 
 
 
AA 
5.HETE 5-LOX  <0.001 0.34 
11.HETE COX2 <0.001 0.37 
PGE2 COX <0.001 0.24 
TXB2 COX <0.001 0.22 
12S.HHTrE COX0 <0.001 0.17 
 
 
LA 
12.13.EpOME CYP450 NS  
9.HODE 5-LOX NS  
13.HODE 15-LOX <0.001 0.30 
12.13.DiHOME CYP4500 0.003 -0.14 
9.12.13.TriHOME CYP450 <0.001 -0.42 
ALA 9.HOTrE LOX <0.001 -0.20 
DGLA PGF1a COX   
EPA 17.18.DiHETE CYP450   
DHA 19.20.DiHDPA CYP450   
10.HDoHE Auto-oxidation   
ρ: Spearman rank correlation coefficient, NS: Not significant. 
 
 
Table s8. Amino acid (AAAC) and fatty acid (FAAC) derived acylcarnitines covered in this study.
Table S8. Amino acid (AAAC) and fatty acid (FAAC) derived acylcarnitines covered in this 
study. 
 -Carnitine Abbreviation Origin 
 
 
AAAC (C2-5) 
Acetyl- C2 Leu, Ile 
Proprionyl- C3 Ile, Val 
Isobutyryl- C4 Val 
2-Methylbutyryl- C5 Ile 
Isovaleryl- C5 Leu 
 
 
 
FAAC (C6-18) 
Hexanoyl- C6:0 Caproic, hexanoic acid 
Octanoyl- C8:0 Octanoic acid 
Octenoyl- C8:1 Octenoic acid 
Decanoyl- C10:0 Decanoiccapric acid 
Myristoyl- C12:0 Myristic acid 
Tetradecanoyl C14:0  
Palmitoyl- C16:0 Palmitic acid 
Stearoyl- C18:0 Stearic acid 
Linoleyl- C18:2  
    
 
 
Table s9.Correlation of ∆Nadir and Nadir of plasma acylcarnitines levels with phenotypic parameters.
 
Table S9.Correlation of ∆Nadir and Nadir of plasma acylcarnitines levels with phenotypic 
parameters. 
 ∆Nadir  vs. HOMA ∆Nadir  vs. LBM Nadir vs. HOMA Nadir vs. LBM 
Acylcarnitines P  ρ  P  ρ P  ρ P  ρ 
Acetylcarnitine (C2) 0.01 0.30   0.03 0.26   
2Methylbutyrilcarnitine (C4) 0.04 -0.25       
Deoxycarnitine (C0) 0.03 -0.26       
Tetradecanoylcarnitine (C14)   0.005 0.34     
Linoleylcarnitine (C18:2)   0.02 0.37     
Octanoylcarnitine (C8)   0.02 0.30     
Tetradecenoylcarnitine (C14)   0.02 0.27     
Hexanoylcarnitine (C6)     0.001 0.39   
Butyrylcarnitine (C4)     0.0003 0.44   
Propionylcarnitine (C3)     0.001 0.39   
Carnitine (C0)       0.01 0.30 
Isobutyrylcarnitine (C4)       0.01 -0.31 
          LBM: Lean body mass, ρ: Spearman's rank correlation coefficient. Only correlations with p<0.05 have been indicated. 
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AbsTRAcT
It has been proposed that the ability of a person to respond to a metabolic stressor reflects 
the capacity to adapt to a new situation and that this can provide a better indication of health 
and disease risk than a measurement at fasting.For individual metabolites such correlations 
can be established, but this provides a fragmented view on the involved pathways. This can 
be overcome by Goeman’s global testing approach, which explicitly considers that metabolites 
are connected in pathways. The application of Goeman’s global test to two intervention stud-
ies indicates that it can provide a direct view on involvement of a priori defined pathways in 
phenotype shifts. In one study obese subjects received a mixed meal challenge before and af-
ter weight loss and in a second study obese subjects received a high fat mixed meal challenge 
before and after a polyphenol intervention. The effect of weight loss intervention on a priori 
defined metabolic pathways observed in the fasting and postprandial plasma metabolome 
was consistent with previous studies. In both studies Goeman’s global test showed that inter-
ventions affected more metabolic pathways at fasting than during the postprandial response. 
For the population of the weight loss intervention study, Goeman’s global test revealed that 
HOMA correlated with the fasting levels of the TCA cycle, BCAA catabolism, the lactate, Ar-
ginine-Proline and Phenylalanine-Tyrosine pathways. For the population of the polyphenol 
intervention study, HOMA correlated with fasting metabolite levels of TCA cycle, fatty acid ox-
idation and Phenylalanine-tyrosine pathways. Also these correlations were more pronounced 
for metabolic pathways in the fasting state, than during the postprandial response. Hence we 
cannot confirm that the postprandial metabolic response to a mixed meal challenge provides 
a more sensitive read-out for a shift in phenotypic flexibility than fasting metabolism.
Keywords. Goeman’s global test,phenotypic flexibility
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InTROducTIOn
Health is maintained by well-orchestrated interactions between physiological processes. 
These processes have to function in a changing environment and thus they collectively strive 
to maintain homeostasis by continuous adaptations. The ability to adapt to stressors such as 
diet and exercise has been coined as phenotypical flexibility (PF) and has been proposed as a 
measure for health [1, 2]. PF has been brought forward as a broad concept [1], but comprises 
the well-established concept of metabolic flexibility (MF), which is the efficiency of the post-
prandial switch between fasting lipid catabolism to postprandial carbohydrate anabolism [3]. 
Several studies have claimed that the ability of a person to respond to a metabolic stressor re-
flects the capacity to adapt to the new situation and this provides a better indication of health 
and disease risk comparing to fasting measure [4, 5]. Challenge tests have been put forward to 
measure the phenotypic flexibility of a biological system, meaning how well the system is able 
to undo the perturbation of a challenge and bring the system back to steady state. 
In earlier studies univariate statistics was used to find differences between metabolic phe-
notype, at the level of baseline metabolism or in the response to a challenge. This approach 
is compromised by the multiple testing problem, and also cannot unambiguously establish 
whether a phenotype shift is better reflected in a shift in baseline metabolism or in an altered 
response to a dietary challenge. 
In this work we will explore an approach where we exploit prior knowledge on involve-
ment of metabolic pathways in shifts in baseline metabolism or altered postprandial respons-
es. In order to exploit this prior knowledge we will use Goeman’s global test, which is a robust 
test whether metabolites that are connected in a pathway collectively respond to a change in 
conditions [6]. 
We will explore this approach in two studies, where mixed-meal challenges were car-
ried out to assess the efficacy of two types of dietary interventions. The first study examined 
whether a mixed meal challenge response could provide a readout for a shift in phenotypical 
flexibility upon weight loss in obese male subjects. This study showed a significant effect of 
weight loss on improved insulin sensitivity [7] and thus provides a relevant case for testing 
our approach. In the second study, the effect of long term polyphenol consumption on phe-
notypical flexibility was also assessed by means of a mixed meal challenge. The polyphenol 
intervention did not have an effect on insulin sensitivity and MF but increased baseline and 
postprandial fat oxidation as compared to placebo [8]. In both studies the responses of amino 
acids and acylcarnitines were measured, as well as metabolites related to the TCA cycle. This 
set of metabolites was selected since previous studies most convincingly related them with the 
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ability to effectively switch from lipid to carbohydrate metabolism in the postprandial phase, 
i.e. metabolic flexibility. We explore Goeman’s global testing approach to assess the effect of 
the weight loss and polyphenol intervention on both baseline and mixed meal challenge re-
sponse. Furthermore, we will use this approach to establish correlations between phenotypi-
cal parameters related to insulin sensitivity and metabolic flexibility. 
MATeRIAls And MeThOds
subject characteristics 
Weight loss intervention study. 29 abdominally overweight / obese men (BMI= 30.3 ± 2.4kg/
m2) participated in the study. None of the subjects were diagnosed with clinical diseases. Sub-
jects characteristics can be found in Supplementary Table S1-a.
Polyphenol intervention study. 38overweight and obese subjects (BMI= 29.7 ± 0.5 kg/m2) 
participated in this study, 28 subjects were randomly selected for metabolomics analysis. 
Characteristics of the subjects who completed the study are summarized in Supplementary 
Table S1-b. 
study design 
Weight loss intervention study. Lean subjects were only studied cross-sectional, and obese/
overweight subjects before and after random assignment to a weight-loss intervention of 8 
weeks. Before the weight loss intervention (D1), all subjects underwent a mixed meal chal-
lenge test and subsequently blood samples were collected during 4 hours. Subjects assigned 
to either a weight-loss (WL) or control (CTRL) programme for 8 wk. After this period (D2), sub-
jects again underwent a mixed meal challenge and blood samples were collected at the same 
time intervals as on D1. HOMA was measured at both D1 and D2. Details on the design can be 
found in an earlier study [7] . 
Polyphenol intervention study. In this randomized, double-blind, placebo-controlled, par-
allel-intervention trial, subjects received either a polyphenol supplement (epigallocatechin 
gallate and resveratrol; 282 and 80 mg/d, respectively) or a placebo (partly hydrolyzed mi-
crocrystalline cellulose-filled capsules) for a period of 12 wk to assess effects of polyphenol 
supplementation on tissue-specific insulin sensitivity (primary outcome) and metabolic pro-
file, skeletal muscle oxidative capacity, fat oxidation, and lipolysis (secondary outcomes). The 
supplementation period started the day after the last baseline measurement in week 0 and 
was continued throughout measurements in week 12. In total, subjects were asked to visit 
the university 10 times for medical screening, 3 clinical investigation days (CIDs) before the 
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start of supplementation (within 7 d), 3 control visits during the supplementation period, and 
3 CIDs in the last week of supplementation (within 7 d). In this study we use the data from 
CID2 where high-fat mixed meal (HFMM) challenges was performed. At CID2, besides HOMA 
also energy expenditure (EE), respiratory quotient (RQ), fat and carbohydrate oxidation were 
measured by indirect calorimetry by using the open-circuit ventilated hood system (Omnical; 
Maastricht University) and were calculated according to the formulas of Weir and Frayn, re-
spectively. Also a hyperinsulinemic-euglemic clamp with an isotope labelled glucose infusion 
tracer was performed to assess rate of disappearance (Rd, as measured for peripheral insulin 
sensitivity) and endogenous glucose production (% EGPm a measure for hepatic insulin resis-
tance). Full details of the study can be found elsewhere [8]. 
sample collection
Weight loss intervention study. Subjects were asked not to perform any strenuous physical 
exercise or to consume alcohol and high-fat foods on the day before blood sampling. Blood 
samples were taken at fasting and after mixed meal consumption both before and after the 
weight loss intervention at 6 time points (fasting (T0) and 30, 60,120,180 and 240 minutes in 
the postprandial state). The standardized mixed meal consisted of two muffins and 300 ml 0% 
fat milk, which provided 1100 kcal: 56.6 g fat, 26.5 g protein and 121 g carbohydrate. Metabolic 
profiling was performed on all time points.
Polyphenol intervention study. After inserting a cannula into the antecubital vein, substrate 
oxidation was measured for 30 min under fasting conditions (T0) and for 4 h after the inges-
tion of a liquid high-fat mixed meal (HFMM) (625 kcal, 61% of energy from fat, 33% of energy 
from carbohydrate, 6% of energy from protein), which was consumed within 5 min at t = 0. 
Blood samples were taken under fasting (0 min) and postprandial (t = 30, 60, 90, 120, 150, 180, 
210, and 240 min) conditions. Full details of the study can be found elsewhere [8].
Plasma metabolic profiling
Amino acids and biogenic amines, organic acids and acylcarnitines were measured for 
both the weight loss and polyphenol intervention studies, with a total 170 metabolites. Amino 
acids and biogenic amines in plasma were derivatized (Acc-TAG) and measured by a UPLC sys-
tem which was interfaced to quadrupole mass spectrometer. Acylcarnitines in plasma were 
also measured by UPLC-MS, but without derivatisation. Organic acids in plasma were mea-
sured by GC-MS, after oximation and silation derivatization. Oxylipins were only analyzed for 
the weight loss study. First an SPE extraction was performed and subsequently aLC separation 
coupled to ESI on a triple quadrupole mass spectrometer. Oxylipins were detected in negative 
ion mode using dynamic SRM. Full details of these platforms have been described in earlier 
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studies [9-12]. Serum metabolites were measured by NMR in a quantitative manner, full ex-
perimental details can be found in earlier work [11]. In short, serum samples were ultrafiltrat-
ed and automated quantum mechanical line shape fitting of 1H NMR spectra was performed 
using PERCH in order to obtain absolute metabolite concentrations.
statistical analysis
Analysis of variance (ANOVA) was used for between group comparisons at baseline. Lin-
ear mixed model was used to assess the fasting comparison and difference of response effect 
between groups. P<0.05 was considered to be statistically significant. To account for multiple 
testing, local false discovery rates (lFDR) were calculated for each metabolite [13, 14]. The post-
prandial response was considered as incremental area under the curve (iAUC), taking the first 
measurement (t0) as a reference. The iAUC was calculated in two ways. First, by considering 
that the AUC comprises both negative AUC (AUC−) and positive AUC (AUC+) contributions, we 
refer to this value as iAUC. Secondly, we also calculated the positive iAUC where the absolute 
values contributing to the curve were summed up, we refer to these values as piAUC [15, 16]. 
For both iAUC and piAUC we use the trapezoidal calculation method [17].
For pathway analysis, Goeman’s global test for metabolomics was applied to test groups of 
covariates (or features) for association with a response variable using the global test R library 
[6, 18]. In this approach a priori biological information, such as knowledge of pathways is used 
as cellular processes arise as the result of many reactions between metabolic intermediates 
[19]. In the metabolomics field, predefined groups of pathways or functional modules can be 
used [19-21]. More detail about this approach can be find elsewhere [6, 18]. Nadir acylcarni-
tine values were defined as the lowest value achieved during the 4 hours after the meal [22]. Δ 
nadir was calculated as difference between nadir and T0 values. All analyses were done using 
R (version 3.1.2).
ResulTs
univariate assessment of intervention effects and correlations with 
phenotype parameters
Weight loss intervention study. Figure 1A and B shows the P-value distribution of values for 
the weight loss effect on respectively fasting metabolite levels and their postprandial response 
as expressed by iAUC. As it is shown in the figure there is a more pronounced effect at fasting as 
compared to the postprandial response. Comparing obese subjects that underwent the weight 
loss and control interventions at fasting and with respect to challenge response, we found that 
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a range of metabolites are significantly different between two groups in either comparison. 
Metabolites that are significantly different between groups at fasting upon weight loss (Sup-
plementary Table S2A) are not changed upon a mixed meal challenge (Supplementary Table 
S2B). Branched chain amino acids (BCAA) and amino acid derived acylcarnitines (AAAC) were 
among the most significantly different metabolites between groups at baseline. 
Polyphenol intervention study. The P-value distribution of the polyphenol intervention ef-
fect on metabolite baseline and response (iAUC) values are presented in Figure 1C and D, re-
spectively. The P-value distribution shows that only a small number of metabolites are signifi-
cantly different between two groups either at fasting or in their postprandial response. This is 
also in line with the small number of metabolites on which the polyphenol intervention had a 
significant effect according to univariate testing (Supplementary Table S3A and 3B). 
Correlation with phenotype parameters. For the weight loss study population a number 
of univariate correlations between metabolite levels and HOMA can be established [12]. The 
correlations between HOMA and branched chain amino acids, phenylalanine and tyrosine 
are in line with previous studies [23, 24]. In addition we could also find correlations between 
HOMA and C2/Cn acylcarnitine ratios, which were recently brought forward as putative read-
outs for β-oxidation rate [25]. In an earlier study, we also found correlation between HOMA 
and Δ nadir and nadir acylcarnitine levels, in particular for amino acid derived ones [12]. The 
Δ nadir and nadir acylcarnitine values can be considered as a single parameter summary of 
their postprandial response [22] and the correlations with HOMA suggest they are related to 
fatty acid oxidation flux.
For the polyphenol intervention study, besides HOMA also ΔRQ and fat oxidation were 
measured via indirect calorimetry. We can observe a number of significant correlations be-
tween these phenotypical parameters with metabolites at fasting (Supplementary Table S4). 
These correlations however provide a scattered view on involvement of metabolic pathways. 
We also assessed whether fasting plasma C2/Cn acylcarnitine ratios correlated with HOMA, 
ΔRQ, and fat oxidation. The only significant effect was correlation of C2/2-methylbutyroylca-
nitine with HOMA (P= 0.02, ρ=-0.31). For the population of the polyphenol intervention study, 
correlation of ∆ nadir and nadir acylcarnitine levels with phenotypic parameters (HOMA, 
ΔRQ, fat oxidation) did not show any significant effects. 
Goeman’s global test for assessment of intervention effects on plasma 
metabolome
Metabolites from the TCA cycle and the lactate pathway were grouped according to the 
KEGG database. For amino acid and fatty acid derived acylcarnitines no pathway informa-
tion has been entered in KEGG. Hence we grouped metabolites according to branched amino 
144
acid catabolism, comprising branched chain amino acids and derived acylcarnitines. Fatty 
acid derived carnitines (C8-C18) were also grouped in a pathway. We also grouped phenylala-
nine and tyrosine, since both these amino acids have consistently been associated with insu-
lin resistance [24]. Oxylipins derived from arachidonic acid were also grouped in a pathway. 
An overview of metabolites collected in pathways is given in Table 1. The result of Goeman’s 
global testing for assessment of lean vs obese differences and effect of weight loss on obese 
is presented in Table 2. Three pathways, including the TCA cycle and BCAA catabolism are 
different between obese and lean subjects at fasting. The combination of phenylalanine and 
tyrosine was also significantly different between lean and obese. The last two pathways were 
also different between obese subjects before and after a weight loss intervention. Regarding 
the postprandial metabolic response, the difference between obese and lean subjects was lim-
ited to lactate and the Arg-Pro pathway. We note that here we present effects for iAUC values, 
which account for positive and negative contributions. The effects are similar when piAUC 
values are considered (Supplementary Table S5). The Goeman’s global test could however not 
reveal significant (P<0.05) weight loss induced differences in postprandial response in obese 
subjects. The effect of weight loss on the enzymatic oxidation pathway of arachidonic acid 
did not reach statistical significance (P<0.09). The Goeman’s global testing approach was also 
deployed to reveal pathways that were affected by the polyphenol intervention. No significant 
effect could however be observed for neither baseline metabolite levels nor the metabolic 
postprandial responses, irrespective of whether iAUC or piAUC values were used. 
Goeman’s global test for assessment of correlations of plasma metabolome 
with phenotypical variables
The populations of the weight loss and polyphenol intervention studies were well charac-
terized with respect to insulin sensitivity (HOMA), metabolic flexibility (RQ) and baseline fat ox-
idation (Table 1a and 1b). HOMA was determined in both the weight loss and polyphenol inter-
vention studies, whereas RQ and baseline fat oxidation were only determined in the polyphenol 
study. We explored whether the Goeman’s global testing approach would provide a means to 
establish correlations between phenotype parameters and metabolic pathways. Goeman’s glob-
al test revealed that for the population of the weight loss intervention study HOMA correlated 
with the fasting levels of metabolites from the TCA cycle, BCAA catabolism, lactate-glucose, Argi-
nine-Proline and Phenylalanine-tyrosine pathways (Table 3). For this population the correlation 
between pathways and HOMA were more pronounced at fasting than for the postprandial re-
sponse as expressed by iAUC (Table 3) or piAUC (Supplementary Table S5).
For the polyphenol study Goeman’s global test revealed that HOMA is correlated with TCA 
cycle (P=0.02) and fatty acid oxidation pathways (P=0.06) as observed in fasting levels (Ta-
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ble 3). For ΔRQ, fat oxidation, hepatic insulin resistance and peripheral insulin sensitivity no 
correlations could be established for any of the pathways when fasting levels were consid-
ered. Goeman’s test also found no correlations between any of the phenotypical parameters 
(HOMA, ΔRQ, fat oxidation, hepatic insulin resistance, peripheral insulin sensitivity) and post-
prandial responses (iAUC and piAUC) when these were grouped in pathways.
dIscussIOn 
Global testing of intervention effects on metabolic pathways. We applied Goeman’s global 
test to determine whether sets of metabolites that are connected within a pathway collectively 
respond to an intervention. Our aim was to examine whether a phenotypic flexibility can be 
defined as a shift in baseline metabolism or by the postprandial metabolic response. A study 
by Hendrickx et al. revealed that Goeman’s global test can be used to determine if the be-
haviour of a group of metabolites within the same pathway, is related to a specific outcome of 
interest [6]. We applied the Goeman’s global test on two studies where volunteers respectively 
underwent a weight loss and polyphenol intervention. The weight loss intervention caused 
a more pronounced shift in baseline levels rather than in postprandial response as is shown 
in P distribution plot in Figure 1. For the weight loss intervention Goeman’s global tests in-
deed showed significant effects at pathway level at fasting (Table 2). Metabolites involved in 
the TCA cycle have significantly different pattern between obese and lean subjects at fasting, 
which is in line with other studies [24]. Moreover, we observed an effect of weight loss on 
BCAA catabolism, and the combination of Phe-Tyr, which is in line with previous observations 
of changes in metabolic profiles accompanying an improvement in insulin resistance [23, 24]. 
In Chapter 4 we observed that the main metabolites for which the postprandial response was 
different before/after weight loss were oxylipins derived from arachidonic acid by enzymatic 
oxidation.  Although the individual P values were significant for arachidonic acid  derived 
oxylipins, when we test them collectively in Goeman’s test the effect of weight loss  on the 
postprandial response of this pathway was only P = 0.09.
In the dietary polyphenol intervention study, the P distribution plot indicated that only a 
small number of metabolites were affected at baseline or in their postprandial response. This 
was also reflected in the small number of metabolites that showed a significant effect accord-
ing to univariate testing (Supplementary Table S3). Goeman’s global test indeed did not reveal 
pathways that were significantly different before and after the polyphenol intervention. This 
is in line with the relative small effect of the polyphenol intervention on phenotypical pa-
rameters. Although the prolonged polyphenol supplementation stimulated fat oxidation and 
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increased mitochondrial capacity comparing to placebo, no significant effect on tissue-specific 
insulin sensitivity and metabolic flexibility in obese subjects was observed [8].  
Goeman’s global testing of correlations between pathways and phenotype parameters. The 
observed correlations of HOMA with metabolites involved in TCA cycle, BCAA catabolism and 
lactate pathway can be explained by their positive correlation with insulin resistance [23, 24]. 
However, Goeman’s global test showed that the changes in postprandial response are smaller 
than the change at T0 after the intervention (Table 3). In the population of the weight loss 
study, more pathways were significant than for the polyphenol intervention study, in particu-
lar at fasting. As the HOMA range of obese subjects  of  two studies is comparable (Supplemen-
tary Table S1a, S1b), the lack of pronounced effects in polyphenol study might be due to lack 
of power and/or confounding with other phenotype parameters.
cOnclusIOn
The application of Goeman’s global test to two intervention studies indicates that it can 
provide a direct view on involvement of a priori defined pathways in phenotype shifts. The 
effect of weight loss intervention on a priori defined metabolic pathways was consistent with 
previous studies, as well as correlation of pathways with insulin sensitivity as described by 
HOMA. Goeman’s global test, indicated that metabolic flexibility is more strongly reflected in 
pathways observed at baseline, than in their postprandial response. Hence we cannot confirm 
that the postprandial metabolic response to a mixed meal challenge provides a more sensitive 
read-out for a shift in phenotypic flexibility than fasting metabolism.
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Table 1. Collection of metabolites in pathways for Goeman’s global testing  
Pathway 
 
Number of metabolites 
in the group 
Metabolites 
TCA cycle 8 Citric acid, malic acid,2-ketoglutaric 
acid, succinic acid, fumaric acid, 
pyroglutamic acid, cis-aconitic acid, 
pyrovate 
BCAA catabolism 8 C3, C4, C4DC, C5, C5, Val, Leu, Ile 
Fatty acid oxidation 17 C8, C10, C12, C14, C16, C18 
Lactate pathway 2 Lactate, Pyruvate, Glucose 
Arg, Pro  6 Methionine, Proline, 
Ornithine,Citrulline,4-hydroxyproline, 
Arginine 
Phe, Tyr 2 Phenylalanine, Tyrosine 
Enzymatic oxidation of 
arachidonic acid 
5 TXB2, PGE2, 12S.HHTrE, 5.HETE, 
11.HETE 
   
 
 
 
Table 1. Collection of metabolites in pathways for Goeman’s global testing 
Table 2. Goeman’s global testing of differences in metabolic pathways (Table 1) between lean and obese volunteers 
and the effect of a weight loss (WL) intervention (compared to a control (CRT) intervention). Differences were tested 
for baseline values (T0) and postprandial response (iAUC).
Table 2. Goeman’s global testing of differences in metabolic pathways (Table 1) between lean and 
obese volunteers and the effect of a weight loss (WL) intervention (compared to a control (CRT) 
intervention). Differences were tested for baseline values (T0) and postprandial response (iAUC). 
 
 
 
 
 
 
 
 
 
Pathways and number of metabolites 
Fasting Response 
T0 
Obese vs lean 
∆ T0 
WL vs CRTL 
iAUC 
Obese vs lean 
∆iAUC 
WL vs CRTL 
TCA cycle 8 0.01 0.2 0.4 0.3 
BCAA catabolism 7 0.02 0.02 0.5 0.5 
Fatty acid oxidation 17 0.07 0.4 0.7 0.5 
Lactate pathway 3 0.06 0.5 0.03 0.3 
Arg, Pro  6 0.5 0.1 0.02 0.6 
Phe, Tyr 2 0.01 0.03 0.3 0.3 
Enzymatic oxidation of Arachidonic acid 5 0.6 0.5 0.3 0.09 
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Table 3. Goeman’s global test results for correlations between baseline values, postprandial response (expressed 
as iAUC) and HOMA. The Goeman’s global tests were performed separately for volunteers from the weight loss 
and polyphenol intervention studies. No significant effects were observed of effect of polyphenol intervention on 
postprandial response. Note that no arachidonic acid (AA) metabolites (oxylipins) were measured for the polyphenol 
intervention study.
Table 3. Goeman’s global test results for correlations between baseline values, postprandial response 
(expressed as iAUC) and HOMA. The Goem n’s global te ts were perf rmed separately for 
volunteers from the weight loss and polyphenol intervention studies. No significant effects were 
observed of effect of polyphenol intervention on postprandial response. Note that no arachidonic acid 
(AA) metabolites (oxylipins) were measured for the polyphenol intervention study. 
 
 
 
 
 
 
 
 
 
Pathways and number of metabolites 
Fasting Postprandial 
response 
Weight loss 
intervention 
group 
Polyphenol 
intervention 
group 
Weight loss 
intervention group 
 
TCA cycle 8 0.01 0.02 0.4 
BCAA catabolism 7 0.04 0.4 0.6 
Fatty acid oxidation 17 0.7 0.06 0.4 
Lactate pathway 3 0.05 0.9 0.02 
Arg, Pro 6 0.04 0.6 0.7 
Phe, Tyr 2 0.02 0.04 0.5 
Enzymatic oxidation of arachidonic acid 5 0.7 NA 0.4 
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Figure 1. P- value distribution of effect of weight loss on baseline values in obese subjects (ΔWL T0 vs. Δ CTRL 
T0) (A), effect of weight loss on challenge response values in obese subjects (iAUC WL vs. iAUC CTRL) (B), effect 
of polyphenol intervention on baseline values in obese subjects (Δ PolyphenolT0 vs. Δ Placebo T0) (C), effect of 
polyphenol intervention on challenge response values in obese subjects (iAUC Polyphenol vs. iAUC Placebo) (D).
Metabolites with P<0.05 were coloured green and otherwise red.
 
 
Figure 1. P- value distribution of effect of weight loss on baseline values in obese subjects (ΔWL T0 
vs. Δ CTRL T0) (A), effect of weight loss on challenge response values in obese subjects (iAUC WL 
vs. iAUC CTRL) (B), effect of polyphenol intervention on baseline values in obese subjects (Δ 
PolyphenolT0 vs. Δ Placebo T0) (C), effect of polyphenol intervention on challenge response values 
in obese subjects (iAUC Polyphenol vs. iAUC Placebo) (D).Metabolites with P<0.05 were coloured 
green and otherwise red. 
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Table S1-a.Characteristics of lean subjects and obese subjects before and after weight loss (WL) or 
control (CRTL) interventions. 
 Lean  WL(D1) WL(D2) CTRL(D1) CTRL(D2) 
Number 15 14 14 15 15 
Age(y)  47.4 ± 4.5 44 ± 3.7  44.8 ± 3.4  
BMI(kg/m2) 23.0 ± 0.6 30.0 ± 0.5 26.9 ± 0.5* 30.7 ± 0.7 30.4 ± 0.7 
Glucose (mol/L) 5.1 ± 0.07 5.3 ± 0.12 5.0 ± 0.09 5.3 ± 0.09 5.3 ± 0.37 
HOMA(IR) 1.62±0.1 3.00±0.4 1.75±0.2* 2.89±0.4 2.92±0.3 
Data are presented as mean ± SEMs. *: A significant effect of weight loss (P<0.05). WL: weight loss, CTRL: 
control, D1, D2: before and after intervention (see also Figure 1), BMI: Body mass index. 
 
 
Table s1-a. Characteristics of lean subjects and obese subjects before and after weight loss (WL) or control (CRTL) 
interventions.
Table s1-b. Characteristics of the subjects of the polyphenol study before and after intervention.
 
Table S1-b. Characteristics of the subjects of the polyphenol study before and after intervention. 
 Placebo Polyphenol 
 Week 0 Week 12 Week 0 Week 12 
Number  14  13  
Age (y) 41.4 ± 2.5  35 ± 3.1  
BMI (kg/m2) 28.5 ± 0.8  29.6 ± 0.8  
Glucose(mol/L) 5.1 ± 0.1 5.1 ± 0.1 5.1 ± 0.07 5.1 ± 0.1 
HOMA(IR) 2.2± 0.4 2.3 ± 0.3  1.9 ± 0.2 1.7 ± 0.1 
RQ 0.78 ± 0.01 0.82 ± 0.02 0.80 ± 0.01 0.79 ± 0.01 
ΔRQ 0.08 ± 0.01 0.06 ± 0.01  0.07 ± 0.01 0.08 ± 0.01 
Fat oxidation  0.08 ± 0.006 0.06 ± 0.01 0.07 ± 0.005 0.07 ± 0.008 
Data are means ± SEMs. BMI: Body mass index 
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Table s2A. Univariate comparisons of effect of weight loss intervention 
on baseline values in obese subjects (ΔWLT0 vs. Δ CTRL T0)
able S2A. Univariate comparisons of effect of weight loss intervention on baseline values in obese 
subjects (ΔWLT0 vs. Δ CTRL T0)  
 
Metabolite P lFDR 
Amino acids & related 
metabolites   
Creatinine <0.01 NS 
Glycine <0.01 NS 
2 aminoadipic acid 0.01 NS 
Isoleucine 0.01 NS 
Leucine 0.01 NS 
Creatine 0.02 NS 
Carnitine 0.02 NS 
Betaine 0.02 NS 
4 hydroxyproline 0.03 NS 
Tyrosine 0.05 NS 
Valine 0.05 NS 
Acylcarnitines   
Propionylcarnitine (C3) <0.01 NS 
2-Methylbutyroylcarnitine (C5) <0.01 NS 
TCA cycle & related metabolites   
Succinic acid 0.03 NS 
Glutamic acid 0.04 NS 
P<0.05 was considered significant. lFDR: local false discovery rate 
 
NS:not significant
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Table S2B. Comparison of effect of weight loss intervention on challenge response values in 
obese subjects ( iAUC WL vs. iAUC CTRL ) 
 
Metabolites Day*Condition lFDR 
Amino acids & related 
metabolites   
 SDMA 0.02 NS 
 Dimethylglycine 0.03 NS 
Methionine 0.04 NS 
Asparagine 0.04 NS 
 Succinate 0.04 NS 
Arginine 0.05 NS 
Acylcarnitines   
Myristoyl (C12) 0.05 NS 
 Choline 0.05 NS 
Oxylipins   
12.13.DiHOME <0.01 NS 
12S.HHTrE 0.04 NS 
9.10.DiHOME 0.04 NS 
   
P<0.05 was considered significant subjects according to 
univariate linear mixed models.lFDR: local false discovery rate 
  NS: not significant
Table s2b. Comparison of effect of weight loss intervention on challenge 
response values in obese subjects ( iAUC WL vs. iAUC CTRL )
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Table S3A.Univariate comparisons of effect of polyphenol intervention on baseline values in 
obese subjects (Δ Polyphenol T0 vs. Δ Placebo T0) 
 
Metabolite P lFDR 
Amino acids & 
related metabolites   
Histidine 0.03 NS 
 Dopamine 0.05 NS 
Acylcarnitines   
Octanoyl (C8) 0.01 NS 
Decanoyl (C10) 0.03 NS 
P<0.05 was considered significant.lFDR: local false discovery rate 
 
NS:not significant
Table s3A. Univariate comparisons of effect of polyphenol 
intervention on baseline values in obese subjects (Δ Polyphenol T0 
vs. Δ Placebo T0)
Table s3b. Comparison of effect of the polyphenol intervention on challenge 
response values in obese subjects ( iAUC Polyphenol vs. iAUC Placebo )
 
Table S3B. Comparison of effect of the polyphenol intervention on challenge response values in 
obese subjects ( iAUC Polyphenol vs. iAUC Placebo ) 
 
Metabolite Day*Group lFDR 
Amino acids & related 
metabolites   
 Cystathionine 0.01 NS 
Acylcarnitines   
Myristoyl (C12) 0.01 NS 
 Deoxy (C0) 0.01 NS 
Isovaleryl (C5) 0.05 NS 
Organic acids    
3 Hydroxybutyric acid 0.04 NS 
P<0.05 was considered significant. lFDR: local false discovery rate 
 
NS:not significant
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Table S4. Univariate correlation of the fasting plasma metabolome of volunteers in polyphenol 
intervention study with HOMA, fat oxidation and ΔRQ. 
  ∆RQ HOMA FAT Oxidation 
Metabolites P ρ P ρ P ρ 
Proline <0.01 -0.42         
Tiglylcarnitine <0.01 -0.39         
Isovalerylcarnitine <0.01 -0.38         
Glutathione 0.01 0.34 0.03 -0.30     
Betaine 0.01 -0.33         
Glycylglycine 0.02 0.32         
Methionine.sulfone 0.03 0.30         
Saccharopine 0.03 -0.30         
Pivaloylcarnitine 0.04 -0.30         
DL.3.aminoisobutyric acid 0.04 -0.28         
Propionylcarnitine 0.05 -0.28         
3.Methoxytyramine     <0.01 0.48     
Citricacid     <0.01 -0.46     
Beta.Alanine     <0.01 0.41     
Acetylcarnitine     <0.01 -0.37     
Oleylcarnitine     0.01 -0.36     
Asparagine     0.02 -0.33     
4.hydroxy.proline     0.02 0.32     
Norepinephrine     0.03 -0.32     
Tyrosine     0.03 0.31     
Cis.aconitic acid     0.03 -0.30     
Homocysteine         <0.01 0.40 
S.Methylcysteine         <0.01 0.40 
Kynurenine         0.01 0.36 
Succinic acid         0.01 -0.34 
Cysteine         0.02 0.32 
Cystathionine         0.04 0.28 
 
ρ: Pearson correlation coefficient. 
 
 
 
Table s4. Univariate correlation of the fasting plasma metabolome of volunteers in polyphenol intervention study 
with HOMA, fat oxidation and ΔRQ.
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Table S5. Goeman’s global testing of differences in metabolic pathways observed during the 
postprandial response, expressed as piAUC. Goeman’s global tests were performed separately for 
volunteers from the weight loss and polyphenol intervention studies. No significant effects were 
observed for effect of weight loss or polyphenol intervention on postprandial response, expressed as 
piAUC (data not shown). 
 
 
 
 
 
 
 
 
Pathways and number of metabolites 
 Difference 
obese vs lean 
Correlation with 
HOMA for weight 
loss intervention 
group 
 
TCA cycle 8 NS NS 
BCAA catabolism 7 NS  NS 
Fatty acid oxidation 17 NS NS 
Lactate pathway 3 0.06 0.05 
Arg, Pro  6 0.1 NS 
Phe, Tyr 2 NS NS 
Enzymatic oxidation of arachidonic acid 5 NS NS 
NS:not significant
Table s5. Goeman’s global testing of differences in metabolic pathways observed during the 
postprandial resp ns , expressed as piAUC. G eman’s gl bal tests were performed separately f r 
volunteers from the weight loss and polyphenol intervention studies. No significant effects were 
observed for effect of weight loss or polyphenol intervention on postprandial response, expressed 
as piAUC (data not shown).
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General discussion
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Recapturing aim 
The metabolic phenotype is the product of interactions between several factors such as ge-
netics, diet, lifestyle, and environment. The aim of this thesis was to measure health improve-
ments by assessing subtle shifts in metabolic phenotype. Two approaches were applied to 
identify a phenotype shift. First, by looking at the effect of prolonged resistance-type exercise 
training on skeletal muscle tissue in older subjects and examining the possible shift toward 
younger subjects as a reference for a healthier phenotype. Second, by observing the response 
to a dietary challenge in obese subjects and examining the possible shift toward lean subjects 
as a reference for a healthier phenotype.
Main findings of this thesis
Chapter 2 and 3 of this thesis showed how the significant remaining plasticity of ageing 
skeletal muscle can adapt to resistance-type exercise training. It was shown that frail and 
healthy older subjects are two distinct phenotypes according to the skeletal muscle tissue me-
tabolite profiles and that exercise training shifts aged muscle towards a more younger phe-
notype. It was also shown that the effect of exercise on amino acid derived acylcarnitines 
(AAAC’s) in older subjects points towards decreased branched chain amino acid catabolism, 
possibly due to compromised activation of the branched chain α-keto acid hydrogenase (BCK-
DH) complex. The protocadherin gamma gene cluster was identified as a possible contributor 
to aged-muscle denervation and re-innervation. Moreover, it was found that plasma is not a 
direct indicator of muscle metabolism, emphasizing the need for direct assessment of metab-
olism in muscle tissue.
Chapter 4 and 5 of this thesis addresses whether a mixed meal challenge response could 
provide a readout for a shift in phenotype upon weight loss in obese male subjects. It was 
concluded that the impact of weight loss on the mixed meal postprandial response of plasma 
metabolites and PBMC gene expression was modest. Furthermore, assessment of metabolic 
health at the fasted state and during a post-prandial test yield distinct types of information.
Training induced shifts of older phenotypes toward young 
In this thesis, healthy and frail older subjects were subjected to supervised resistance-type 
exercise training, a widely accepted strategy for tackling muscle wasting and weakness. Our 
study suggests a significant remaining plasticity of ageing skeletal muscle to adapt to regular 
resistance-type exercise and also a shift in the expression of a subset of genes towards levels 
observed in the younger group. At the gene expression level, the most striking finding in our 
study was the association of protocadherin gamma gene cluster (related to denervation and 
re-innervation) in skeletal muscle with age and muscle weakness, which might provide novel 
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insights into whether or not denervation and re-innervation is modulated by interventions 
or lifestyle factors such as nutrition and physical activity. Nevertheless, there is a lack of the 
knowledge at the pathway level to be able to target the expression of protocadherin gamma to 
improve age-related muscle weakness and functional decline (Chapter 2).
It has been shown that resistance-type exercise combined with amino acid ingestion elicits 
the greatest anabolic response and may help older subjects in producing a ‘youthful’ muscle 
protein synthetic response [1]. However, it is still debated whether older subjects respond in a 
similar manner to that of younger adults [2]. In this thesis, it was found that skeletal muscles 
of older subjects move toward a younger phenotype after resistance-type exercise training. 
Accordingly, resistance-type exercise in the elderly causes skeletal muscle to adopt features of 
more youthful skeletal muscle.
The primary differences in skeletal muscle metabolite levels between healthy older and 
young subjects were related to mitochondrial function, fibre type, and tissue turnover (Chap-
ter 3). At the metabolite level, the most remarkable effects of resistance-type exercise training 
in older subjects were a significant decrease in the level of amino acid derived acylcarnitines 
(AAAC’s) accompanied by an increase in branched chain amino acids level after training. This 
suggests a compromised response of a flux-determining mitochondrial branched chain α-keto 
acid hydrogenase (BCKDH) to prolonged resistance-type exercise training[3]. A decrease in 
branched chain amino acids oxidation may stimulate mTOR (a protein complex influencing 
protein synthesis and breakdown) related pathways activation [4, 5] and consequently pro-
tein synthesis, which is likely beneficial for older subjects. However, this mechanism occurs at 
the level of enzymatic activity, which prevents us from reaching strong conclusions based on 
the present data. Dickinson et al. demonstrated that mTOR signalling is necessary to stimulate 
the rate of muscle protein synthesis after resistance exercise [6]. A meta-analysis by Markofski 
et al. showed that there is no difference in fasting protein synthesis rates between young and 
old skeletal muscle, but both total and phosphorylated mTOR were elevated in muscle from 
fasted elderly individuals [7]. This may be due to either a compensatory response reflecting 
increased relative muscle loading in daily life or may be due to a dysregulation of the mTOR 
complex, influencing muscle mass in a complex and non-linear manner [8].
The gains in muscle strength and function in response to resistance-type exercise reflect 
improvements in multiple physiological factors, including coordination, muscle mass, and 
neuromuscular function. These improvements are observed in most healthy subjects that 
take up a resistance exercise program. Whether this also holds true for older subjects with 
pre-existing skeletal problems or disease such as diabetes is not fully clear [2]. A study by 
Churchward et al. demonstrated that there are no non-responders to the benefits of resis-
tance-type exercise training (regarding lean body mass, fiber size, strength or function) in 
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older subjects. This implies that resistance-type exercise should be promoted without restric-
tion to support healthy aging in the older population [9]. In our study population, all older 
subjects regardless of their health status (frail or healthy)and gender improved in muscle 
performance following 6 months of resistance-type exercise training, as illustrated by a sig-
nificantly increase in leg extension and leg press strength post training [10-12]. However, lean 
body mass did not necessarily increase in all subjects, indicating that the strength increase 
must be primarily due to an increase in muscle quality, calcium handling, cross-bridge cy-
cling, and neuromuscular adaptation instead of an increase in muscle cross-sectional area 
[10]. A review by Timmons et al., however, concluded that in human studies the demonstra-
tion of the efficacy of resistance-type training in older subjects is compromised by ‘population 
stratification’ [13]. Many human studies report spurious observations based on small sample 
size and high inter-subject variation. Therefore, not all researchers in the field agree on the 
scale of heterogeneous outcomes from exercise training. Using larger-scale prolonged studies 
and improving diagnostics of an individual’s potential to respond to standardised physical 
training will help to perform studies with sufficient statistical power to allow for population 
stratification [13]. The key question is whether these kinds of studies are actually feasible? In 
this context, the standardisation of protocols (such as exercise load, meal composition, etc.) 
will be of prime importance to enable integration of independent studies. For body fluids the 
use of such standardised protocols has now become common practice in large scale metabo-
lomics studies [14-16].
weight loss induced shift of obese phenotypes 
This thesis examined the phenotypic flexibility after applying a mixed meal challenge test 
with a combination of carbohydrates, fat and protein, i.e., an oral protein–glucose–lipid toler-
ance test. The assumption that underlies the use of mixed meal challenges is that it triggers 
all aspects of phenotypic flexibility [17].The observed plasma glucose responses in response 
to the mixed meal challenge were similar as compared to an OGTT, while the insulin response 
was prolonged in comparison with the glucose response [18]. The postprandial metabolic re-
sponse was found to be different between obese and lean subjects, yet the difference was not 
as pronounced as for the OGTT challenge [19], which may be explained by the complexity of 
our mixed meal, affecting multiple metabolic pathways. A study by Esser at al. revealed that 
a MUFA challenge is more potent in eliciting differences between lean and obese subjects as 
compared to a SFA challenge [20]. Notably, the lipid composition of the mixed meal in our 
study is similar to SFA. It is possible that the usage of one single nutrient might be more effec-
tive at evoking differences in phenotypic responses between subjects. In addition, it allows for 
better understanding of the underlying biological mechanisms.
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A mixed meal challenge is expected to provoke a more prolonged insulin response [17], 
possibly allowing for better differentiation between individuals. However, differentiation 
based on postprandial mixed meal responses was modest. Although a clear improvement in 
insulin sensitivity could be observed, the weight loss intervention had only a subtle effect on 
fasting and especially postprandial metabolites[21, 22] [4]. A recent study by Kardinaal et al. 
found that the changes observed in response to a challenge are a more sensitive biomarker 
of metabolic resilience than changes in fasting concentrations [23]. Compared to our study, 
the discrepancy might be due to the population under study, as the study by Kardinaal et 
al. involved subjects with the metabolic syndrome, whereas in our study the subjects were 
healthy overweight/obese. An alternative explanation may be differences in the type of chal-
lenge used. Indeed, Kardinaal et al. performed a high fat challenge, whereas in our weight loss 
study a mixed meal challenge was applied. 
Therefore, based on our data we conclude that there is a moderate effect of weight loss on 
the mixed meal challenge response of the plasma metabolome and transcriptome of periph-
eral blood mononuclear cells of obese subjects. A recent study also found a modest number of 
differences in postprandial response to an OGTT between obese and lean subjects [19]. These 
differences were discussed qualitatively, without attempt to discuss statistical significance. 
The authors noticed a much stronger heterogeneity in the OGTT postprandial response of 
obese compared to lean. It is very likely that the heterogeneity in postprandial response to a 
mixed meal also explains why in our study only modest effects of weight loss were observed. 
Moreover, it is possible that the differences between lean and obese in the postprandial met-
abolic switch may be concealed by the direct influx of dietary amino acids and fatty acids. 
FuTuRe PeRsPecTIves
how to follow up with the challenge concept? 
Chapter 4 and 5 showed, that the impact of weight loss on the mixed meal postprandi-
al response of plasma metabolites and PBMC gene expression was modest. Based on these 
observation, the concept of using dietary challenge test to amplify differences in phenotypic 
flexibility between individuals may itself be challenged.
Firstly, the design of the challenge test should be carefully considered. Currently, there 
is no consensus on the composition of challenge tests for quantifying phenotype flexibility. 
Measuring a person’s phenotypic flexibility can be performed by perturbing the homeostasis 
of that person, and quantifying the response of single or multiple markers during the post-
prandial phase. In Figure 1 the main physiological processes relevant to phenotypical flexibil-
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ity are shown [17]. The overview in this figure illustrates the multitude of processes that can 
be perturbed by dietary challenges. Even a single dietary challenge like OGTT will impact on 
multiple organs, either directly or indirectly. In the postprandial phase also these organs will 
mutually interact as they are networked in our body. Unravelling the direct and indirect post-
prandial responses induced by single challenges is challenging but feasible [24]. It has been 
claimed that a multiple challenge such as a mixed meal is preferable since it more closely re-
sembles metabolic perturbations encountered in daily life [17]. The outcome of the analysis in 
Chapter 4 however indicate that the metabolic response to a mixed meal challenge is difficult 
to be interpreted, even when using a range of profiling platforms to widely cover the plasma 
metabolome.
Secondly, those metabolic markers should be identified that can provide information on 
specific organ-dependent processes involved in phenotypical flexibility. Such processes can 
be measured by identifying the dynamics of the metabolic stress response in blood [17]. Upon 
a mixed meal challenge, the system is however flooded with dietary amino acids, fatty acids, 
carbohydrates, which may conceal the detection of the effects of the intervention on path-
ways involved in phenotypical flexibility. This can be resolved by observing the postpran-
dial dynamics of acylcarnitines as acylcarnitines are only produced in the body and can be 
considered as proxies of amino acid and fatty acid metabolism. Both in muscle metabolom-
ics (Chapter 3) and in the challenge responses (Chapter 4), clear effects of phenotype shifts 
were observed in the levels of acylcarnitines. A study by Ramos-Roman suggested the use of 
postprandial changes in plasma acylcarnitine concentrations as markers of fatty acid flux in 
overweight subjects [25]. Plasma acylcarnitines also have been proposed as biomarkers of in-
sulin resistance and metabolic inflexibility in adults [26, 27], although this notion was recently 
contested [28]. It has been suggested that increased acylcarnitine levels in obese subjects may 
not only be due to an impairment in metabolism, but may also represent a natural response to 
an excess supply of lipid. Indeed, the increased production of acylcarnitine could result from 
excess fatty acid flux originating from lipid stored either intracellularly or peripherally [25].
These findings underscore the need for a better understanding of the postprandial response 
of acylcarnitines during the transition from fasting state to fed states in determining of how 
substrate overload might contribute to postprandial metabolic dysfunction.
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Figure 1.Overview of the physiological processes involved in phenotypic flexibility. By applying an optimal nutritional 
challenge, health effects related to nutrition can be quantified. (Figure reproduced from Stroeve et al. [17]).
Integration of metabolome with transcriptome. 
Data integration is now a very commonly used practice in the life sciences and refers to 
the situation where, for a given system, multiple sources of data are available that are studied 
integratively to improve knowledge discovery [29]. It is becoming increasingly accepted that 
the integration of ‘omics’ data, such as transcriptomics, proteomics, and metabolomics will 
provide a better understanding of biological systems [30]. One of the challenges in data inte-
gration is the generation of interpretable results, which should help answer questions such as: 
which variables from multi-omics data sets are correlated with each other and which relevant 
variables provide the most insight into the biology underlying the experimental hypotheses?
This challenge can be addressed by performing variable selection, while combining the 
two types of variables in the modelled integration process. Gonzalez et al. developed and im-
plemented a useful approach: a variant of partial least squares (PLS) regression called sparse 
PLS [30, 31], which simultaneously integrates and selects variables using lasso penalization 
[32]. In Chapter 2 sPLS regression analysis was carried out to calculate leg strength based on 
the expression levels of genes that are robustly changed after prolonged exercise training in 
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both groups in the baseline samples. It was shown using sPLS that there is a link between mus-
cle strength and protocadherin gamma gene cluster. In Chapter 3 sPLS was used to integrate 
muscle changes in transcriptome and metabolome after training. We observed that amino 
acids, particularly branched chain amino acids, correlate with genes related to connective tis-
sue/extracellular matrix. A direct link between the expression of these genes and the levels of 
these metabolites is unlikely, yet it does imply that these changes in amino acid levels are part 
of the adaptive response to resistance-type exercise training. In Chapter 4 it was shown that 
the effect of a stressor (mixed meal) on PBMC gene expression is rather weak. Accordingly, 
using PBMC gene expression to measure phenotypic flexibility might not be an appropriate 
approach. Moreover, integrated interpretation of the PBMC transcriptome with the plasma 
metabolome is difficult since they both represent systemic effects, meaning that they reflect 
the response of multiple organs to a phenotype shift. Besides that, many regulatory mecha-
nisms occurs at the enzymatic level, requiring a proteomics type of approach. Furthermore, 
attempts to integrate the plasma metabolome, proteome and gene expression in PBMCs may 
be hampered due to different time-scales in regulation of metabolism, protein turnover and 
gene expression. Integration of different omics levels (metabolomics, proteomics, transcrip-
tomics) applied to body fluids sampled from the systemic circulation will therefore not likely 
be successful. An organ-focussed approaches that integrate multiple omics levels using system 
biology approaches is expected to be more feasible [33]. In such approaches, the metabolome, 
proteome and transcriptome can be sampled from a single compartment, and time-depen-
dent relationships can be modelled in a direct manner.
Metabolomics profiling of tissues: how to move on? 
Chapter 3 showed that the correlation between skeletal muscle and plasma metabolites 
is rather weak. This finding indicates that plasma metabolites provide a poor reflection of 
muscle metabolism, suggesting that they cannot be used as a substitute biomarker. Current 
procedures for obtaining tissue biopsies from human volunteers are labour intensive, can 
cause discomfort, pain and in some cases risk, thereby raising the bar for obtaining ethical 
approval. Examples are liver biopsy or repeated muscle biopsies. As a consequence, most hu-
man studies focusing on organ metabolomics and/or transcriptomics are carried out on a min-
imal number of volunteers and are poorly powered. To allow for larger scale organ specific 
studies, we need innovative tissue sampling methods that can be used with high-throughput 
and without discomfort and risk for human volunteers. Availability of less invasive/painful 
sampling techniques would in particular enable larger scale studies on adipose tissue and 
skeletal muscle.
The Bergstrom needle muscle biopsy technique has long been considered as the gold stan-
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dard in muscle tissue sampling [34] and has provided a wealth of information for researchers. 
However, its major drawback is that it is moderately invasive, requiring an incision through 
the skin and fascia ranging from 5 to 10 mm [34]. Consequently, this technique may not be suit-
able for research designs that require repeated sampling. As a minimally invasive technique 
‘microbiopsy’ (or fine needle aspiration) has been implemented using a small gauge needle 
for tissue sampling without the need for an incision [35, 36], allowing for less invasive col-
lection of skeletal muscle samples. However, the small sample size obtained is often deemed 
insufficient for certain analyses. Using a recently developed robust extraction procedure, me-
tabolites could be recovered at high yields and in a reproducible manner [37, 38]. For dietary 
studies, Beynen and Katan [39] adapted the original needle-biopsy method of Hirsch et al. [40] 
by using an 18-gauge needle, and reported collecting a ‘small amount of visible material’. This 
mini-biopsy technique collects essentially small globules of fat sufficient for dietary studies. 
Another study compared two sampling methods of subcutaneous adipose tissue using either a 
14 gauge needle with incision versus a 16 gauge needle without incision to examine biomark-
ers of cancer risk [41]. Having less invasive sampling techniques and using small amounts of 
tissue would enable larger scale human studies to more accurately define phenotypical shifts 
due to diet or lifestyle interventions.
168
ReFeRences 
1. Breen L, Phillips SM: Skeletal muscle protein metabolism in the elderly: Interven-
tions to counteract the ‘anabolic resistance’ of ageing. Nutr Metab (Lond) 2011, 8:68.
2. Greig CA, Gray C, Rankin D, Young A, Mann V, Noble B, Atherton PJ: Blunting of adap-
tive responses to resistance exercise training in women over 75y. Exp Gerontol 2011, 
46:884-890.
3. Shimomura Y, Murakami T, Nakai N, Nagasaki M, Harris RA: Exercise promotes BCAA 
catabolism: effects of BCAA supplementation on skeletal muscle during exercise. J 
Nutr 2004, 134:1583s-1587s.
4. Newgard CB: Interplay between lipids and branched-chain amino acids in develop-
ment of insulin resistance. Cell Metab 2012, 15:606-614.
5. Um SH, D’Alessio D, Thomas G: Nutrient overload, insulin resistance, and ribosomal 
protein S6 kinase 1, S6K1. Cell Metab 2006, 3:393-402.
6. Dickinson JM, Fry CS, Drummond MJ, Gundermann DM, Walker DK, Glynn EL, Timmer-
man KL, Dhanani S, Volpi E, Rasmussen BB: Mammalian target of rapamycin com-
plex 1 activation is required for the stimulation of human skeletal muscle protein 
synthesis by essential amino acids. J Nutr 2011, 141:856-862.
7. Markofski MM, Dickinson JM, Drummond MJ, Fry CS, Fujita S, Gundermann DM, Glynn 
EL, Jennings K, Paddon-Jones D, Reidy PT, et al: Effect of age on basal muscle pro-
tein synthesis and mTORC1 signaling in a large cohort of young and older men and 
women. Exp Gerontol 2015, 65:1-7.
8. Phillips BE, Williams JP, Gustafsson T, Bouchard C, Rankinen T, Knudsen S, Smith K, Tim-
mons JA, Atherton PJ: Molecular networks of human muscle adaptation to exercise 
and age. PLoS Genet 2013, 9:e1003389.
9. Churchward-Venne TA, Tieland M, Verdijk LB, Leenders M, Dirks ML, de Groot LC, van 
Loon LJ: There Are No Nonresponders to Resistance-Type Exercise Training in Old-
er Men and Women. J Am Med Dir Assoc 2015, 16:400-411.
10. Hangelbroek RWJ, Fazelzadeh P, Tieland M, Boekschoten MV, Hooiveld GJEJ, van Duyn-
hoven JPM, Timmons JA, Verdijk LB, de Groot LCPGM, van Loon LJC, Müller M: Expres-
sion of protocadherin gamma in skeletal muscle tissue is associated with age and 
muscle weakness. Journal of Cachexia, Sarcopenia and Muscle 2015.
11. Tieland M, Dirks ML, van der Zwaluw N, Verdijk LB, van de Rest O, de Groot LCPGM, 
van Loon LJC: Protein Supplementation Increases Muscle Mass Gain During Pro-
longed Resistance-Type Exercise Training in Frail Elderly People: A Randomized, 
Double-Blind, Placebo-Controlled Trial. Journal of the American Medical Directors As-
sociation 2012, 13:713-719.
G e n e r a l  d i s c u s s i o n
169
6
12. Leenders M, Verdijk LB, Van der Hoeven L, Van Kranenburg J, Nilwik R, Wodzig WKWH, 
Senden JMG, Keizer HA, Van Loon LJC: Protein supplementation during resis-
tance-type exercise training in the elderly. Medicine and science in sports and exercise 
2013, 45:542-552.
13. Timmons JA, Gallagher IJ: Molecular studies of exercise, skeletal muscle, and age-
ing. F1000Res 2016, 5.
14. Dona AC, Jimenez B, Schafer H, Humpfer E, Spraul M, Lewis MR, Pearce JT, Holmes E, 
Lindon JC, Nicholson JK: Precision high-throughput proton NMR spectroscopy of hu-
man urine, serum, and plasma for large-scale metabolic phenotyping. Anal Chem 
2014, 86:9887-9894.
15. Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, Nicholson JK: Metabol-
ic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of 
urine, plasma, serum and tissue extracts. Nat Protoc 2007, 2:2692-2703.
16. Emwas AH, Luchinat C, Turano P, Tenori L, Roy R, Salek RM, Ryan D, Merzaban JS, Kad-
durah-Daouk R, Zeri AC, et al: Standardizing the experimental conditions for using 
urine in NMR-based metabolomic studies with a particular focus on diagnostic 
studies: a review. Metabolomics 2015, 11:872-894.
17. Stroeve JH, van Wietmarschen H, Kremer BH, van Ommen B, Wopereis S: Phenotyp-
ic flexibility as a measure of health: the optimal nutritional stress response test. 
Genes Nutr 2015, 10:459.
18. Casas-Agustench P, Lopez-Uriarte P, Bullo M, Ros E, Gomez-Flores A, Salas-Salvado J: 
Acute effects of three high-fat meals with different fat saturations on energy ex-
penditure, substrate oxidation and satiety. Clin Nutr 2009, 28:39-45.
19. Geidenstam N, Spegel P, Mulder H, Filipsson K, Ridderstrale M, Danielsson AP: Metabo-
lite profile deviations in an oral glucose tolerance test-a comparison between lean 
and obese individuals. Obesity (Silver Spring) 2014, 22:2388-2395.
20. Esser D, van Dijk SJ, Oosterink E, Lopez S, Muller M, Afman LA: High fat challenges 
with different fatty acids affect distinct atherogenic gene expression pathways in 
immune cells from lean and obese subjects. Mol Nutr Food Res 2015, 59:1563-1572.
21. Shah SH, Crosslin DR, Haynes CS, Nelson S, Turer CB, Stevens RD, Muehlbauer MJ, Wen-
ner BR, Bain JR, Laferrere B, et al: Branched-chain amino acid levels are associated 
with improvement in insulin resistance with weight loss. Diabetologia 2012, 55:321-
330.
22. Wahl S, Vogt S, Stuckler F, Krumsiek J, Bartel J, Kacprowski T, Schramm K, Carstensen 
M, Rathmann W, Roden M, et al: Multi-omic signature of body weight change: results 
from a population-based cohort study. BMC Med 2015, 13:48.
170
23. Kardinaal AF, van Erk MJ, Dutman AE, Stroeve JH, van de Steeg E, Bijlsma S, Kooistra T, 
van Ommen B, Wopereis S: Quantifying phenotypic flexibility as the response to a 
high-fat challenge test in different states of metabolic health. Faseb j 2015, 29:4600-
4613.
24. Wopereis S, Wolvers D, van Erk M, Gribnau M, Kremer B, van Dorsten FA, Boelsma E, 
Garczarek U, Cnubben N, Frenken L, et al: Assessment of inflammatory resilience 
in healthy subjects using dietary lipid and glucose challenges. BMC Med Genomics 
2013, 6:44.
25. Ramos-Roman MA, Sweetman L, Valdez MJ, Parks EJ: Postprandial changes in plasma 
acylcarnitine concentrations as markers of fatty acid flux in overweight and obe-
sity. Metabolism 2012, 61:202-212.
26. Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, Hwang DH, Newman JW, 
Garvey WT: Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid 
beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic Afri-
can-American women. J Nutr 2009, 139:1073-1081.
27. Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, Toledo FG, DeLany JP: In-
creased levels of plasma acylcarnitines in obesity and type 2 diabetes and identifi-
cation of a marker of glucolipotoxicity. Obesity (Silver Spring) 2010, 18:1695-1700.
28. Schooneman MG, Napolitano A, Houten SM, Ambler GK, Murgatroyd PR, Miller SR, Hol-
lak CE, Tan CY, Virtue S, Vidal-Puig A, et al: Assessment of plasma acylcarnitines be-
fore and after weight loss in obese subjects. Arch Biochem Biophys 2016, 606:73-80.
29. Gomez-Cabrero D, Abugessaisa I, Maier D, Teschendorff A, Merkenschlager M, Gisel A, 
Ballestar E, Bongcam-Rudloff E, Conesa A, Tegnér J: Data integration in the era of om-
ics: current and future challenges. BMC Systems Biology 2014, 8:1-10.
30. Lê Cao K-A, González I, Déjean S: integrOmics: an R package to unravel relationships 
between two omics datasets. Bioinformatics 2009, 25:2855-2856.
31. Le Cao KA, Martin PG, Robert-Granie C, Besse P: Sparse canonical methods for biological 
data integration: application to a cross-platform study. BMC Bioinformatics 2009, 10:34.
32. Tibshirani R: Regression shrinkage and selection via the lasso: a retrospective. Jour-
nal of the Royal Statistical Society: Series B (Statistical Methodology) 2011, 73:273-282.
33. Zewail AH: Physical Biology: From Atoms to Medicine. 2008:567 
34. Bergstrom J: Percutaneous needle biopsy of skeletal muscle in physiological and 
clinical research. Scand J Clin Lab Invest 1975, 35:609-616.
35. Friedmann-Bette B, Schwartz FR, Eckhardt H, Billeter R, Bonaterra G, Kinscherf R: Simi-
lar changes of gene expression in human skeletal muscle after resistance exercise 
and multiple fine needle biopsies. J Appl Physiol (1985) 2012, 112:289-295.
G e n e r a l  d i s c u s s i o n
171
6
36. Pietrangelo T, D’Amelio L, Doria C, Mancinelli R, Fulle S, Fano G: Tiny percutaneous 
needle biopsy: An efficient method for studying cellular and molecular aspects of 
skeletal muscle in humans. Int J Mol Med 2011, 27:361-367.
37. Alves RAM, Dane A, Harms A, Strassburg K, Seifar R, Verdijk L, Kersten S, Berger R, 
Hankemeier T, Vreeken R: Global profiling of the muscle metabolome: method op-
timization, validation and application to determine exercise-induced metabolic 
effects. Metabolomics 2015, 11:271-285.
38. Chen S, Hoene M, Li J, Li Y, Zhao X, Haring HU, Schleicher ED, Weigert C, Xu G, Lehmann 
R: Simultaneous extraction of metabolome and lipidome with methyl tert-butyl 
ether from a single small tissue sample for ultra-high performance liquid chroma-
tography/mass spectrometry. J Chromatogr A 2013, 1298:9-16.
39. Beynen AC, Katan MB: Rapid sampling and long-term storage of subcutaneous ad-
ipose-tissue biopsies for determination of fatty acid composition. Am J Clin Nutr 
1985, 42:317-322.
40. Hirsch J, Farquhar JW, Ahrens EH, Jr., Peterson ML, Stoffel W: Studies of adipose tissue 
in man. A microtechnic for sampling and analysis. Am J Clin Nutr 1960, 8:499-511.
41. Campbell KL, Makar KW, Kratz M, Foster-Schubert KE, McTiernan A, Ulrich CM: A pilot 
study of sampling subcutaneous adipose tissue to examine biomarkers of cancer 
risk. Cancer prevention research (Philadelphia, Pa) 2009, 2:37-42.
172
Summary
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Human health is impacted by a complex network of interactions between biological path-
ways, mechanisms, processes, and organs, which need to be able to adapt to a continuously 
changing environment to maintain health. This adaptive ability is called ‘phenotypic flexibil-
ity’. It is thought that health is compromised and diseases develop when these adaptive pro-
cesses fail. As the product of interactions between several factors such as genetic makeup, diet, 
lifestyle, environment and the gut microbiome, the ‘metabolic phenotype’ provides a readout 
of the metabolic state of an individual. Understanding these relationships will be one of a ma-
jor challenges in nutrition and health research in the next decades. To address this challenge, 
the development of high-throughput omics tools combined with the application of elaborate 
statistical analyses will help characterize the complex relationship of (bio) chemicals in hu-
man systems and their interaction with other variables including environment and lifestyle 
to produce the measured phenotype.
An important aim of this thesis was to identify phenotype shifts by looking at effect of 
prolonged resistance-type exercise training on skeletal muscle tissue in older subjects and the 
possible shift toward the features of younger subjects as a reference for a healthier pheno-
type. A second aim was to identify phenotype shifts by looking at the response to a challenge 
in obese subjects and the possible shift toward lean subjects as a reference for a healthier 
phenotype.
Chapter 2 and 3 of this thesis show how the significant remaining plasticity of ageing skel-
etal muscle can adapt to resistance-type exercise training. The data indicate that frail and 
healthy older subjects have two distinct phenotypes according to the skeletal muscle tissue 
metabolite profiles and that exercise training shifts aged muscle towards a younger pheno-
type. We showed that the effect of exercise on amino acid derived acylcarnitines (AAAC’s) in 
older subjects points towards decreased branched chain amino acid catabolism, likely due to 
compromised activation of the branched chain α-keto acid hydrogenase (BCKDH) complex. 
Furthermore, we found that the protocadherin gamma gene cluster might be involved in 
aged-muscle denervation and re-innervation. Finally, plasma was found to be a poor indicator 
of muscle metabolism, emphasizing the need for direct assessment of metabolites in muscle 
tissue. 
Chapter 4 of this thesis examines whether a mixed meal challenge response provides a 
readout for a shift in phenotype upon weight loss in obese male subjects. We concluded that 
weight loss moderately affects the mixed meal challenge response of both plasma metabo-
lome and transcriptome of peripheral blood mononuclear cells in obese subjects. Measure-
ments at the fasted and postprandial state also provide us with a different type of information. 
In Chapter 5 it is demonstrated that the global testing of pathways could provide a concise 
summary of the multiple univariate testing approach used in Chapter 4.
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In Chapter 6 it is discussed how the findings of this thesis increase our understanding of 
how to measure phenotypic flexibility as a proxy of health. In this thesis it is shown that the 
correlations between tissue and plasma metabolites are rather weak, emphasising the need 
to perform organ-specific studies. Availability of less invasive/painful sampling techniques 
and the use of small amounts of tissue would enable larger scale human studies on adipose 
tissue and skeletal muscle to more accurately define phenotypical shifts due to diet or lifestyle 
interventions. With respect to the assessment of phenotypical flexibility by omics approaches, 
significant complications can be expected in trying to relate plasma metabolism to PBMC gene 
expression. Organ-focussed approaches that integrate multiple omics levels using system biol-
ogy approaches are considered to be a lot more promising.
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